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“If I have seen further, it is by standing on the shoulders of giants” 
Preface 
Although there might be some discussion to whom we can attribute 
this quote, we cannot argue that (big and small) advances in science 
are a consequence of the work of our predecessors. It seems no more 
than right to briefly sketch some of the breakthroughs in the field of 
genetics that made the research presented here, possible. One of these 
giants in genetics is, undoubtedly, Gregor Mendel, a scientist and monk 
that lived in the 19th century and that is currently considered to be the 
father of genetics. In his experiments on peas, he discovered that 
phenotypes (“how does it look?”) are transmitted in a predictable 
manner. In the 20th century, numerous discoveries revolutionized the field. 
In 1953, Watson, Crick, Wilkins and Franklin (the last one might be one 
of the most overlooked scientists) discovered that deoxyribonucleic acid 
(DNA) is organized in a double helix. Frederick Sanger proposed in 
1977 a method that enables the accurate determination of the sequence 
of nucleotides (= the building blocks) of the DNA. This method is now 
known as “Sanger” sequencing. A downside at this point was the need 
for large amounts of starting material. This was resolved by Mullis in 
1987 by the development of the polymerase chain reaction (PCR). This 
technique enables in vitro exponential amplification of specific DNA pieces 
(= DNA templates) and with some modern modifications, this is still one 
of the most widely used standard procedures in the lab. 
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 These and other techniques were all necessary for what might be 
one of the milestones of the 21st century: the publication of the first draft 
of the human genome. Since then, the pace is ever increasing: newer 
sequencing technologies enable an enormous throughput, faster computing 
algorithms are developed and the genome of several thousands of 
organisms has been analysed.  
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Looking for the needle(s) in the haystack 
1 Introduction 
The dog, or Canis familiaris, has been accompanying us, humans, for 
several thousands of years and has a remarkable phenotypic diversity in 
terms of colour, size, skull shape, etc1,2 (Figure 1.1). This is a 
consequence of the selective breeding of dogs with specific qualities and 
has resulted in well over 300 different breeds3. In modern times, the 
worldwide breeding of pedigree dogs is regulated by Kennel Club 
guidelines in order to meet the unique characteristics for each breed. To 
achieve this, intense inbreeding practices and a small number of popular 
sires have often been used4. It is generally accepted that, as a 
consequence of these breeding practices, the general health of pedigree 
dogs has been compromised compared to cross-breed dogs4. These 
concerns about the health of our pedigree dogs have also been raised in 
the documentary “Pedigree Dogs exposed”, broadcasted by the BBC in 
20085,6. 
The Kennel Club’s breeding standards are mainly focused on 
conformational characteristics rather than health characteristics. The hair 
ridge in the Rhodesian Ridgeback is associated with dermoid sinus. 
Breeding ridgeless dogs could eliminate dermoid sinuses7. Other examples 
are brachycephalic airway obstructive syndrome in the brachycephalic dog 
breeds or skin fold dermatitis in breeds with excessive skin folds5. Based 
on these examples, it is clear that some disorders are directly associated 
with these breeding guidelines. However, as other genetic disorders are 
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also highly prevalent in the dog, health issues cannot be contributed to 
conformational guidelines alone6,8.  
In order to improve our dog’s health, several propositions have been 
made9. This entails more than the mere exclusion of all dogs that carry a 
deleterious allele as every dog, just like humans, carries some disease-
associated variants4. A good strategy starts with getting an overview of 
which disorders are important for which breed. After deciding which 
disorders to tackle first, proper screening tools have to be developed and 
implemented in breeding strategies. For heritable disorders, the best 
screening tools are DNA tests as they are not influenced by environmental 
variation. Continuous follow-up of the achieved breeding progress is 
required. Simultaneously, awareness regarding emerging disorders is 
important to guarantee a positive evolution.  
According to the public Online Mendelian Inheritance in Animals 
(OMIA) database10, a total of 653 genetic disorders are known in the 
dog. Two hundred and sixty three are Mendelian traits and for 193 of 
them, the causal variant is known. This implies that for the large majority 
of disorders, the causal variant(s) still need to be elucidated. In this 
chapter, the history and current state of the canine genome is discussed. 
Next, possible tools that can be used to link mutations to phenotypes, are 
described.  
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Figure 1.1. Examples of the phenotypic variation in the domesticated dog11,12. 
(From left to right: top row: crossbreed, Cocker Spaniel; bottom: Jack Russell 
Terrier, Poodle, Boxer.) 
1.1 The dog and its genome 
A genome is defined as the organism’s complete set of DNA13. The 
dog genome consists of 39 pairs of chromosomes (38 pairs of 
autosomes and the X and Y sex chromosomes)14 (Figure 1.2). Only 
two years after the first draft of the human genome, the group of Venter 
published the first assembly of the canine genome (with a 1.5x 
coverage)15. The supplier of the DNA was Shadow, the poodle of Venter 
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himself (Figure 1.1). This was followed by an updated version with a 
7.5x coverage by sequencing Tasha, a female Boxer (Figure 1.1)2. By 
comparing these two genomes and low-pass shotgun sequencing of 
several dog breeds, wolves and a coyote, the first dense single nucleotide 
polymorphism (SNP) map was published at the same time2. In 2014, 
the present assembly (CanFam 3.1) was published, with reduced gaps 
and an improved annotation16. 
 
Figure 1.2. Karyogram of the dog17. 
In the process of domestication and breed creation, the dog population 
went through several bottlenecks2,18,19. Compared with the human genome, 
this resulted in large haplotype blocks within a breed and short blocks 
between breeds2,20–22. A haplotype is a set of DNA variants that tend to 
be inherited together13. In addition, the haplotype diversity within a breed 
is limited as well21. The length of the haplotype blocks varies between 
breeds and is in agreement with the population history of that breed21,22. 
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These characteristics are favorable for genome-wide association studies 
(see 1.3.1). 
1.2 Unravelling the link between a phenotype and a genotype 
As already empirically found by Mendel in the 19th century: the way 
you look is at least partially heritable and linked to your DNA. With the 
discovery of several mutations responsible for all kinds of phenotypes, it 
has become feasible to predict the result of certain combinations by a 
priori performing some genetic tests. Aside from phenotypes, such as coat 
colour, the genetic cause for several diseases has been discovered as 
well10,23. The question is: how can you link a certain genetic mutation to 
a certain phenotype? In this era of fast advances in molecular 
biotechnology, several approaches have been developed that enable us to 
identify this link. 
1.3 Theoretical Background 
Simplified, phenotypes and disorders can be divided into two distinct 
groups24–26. The first group contains the rare Mendelian, monogenic or 
simple phenotypes, where the phenotype is caused by one genetic 
mutation or mutations in one gene and the inheritance pattern is 
dominant, recessive or sex-chromosome linked. In contrast, the complex 
or multifactorial traits are caused by a combination of genetic and 
environmental factors. Typically, these traits are genetically heterogeneous, 
making the identification of disease-causing genes very challenging. This 
heterogeneity is reflected in the genetic part of these common traits being 
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the sum of a combination of relatively common variants and relatively rare 
variants, where the latter will increase the risk more than the former27. 
The difference between common and rare variants is important as it has 
its consequences in the process of linking them to a phenotype.  
Some phenotypes develop through the action of newly formed 
mutations25,26. These so called de novo mutations (and the disease) are 
not present in the healthy parents, as they originate in the meiosis of the 
germline. However, they can be transmitted to the offspring and cause 
disease in these individuals. These mutations will be treated separately. 
Overall, the methods that link causal genetic variation to a phenotype 
can be divided into two groups: the direct and the indirect methods. The 
direct methods try to identify the disease-causing mutations as such. 
Indirect methods use genetic markers nearby the actual disease-causing 
variant to identify the link with the phenotype (Figure 1.3). Examples of 
indirect methods are linkage analysis and genome-wide association studies 
(GWAS). Direct methods are whole genome sequencing (WGS) and 
whole exome sequencing (WES). Depending on the approach, candidate 
gene studies can be direct or indirect. In this introduction, we will focus 
on GWAS, candidate gene studies and WES. Due to the cost, WGS 
studies are currently not often performed. Due to the relatively low 
resolution, the need for large pedigrees and the advances in 
biotechnology, linkage analysis has been largely replaced by GWAS and 
will not be discussed in this introduction.  
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Irrespective of the method used (WGS, WES, GWAS or candidate 
gene studies), the power of a study will be dramatically influenced by 
misclassification of cases and controls28. Therefore, it is of utmost 
importance that the appropriate diagnostic tools and criteria are used. 
Figure 1.3. Direct (Gp) and indirect (Gt) association from genetic variation with a 
phenotype (Ph). Gt is a so-called tagSNP, whereas Gp represents causal variation.  
1.3.1 GWAS 
GWAS are conducted in several steps. The starting point is choosing 
an appropriate study design. Case-control designs are used most often, 
other designs are cohort studies and trio studies (i.e. an affected case 
with two unaffected parents). After genotyping these individuals with a 
GWAS array of choice, several checks can be performed. Overall, a 
sufficient number of SNPs should be called reliably in each sample, 
violations of Hardy-Weinberg equilibrium can be tested, only SNPs are 
retained that occur more frequently than a certain minor allele frequency 
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(MAF) and if duplicate samples are included, their SNP calls should be 
highly concordant18,28,29. Following these checks, a cleaned list of several 
thousands of SNP calls remains for the final association testing. This 
association testing is in essence no more than a comparison of the 
frequencies of alleles or genotypes in cases and controls and several 
statistical tests can be used (e.g. Fisher exact test, χ², logistic or linear 
regression). But what is the underlying principle of a GWAS? 
A graphical representation of the principle of GWAS is presented in 
Figure 1.3. Essentially, it comes down to identifying a link between a 
SNP and a phenotype. Although it is unlikely, it might be that the SNP 
used in the GWAS, is directly causing the phenotype (Gt = Gp)30. This 
will seldom be the case. It is more likely that the link exists because a 
phenotype is associated with a causal genetic variant and, in turn, the 
causal genetic variant is associated with a tagSNP31. For a GWAS, this 
association between the tagSNP and the causal genetic variant is due to 
linkage disequilibrium (LD). LD is defined as the non-random association 
of alleles at two or more loci32. It is possible that LD exists between loci 
on different chromosomes, but it is usually defined in terms of loci on the 
same chromosome now32. In that sense, LD and linkage are “linked”: LD 
is generally stronger when loci are linked more closely together33. Several 
formulas exist to quantify the LD between two loci, but the standard 
formula for two loci with each two alleles, is the following31,32,34: 
(1) DAB = pAB – pA . pB 
With: 
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 pAB = the frequency of the AB haplotype 
 pA = the frequency of allele A (at the first locus) 
 pB = the frequency of allele B (at the second locus) 
If DAB is equal to zero, this is called linkage equilibrium (LE). If it ≠ 0, 
LD exists. 
The amount of LD can also be expressed relative to its maximum 
possible value, given the allele frequencies31,32,34:  
(2) D’ = D / min{pA . (1 – pB ), pB .(1 – pA)} if D > 0 
D’ = D / min{pA . pB, (1 – pA ). (1 – pB)} if D < 0 
To make a GWAS possible, three items are needed: 
- a list of SNPs with their genomic location; 
- LD has to be present between at least one SNP and the 
causal mutation; 
- an easy and reliable method to genotype a large amount of 
SNPs. 
The first prerequisite, a list of SNPs, became publicly available 
together with the second canine genome assembly2. The second 
prerequisite implies that disease-causing alleles in two individuals should 
be identical-by-descent and that the tagSNPs have to be close enough 
so that little recombination took place35. The gradual decay of LD can be 
quantified with the following formula32: 
(3) DAB(t+1) = (1-c) . DAB(t) 
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With:  
 t = the time in generations 
 c = the recombination frequency 
 DAB = the LD for haplotype AB  
It is clear that after a sufficient number of generations, LE will be 
eventually reached, but at a slow rate for closely linked SNPs32. Due to 
the advances in biotechnology, the third prerequisite was fulfilled as well: 
at this point, four GWAS arrays are available for the dog18,19,36,37. Details 
on each array are discussed in section 1.4.2.  
An important issue is the number of tagSNPs that need to be 
interrogated to ensure sufficient coverage of the genome. The aim is 
essentially to capture as much genetic variation as possible, with a 
minimum number of SNPs35. The number of SNPs needed, depends on 
the amount of LD. For the selection process, LD is usually quantified in 
terms of a correlation coefficient, using the following formula32,34,38: 
(4) 𝑟² =  D²
p𝐴 (1 – p𝐴) p𝐵 (1−p𝐵)
 
The idea is that, if several SNPs are highly correlated, it is not 
necessary to genotype them all, as genotyping one of them, gives a fairly 
good knowledge of the genotype of the ungenotyped SNPs as well30. So 
one has to choose the SNP(s) that reflect the LD landscape for a 
certain location in the genome.  
The amount of LD varies between organisms and reflects the 
history of the population. Population bottlenecks, inbreeding and the use of 
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popular sires can increase the LD and thus reduce the number of 
tagSNPs necessary to localize the region that harbors the disease-causing 
mutation1,2,18,21. This explains why LD is more extensive within a breed 
compared with the LD in the human genome1,2,18,21,22. The advantage is 
that, theoretically, far less SNPs would be needed to map a trait. 
However, using less SNPs, the putative region containing the causal 
variant will be larger as well, requiring more work further downstream in 
the analysis. As the LD between canine breeds is far less extensive, an 
option would be to do a two-stage mapping18. The first step is a GWAS 
within a breed, followed by a fine-mapping stage in more breeds. An 
important point is that this will only work if the same ancestral haplotype 
is shared between breeds18.  
An important issue when performing several thousands of statistical 
tests (called “multiple testing”), is the inflation of the type ।-error, also 
known as the false positives. Assuming an α-threshold of 0.05 (which 
implies a chance of 5% of seeing at least the same result when H0 is 
true) for one test, will result in ± 5 000 significant results occurring by 
chance alone when 100 000 tests (= 100 000 SNPs in this case) are 
performed. To correct this, several methods have been suggested. The 
first group of corrections, controls the family-wise error rate (FWER)39. 
As the name suggests, it controls the total number of false positives, for 
the entire “family” of tests. Mathematically, this is represented as P(H0 = 
rejected | H0 = true). One of the most known and used procedures, is 
the Bonferroni correction: 
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(5) 𝛼𝑡 =
𝛼0
𝑛
 
With:  
αt = the α for each individual test 
αo = the overall α  
n = the number of tests 
So by increasing the stringency for each individual test, the overall type I 
error rate is controlled at a certain level. A downside of the Bonferroni 
correction, is that when a lot of tests are performed, the p-value for 
individual tests has to be extremely (unrealistically?) low. Thus, applying 
this correction affects the statistical power. A modified Bonferroni 
correction, called the Holm-Bonferroni correction, uses a stepwise 
correction to improve the power while maintaining a low error rate40. A 
second group of corrections, controls the False Discovery Rate 
(FDR)39,41,42. These methods give information on the probability that H0 
is true, given that H0 was rejected (P(H0 = true | H0 = rejected)). 
This explicitly tells you how many significant results are possibly incorrect, 
in contrast to the FWER. An example is the correction suggested by 
Benjamini and Hochberg41: 
- Sort the n p-values in ascending orders; label these p1, p2, …, 
pn 
- Let k denote the largest index i for which pi ≤ d x i/n, for all i, 
with d the false discovery rate threshold of choice 
- Declare all tests with p-values p1 ,p2, …, pk significant 
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 Permutations can also be used to estimate the FDR, as under H0, the 
case-control labels can be permutated to determine the number of false 
positives42,43.  
A downside of GWAS is that they are sensitive for population 
stratification: it is difficult to distinguish whether a significantly associated 
SNP represents a true association or whether it is caused by differing 
allelic frequencies in subpopulations22,28–30. Although remedial methods have 
been developed to correct for stratification, careful selection of cases and 
controls should always be the first priority44,45.  
In the next three sections, the application of GWAS is discussed for 
Mendelian and common diseases and diseases caused by de novo 
mutations.  
A. Rare Mendelian disorders 
Two properties of genetic diseases are very important. The first one is 
detectance (i.e. P(genotype | phenotype)). If the detectance is 100%, 
there is no genetic heterogeneity and phenocopies are absent. A 
phenocopy is “an individual without the trait mutation that nonetheless has 
the trait due to environmental or other causes” 19. The second feature is 
penetrance (i.e. P(phenotype | genotype)). If penetrance is 100%, 
every genetically affected individual is actually sick. Diseases with 100% 
detectance and 100% penetrance are highly amenable for disease-
association studies. Throughout this introduction, we apply Fisher exact 
tests on 2x2 contingency tables and plot the obtained p-values to 
demonstrate the effect of sample size and reduced detectance and/or 
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penetrance in association testing. These results can be used directly under 
the assumption of a dominant model and a recessive model29. 
Alternatively, allele or genotype frequencies in cases and control can be 
compared directly, without specifying an inheritance model29. In addition, 
the effect of testing with and without a correction for multiple testing is 
demonstrated. To be on the safe side for our estimations, we applied the 
conservative Bonferroni correction in the demonstration. As the number of 
SNPs genotyped varies between arrays (see 1.4.2), the following αt-
thresholds were applied: 
For the 27k array: p ≤ 1.851852 . 10-06 
For the 50k array: p ≤ 1 . 10-06  
For the 172k array: p ≤ 2.906977. 10-07 
The effect of sample size was evaluated first. As demonstrated in 
Figure 1.4, significance can be reached quickly at very low sample sizes 
(total n ≥ 24 or 26 (= sum of cases and controls)). Importantly, we 
assumed that the observed genotype/allele, is in perfect LD (r² = 1) 
with the causal mutation. 
The situation is more difficult when the separation between cases and 
controls is not complete. Reduced penetrance, genetic heterogeneity, 
genotyping errors or phenotypical misclassification are quite common and 
can affect the results significantly. The effect of these factors is 
demonstrated in Figure 1.5 for a total sample size of 100. Although the 
total sample size remains constant and resulted in very low p-values in 
Figure 1.4, it is clear that depending on the distribution, significant values 
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are not always reached. Phenotypical misclassification, genotyping error and 
a low LD can complicate results in every situation. Genetic heterogeneity 
and phenocopies will result in phenotypical cases with an incorrect 
genotype (see Figure 1.5, section A). Reduced penetrance results in 
individuals with an affected genotype but an incorrect phenotype (see 
Figure 1.5, section B). 
Figure 1.4. Relation between the number of cases (x-axis), the uncorrected p-
value (y-axis, left graph) and the uncorrected p-value in log scale (y-axis, right 
graph), using a Fisher-exact test. Results on the left hand side of the vertical 
lines indicate when the p-values become small enough to provide significant 
results when the Bonferroni correction is applied for the 27k, 50k and the 172k 
genome-wide association studies assays, respectively (α0 = 0.05). Filled dots: 
uncorrected p-value > 0.05; open dots: uncorrected p-value ≤ 0.05. 
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B. Common disorders 
Common disorders are far more difficult to map compared to 
Mendelian disorders. At present, the theory is that common diseases are 
caused by common and rare variants27. A simplified representation of a 
situation that might occur, was already presented in Figure 1.5. It shows 
that rare variants (that, per definition, have a low allele frequency) will 
be difficult to detect, even with a total sample size of 100 individuals 
(Figure 1.5, part A). In addition, these variants typically add to the risk 
of developing disease and are not sufficient to cause disease themselves. 
This situation is shown in Figure 1.5, part B. 
In Figure 1.6, the combined effect of these complicating factors 
that are typically associated with complex disorders is demonstrated again 
for a total sample size of 100. Significance is still reached but far less 
often. Based on these figures, it still seems possible to discover genetic 
variation linked to common disorders. However, in reality, the situation is 
even more complex. Common variants are not that common: depending on 
the source, they have been cited to occur at allelic frequencies of 1-5%, 
so to detect them, sample sizes have to be large (n >> 1000)27,33. 
For rare variants, the situation is even worse. Even though it is assumed 
that they contribute “more” to disease, their allele frequency is even 
lower. In addition, an important point of consideration relates to the link 
between LD, the allele frequency and the MAF-cutoff applied in the 
analysis steps. It has been demonstrated that as a prerequisite for a high 
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r² between the tagSNP and the untyped variant, the allelic frequencies of 
both have to be relatively similar33,34. 
Figure 1.5. Relation between the number of individuals (x-axis), the uncorrected 
p-value (y-axis, left graph) and the uncorrected p-value in log scale (y-axis, right 
graph), using a Fisher-exact test. Results on the left hand side of the vertical 
lines indicate when the p-values become small enough to provide significant 
results when the Bonferroni correction is applied for the 27k, 50k and the 172k 
genome-wide association studies assays, respectively (α0 = 0.05). Filled dots: 
uncorrected p-value > 0.05; open dots: uncorrected p-value ≤ 0.05. 
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For example, if the allele frequency of the tagSNP is 50% and if the 
r² has to be at least 0.8, the allelic frequency of the untagged variant 
has to be within ± 6%. The same situation, but with an allele frequency 
of the tagSNP of 5% (a frequently used cut-off for the MAF in the 
quality control in GWAS studies) requires the allelic frequency of the rare 
variant to be within 1%. A MAF of 4% for rare variants is simply too 
high, based on current criteria for human complex diseases27.  
It is not completely clear whether the applied allelic frequency 
thresholds for common and rare variants used in humans can be 
extrapolated directly to the canine population. Due to the population history 
of the dog, it is possible that the allele frequencies of rare variants are 
higher due to the reduced genetic diversity within breeds, but even if the 
allele frequency of rare variants would be sufficiently high, the sample size 
requirements would still be substantial19. Overall, it is very unlikely for rare 
variants associated with common disorders to be detected with GWAS. 
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Figure 1.6. Relation between the number of genetically and phenotypically 
affected individuals (x-axis), the uncorrected p-value (y-axis, left graph) and the 
uncorrected p-value in log scale (y-axis, right graph), using a Fisher-exact test. 
Results between the vertical lines indicate when the obtained p-values are higher 
than the Bonferroni correction threshold for the 27k, 50k and the 172k genome-
wide association studies assays (α0 = 0.05). Filled dots: uncorrected p-value > 
0.05; open dots: uncorrected p-value ≤ 0.05. 
C. De novo mutations 
De novo mutations cannot be identified using GWAS. The reason is 
that GWAS relies on ancestral haplotypes being passed on, with the 
causal variant being in LD with the tagSNP. As de novo mutations arise 
in the germline, the haplotype is only created at that point. In addition, it 
is typically assumed that for de novo mutations, the reproductive fitness is 
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affected, so the novel haplotype, created in the affected proband, will not 
be passed on to the following generations26.  
 To conclude, GWAS has several downsides: 
- it always requires further steps downstream, as it only identifies a 
region containing the causal variant; 
- by design, it is very unlikely to discover rare variants in complex 
diseases and impossible to detect de novo mutations; 
- it is sensitive for population stratification; 
- not specific for GWAS, but a more general issue related to all 
indirect methods: they are always at best as efficient as direct 
methods, never better. 
On the plus side:  
- GWAS have been used successfully in disease-association studies 
for both Mendelian disorders and to identify common variants in 
complex disorders; 
- it allows for an unbiased view of the entire genome and does not 
require prior assumptions in terms of biological knowledge (e.g. 
protein-coding mutations, regulatory mutations). 
An example of a successful GWAS study in the dog is the 
identification of the causal mutation in the SOD1 gene (SOD1:c.118G>A) 
responsible for degenerative myelopathy in the dog, an autosomal 
recessive disorder with age-related incomplete penetrance46. 
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1.3.2 Candidate gene studies 
Depending on the applied method, the candidate gene methodology 
can be direct or indirect. The indirect methodology relies on the same 
principles as GWAS (indirect identification of causal variation due to LD 
with a tagSNP), the direct methodology relies on sequencing with the 
analysis being comparable to whole exome sequencing (see 1.3.3). 
Depending on the number and size of the candidate genes, the technical 
approach varies. Investigating a limited number of genes might be done 
with Sanger sequencing or individual SNP genotyping, whereas for larger 
projects, entire arrays or targeted enrichment designs might be more 
optimal. Irrespective of the indirect or direct methodology, the most 
important point is the appropriate selection of candidate genes47. Even 
though the selection might be perfectly sound, based on scientific 
knowledge at that time, it is not unlikely for a candidate gene study to 
fail. Often, when the causal mutation/gene is identified, it is a new gene 
that was never implicated before in the disease under investigation37. 
Success rates in candidate genes studies are thus rather low48,49.  
Overall, the downsides of both the indirect and direct candidate gene 
approach are the same as those for the GWAS and WES and are 
discussed in their respective sections. There are two additional 
disadvantages: 
- the a priori assumptions that have to be made about the biological 
basis of the disease often turn out to be problematic; 
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- the wet lab tools developed for that project, can only be used for 
that specific project (e.g. primers). 
On the plus side, it is likely the cheapest method, compared to 
GWAS and WES, although the price varies considerably with the project 
size. 
An example of a successful candidate gene study, is the identification 
of a mutation in the MC1R gene that results in a truncated protein that is 
responsible for some of the coat colours seen in dogs50.  
1.3.3 Whole exome sequencing 
The aim of WES is to selectively sequence all the exons throughout 
the genome. In contrast to GWAS, WES is a direct interrogation of the 
genome since the technique is based on sequencing. It is a fairly recent 
technique as it required several biotechnological breakthroughs. First of all, 
although the exome is much smaller compared with the genome (2 to 
6% of the genome, depending on the design), it still comprises several 
millions of bases that need to be sequenced. It is possible to use Sanger 
sequencing to sequence even entire genomes. However, the development 
of second/next generation sequencing (also known as massively parallel 
sequencing) made it certainly more feasible51. A second issue is that 
most techniques relied on the polymerase chain reaction (PCR) to 
specifically target subsets of the genome52. This requires the design of 
large numbers of primers and numerous individual amplification reactions. 
Certainly for large resequencing projects, this is very time-consuming, 
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error-prone and relatively expensive. The development of targeted 
enrichment techniques that allow reproducible resequencing of parts of the 
genome, fulfilled the second prerequisite to make WES feasible. 
Selectively sequencing exons is less expensive compared to whole 
genome sequencing and most disease-causing variants have been 
observed to alter the amino-acid sequence for Mendelian disorders (= 
non-synonymous variants)24,25. In addition, most studies focus initially on 
non-synonymous variants as their effect is much easier to predict 
compared with synonymous or non-protein coding variants. A complicating 
factor for common disorders is the influence of regulatory mutations instead 
of protein-coding mutations alone16. These mutations will be missed in 
WES experiments.  
The starting point of WES studies, is the choice of the “exome”. The 
exact definition of the exome varies. For example, the ex- or inclusion of 
the 5’ and 3’ untranslated regions depends on the choice of the 
developer of WES enrichment designs and varies between commercial 
platforms26,53. With commercial platforms being able to target up to 200 
Mb at this moment, the choice of which regions to include is nowadays 
less an issue of technical limitations but more of practical and theoretical 
considerations. It is important to consider that all designs are always 
based on the current knowledge of the annotation. Although the genome 
of several species has been thoroughly investigated with several 
techniques, it is likely that some of the coding regions are missed due to 
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an incomplete annotation26. With new information becoming available, 
updates and extensions are thus required. 
When variants have been called, they can subsequently be analyzed to 
assess their potential relationship with the phenotype under study. In 
general, the analysis methodologies can be divided into two major groups 
(that, however, are not mutually exclusive). The first group uses heuristic 
filters to filter sequencing variants25. The required sample size for these 
studies is typically low. Often sequencing only a couple of individuals 
(less than 10) is sufficient. In one of the first successful WES studies, 
only 4 individuals were sequenced54. Especially for Mendelian disorders 
and de novo mutations, heuristic filtering is highly amenable24. The second 
group of analysis uses a more statistical approach. This approach will be 
necessary when rare variants related to common disorders are studied. 
Although WES is a direct approach compared with GWAS, the same 
statistical tests can be used to identify putative causal variants.  
A. Rare Mendelian disorders 
The heuristic filtering approach is typically used to study rare 
Mendelian disorders. Often, these filters rely on several assumptions, as 
demonstrated in Figure 1.7. If, after filtering, only a few non-synonymous 
variants remain, the effect of every variant on its protein can be predicted 
with tools as PolyPhen or Provean to prioritize them further25,55,56.  
Often, one of the first steps in filtering consists of the removal of 
previously identified variants present in public databases such as dbSNP. 
This significantly reduces the number of putative variants. Depending on 
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the disease studied, one can choose to use all the variants present in a 
database or to use only those variants that have a certain MAF. As the 
number of variants in these databases increases constantly, is it not 
unlikely for a database to become “contaminated” i.e. contain disease-
causing variants25. Therefore, specifying a MAF might be a safer option. 
B. Common disorders 
As discussed in GWAS (section 1.3.1), several complicating factors 
arise when common disorders are studied. The big benefit of direct 
sequencing-based approaches is the direct interrogation of individual base 
pairs and not having to rely on LD (see Figure 1.5 and Figure 1.6)25. 
Both common and rare variants will thus be detected. However, 
associating these variants with a phenotype will still be difficult. For 
common variants, it will again be easier to do, in comparison with rare 
variants that will require enormous sample sizes when testing them one by 
one for an association. 
To improve the power, different more statistical approaches have been 
proposed25,57–60. Although details vary between methods, several collapse 
variants together into one functional unit of choice and calculate differences 
in variant burden between cases and controls25,57–60. Some of them only 
include rare variants; others also include common variants and apply a 
weighting factor. Several other methods exist as well and focus for 
example on sequence similarity or use regression models57. Other 
propositions to increase the power involve family studies, extreme 
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phenotype sampling and the use of population isolates60. Overall, it is 
clear that detecting these variants remains far from easy. 
Figure 1.7. Standard sequence of heuristic filters applied when filtering sequence 
variants25. 
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C. De novo mutations 
De novo mutations that affect the reproductive fitness (i.e. the 
affected individuals do not reproduce) can only be detected by direct 
sequencing methods as methods relying on LD require a shared ancestral 
haplotype to be passed on26,61. The study design of choice is the trio 
design mentioned earlier26. In this design, the variants in both parents are 
used to filter the variants in the affected individual. Theoretically, if no de 
novo mutations would occur and if sequencing would be perfect (no 
variable coverage of regions between any of the sequenced individuals and 
no errors in variant calling), no single variant would be retained in this 
design. In reality however, they all take place, and this results in a very 
limited number of variants being detected. This immediately points out one 
of the weaknesses: de novo mutations can easily be missed or be 
introduced incorrectly somewhere in the sequencing or computational 
processes. However, it is also clear that the power of this approach is 
substantial, as already demonstrated61.  
In conclusion, WES has some downsides: 
- in general, the assumption for WES is that the putative causal 
variant lies in the protein-coding regions, although this assumption 
might be relaxed depending on the design; 
- the power to detect rare variants for common disorders is still 
rather low; 
- at this point, it is the most expensive method, compared to GWAS 
and candidate genes. 
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On the plus side:  
- it can detect rare variants associated with common disorders; 
- it allows for a more unbiased view compared with candidate 
genes; 
- as a direct method, its efficiency is comparable with indirect 
methods (in the regions they both cover), or better. 
At this point, WES has not been used without prior mapping in the 
dog to identify a disease-causing mutation. It has however been used in 
association with GWAS to identify an insertion deletion (indel) 
(c.2685delA2687_2688insTAGCTA) in the CNGB1 gene that causes 
progressive retinal atrophy62. 
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1.4 Technology 
In this section, two groups of techniques are discussed. The first 
group requires prior knowledge of variants present in the genome. In this 
group, Kompetitive Allele Specific PCR (KASP) and GWAS arrays are 
discussed. The main difference between KASP and the GWAS arrays is 
that KASP is a singleplex technique whereas GWAS arrays allow for the 
simultaneous interrogation of several thousands of variants. The second 
group of techniques is based on sequencing and, in this group, the focus 
will be on Sanger sequencing and Illumina sequencing.  
1.4.1 Probes: KASP 
KASP is a fluorescence-based singleplex genotyping technology that 
allows for the detection of both SNPs and indels. It is based on the 
competition between two allele-specific forward primers with unique tail 
sequences that are each complementary to one of two different 
fluorescence resonance energy transfer (FRET) cassettes63,64. Because 
KASP cassettes are not variant specific, but primer-tail specific, the same 
cassettes can be used for all assays whereas the primers have to ensure 
the specificity for a certain variant. This decreases the cost as primers 
are much cheaper compared with quencher-reporter assays. Overall, KASP 
has proven to be a reliable, cost-effective and flexible genotyping 
technique63. An overview of the KASP technology is presented in Figure 
1.8. 
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Figure 1.8. Overview of the Kompetitive Allele Specific PCR (KASP) genotyping 
technology64. 
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1.4.2 Large scale GWAS arrays 
At this point, four different SNP microarrays are available for GWAS in 
the dog. They differ by the number of SNPs interrogated, the 
manufacturer and technology, but all arrays are based on the CanFam 
2.0. The first GWAS array was developed in 2007 and allows for the 
interrogation of ± 27 000 SNPs18. A second array was designed to 
interrogate ± 50 000 SNPs. Both arrays were commercialized by Affymetrix 
with the first one combining perfect match and mismatch (PM/MM) 
probes and the second one containing PM probes only. The combination 
of PM and MM probes allows for correction of background noise65. In 
both arrays, the genotype is derived by allele-specific hybridization of DNA 
fragments to 25-mer probes.  
The other two arrays, the CanineSNP20 BeadChip and the CanineHD 
BeadChip, are commercialized by Illumina and interrogate ± 22 000 SNPs 
and ± 172 000 SNPs, respectively36,37. In these arrays, after hybridization 
of DNA fragments to 50-mer probes on beads, a single labeled 
nucleotide that is complementary to the allele in the DNA is added 
(“single base extension”) and, after signal amplification, the genotype is 
derived30,65–67. An overview of both the Affymetrix and Illumina genotyping 
is shown in Figure 1.9.  
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Figure 1.9. Principles of Affymetrix and Illumina genotyping technology used in 
the genome-wide association studies assays65. At the top is the fragment of DNA 
harboring an A/C SNP to be interrogated by the probes shown. (a) In the 
Affymetrix assay, the DNA binds to both the PM and MM probes regardless of 
the allele it carries, but it does so more efficiently when it is complementary to 
all 25 bases (bright yellow) rather than mismatching the SNP site (dimmer 
yellow). (b) Attached to each Illumina bead is a 50-mer sequence 
complementary to the sequence adjacent to the SNP site. A single-base 
complementary to the allele carried by the DNA is added and results in the 
appropriately-coloured signal (red or green, respectively).  
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1.4.3 Sanger Sequencing 
Sanger sequencing or chain-termination sequencing has been the 
dominant sequencing technique for several decades. Since its development 
in 1977, it has evolved in several ways, but the key principles 
remained68–73. It is based on the random incorporation of 
deoxyribonucleotide triphosphates (dNTPs) and dideoxyribonucleotide 
triphosphates (ddNTPs) by a DNA polymerase. After incorporation of a 
ddNTP, no nucleotides can be added further due to the lack of a 3’ OH 
group in the ddNTP. By adding these ddNTPs and dNTPs together with a 
DNA polymerase and a primer to a DNA template, a mixture of 
complementary DNA strands of variable length are synthesized. These 
strands of variable length are size-separated using capillary or gel 
electrophoresis. Initially, the ddNTPs were labelled radioactively. Nowadays, 
the four different ddNTPs are linked to unique fluorochromes, enabling the 
combination of all sequencing reactions in one. An overview of the 
technique is provided in Figure 1.10. Sanger sequencing allows high 
quality and long read (> 1000 bp) sequencing, but in terms of large-
scale projects, it cannot compete with second generation sequencing 
techniques69,70,74.  
1.4.4 Next generation sequencing 
Next generation sequencing (NGS), second generation sequencing or 
massively parallel sequencing are three synonyms for novel technologies 
that revolutionized genomics about a decade ago. As depicted by the 
name, they enable relatively cheap generation of enormous amounts of 
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sequencing data. Although several competitors entered initially, Illumina 
dominates the market nowadays.  
 
Figure 1.10. Principles of Sanger sequencing73. 
The standard workflow for Illumina sequencing, can be divided in three 
parts: a library preparation, followed by clonal amplification and sequencing 
(Figure 1.11)51,70,71. The library prep involves DNA fragmentation, followed 
by adapter ligation and enrichment of adapter-ligated DNA fragments. The 
adapter-ligated fragments are clonally amplified by an isothermal bridge 
PCR, resulting in clusters. Contrary to the irreversible chain-termination 
Sanger sequencing, Illumina uses reversible chain-termination sequencing: 
after incorporation and excitation of a fluorescently labelled nucleotide with 
a blocking group, the blocking group and fluorescent dye are chemically 
cleaved and additional nucleotides can be incorporated. As with modern 
Chapter 1 
44 
 
Sanger sequencing, four differentially labelled nucleotides are added 
simultaneously and compete for incorporation in each cycle. Depending on 
the applications and the choice of the user, the number of cycles and 
thus the read lengths can vary, but at this point, the maximum read 
length is limited to 300 bp75.  
Figure 1.11. Basic principles of Illumina sequencing and data analysis76. 
The standard workflow allows for sequencing of entire genomes, but 
this comes at a price, literally. To increase cost-efficiency, several 
techniques have been developed to reduce sequencing to only those 
regions that are of interest. For a limited number of regions/a small 
target size, PCR generated amplicons can be sequenced77. However, at a 
certain point, this becomes a laborious, complex and expensive way of 
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working. To solve this problem, several solutions have been developed. 
One of them is commercialized by Roche Nimblegen and is an in-solution 
based capturing method53. Following standard fragmentation and adapter 
ligation steps, it uses biotinylated oligonucleotide baits complementary to 
the genomic targets to hybridize to genomic DNA. Making use of the 
streptavidin-biotin non-covalent binding, the bound DNA is recovered by 
magnetic streptavidin beads later on, discarding the unwanted genomic 
DNA fragments, and then sequenced. 
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1.5 A short overview of canine hip dysplasia (HD) 
One of the diseases studied in this thesis is HD. In this section, a 
short overview is provided. HD is a common orthopedic disorder in the 
dog. Literally, the term “hip dysplasia” means an abnormal development 
of the hip joint. However, a clearer definition includes the etiopathogenesis 
of HD78: 
“ … varying degree of laxity of the hip joint permitting subluxation 
during early life, giving rise to varying degrees of shallow acetabulum and 
flattening of the femoral head, and finally inevitably leading to 
osteoarthritis.” 
Although the exact etiology of HD is unknown, two primary causes are 
cited: 
- an abnormal degree of joint laxity78 
- a delayed ossification of the bones79,80 
Both result eventually in the development of osteoarthritis. 
The clinical presentation of dogs with hip dysplasia is highly variable. 
Typically, it affects large dogs, but rare cases in smaller breeds and even 
cats have been reported81,82. Clinical symptoms include but are not limited 
to an abnormal gait, bunny hopping and an excessive pelvic swaying 
movement83,84. Hip dysplasia can be the presumptive diagnosis based on 
clinical symptoms, but the definitive diagnose is based on radiographs. 
The most frequently applied technique is called the standard ventrodorsal 
(VD) hip-extended radiograph (Figure 1.12). For this technique, the 
dog is positioned in dorsal recumbency, with the hind limbs in full 
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extension, the femora have to be positioned parallel and are endorotated 
to ensure the patella is projected in the middle of the femur83.  
 
The VD is often used in patients with clinical complaints to confirm 
that the symptoms originate from the hip joint. Frequently, it is also used 
for screening of potential breeding dogs. For that purpose, several 
classification schemes are used worldwide. In Belgium, the scoring system 
Figure 1.12. Positioning of a dog for the standard ventrodorsal hip-extended 
radiograph. 
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of the Fédération Cynologique Internationale (FCI) was adopted. This 
system classifies each dog in five distinct categories (from A to E) 
based on the appearance of the worst of both hips on the radiograph85. 
Dogs with A and B hips are considered non-dysplastic, dogs classified 
from C to E are considered dysplastic85. 
The main aim of the screening of breeding dogs is to reduce the 
prevalence of HD in the population. Unfortunately, even though screening 
has been going on for almost five decades, even the most optimistic 
reports show a very limited improvement86. This can be attributed to 
several factors. First of all, the position of the dog for the VD results in 
a low sensitivity to diagnose laxity of the hip joint and it is that laxity 
which is considered to be the most important primary cause of HD87. This 
would not be that important if the secondary changes (= the 
osteoarthritis) would be readily diagnosed. Unfortunately, most screening 
programs check the hips at an age of 24 months (United States) or 
even younger. A long term follow-up study showed that from all dogs 
that developed osteoarthritis, 78% developed it after two years of age88. 
The screening is thus performed too young to diagnose the secondary 
changes in the majority of the affected animals. Additional complicating 
factors are the unstandardized anesthesia protocols and the low 
interobserver agreement for the diagnosis89–92. 
These issues can be (at least partially) resolved by applying different 
radiographic techniques that allow an accurate assessment of the laxity in 
the hip joint. The most frequently used technique is PennHIP. The 
PennHIP procedure requires three radiographs:  
Chapter 1 
49 
 
- the first one is the standard VD: on this radiograph, only the 
secondary changes are evaluated  
- a compression radiograph: to evaluate the congruency of the hip 
joint 
- a distraction radiograph: to evaluate the laxity of the hip joint 
(more specific, the lateral displacement of the hip joint). 
For both the compression and distraction radiograph, the dog is also 
positioned in dorsal recumbency, but with the hip joints perpendicular to 
the table (called the “neutral” or “standing” position) (Figure 1.13). 
This position allows the accurate diagnosis of hip joint laxity from an age 
of 4 months93,94. An overview of the three radiographs obtained with 
PennHIP is presented in Figure 1.14. Disadvantages of PennHIP are a 
higher exposure to radiation and increased costs due to the two additional 
radiographs. PennHIP requires all veterinarians to go through a certification 
process to ensure the technique is applied correctly. This is of course 
Figure 1.13. Positioning of a dog for the distraction radiograph. 
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positive, but a downside of this certification process is that it limits the 
accessibility for clients as the number of PennHIP certified veterinarians is 
rather limited. Unfortunately, PennHIP or similar techniques have not been 
adopted in any of the screening programs of the three major pedigree 
dogs organizations worldwide. 
Even though several radiographic techniques exist, the fastest progress 
is expected from selection based on genetic information instead of 
selection based on phenotypes86. Our research currently focuses on the 
identification of genetic variation linked to hip dysplasia.  
Screening programs try to reduce the incidence of HD in the next 
generations, but what if a dog is diagnosed with HD? Luckily at that 
point, several treatment options can be chosen from95. The first choice to 
be made is whether conservative or surgical procedures will be used. 
When conservative treatment is chosen, it often involves weight control, 
controlled exercise and when necessary, medication to alleviate pain (e.g. 
NSAIDS). If conservative treatment is not successful or if the indications 
are right, surgical procedures might be preferred. A wide range of surgical 
procedures can be chosen from, each with their specific indications, 
advantages and disadvantages. Irrespectively of the treatment option, 
physio- and hydrotherapy can be used to additionally support the dog and 
improve recovery post-surgery. 
 
Chapter 1 
51 
 
 
A B 
C 
Figure 1.14. An overview of the three radiographs obtained with PennHIP. A. The standard 
ventrodorsal radiographic view. B. The compression radiograph. C. The distraction radiograph. 
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2 Aims and overview 
Dogs take an important place in our society. Whether they are kept 
as working dogs or purely act as companion animals, good health is of 
paramount importance. Unfortunately, the processes that created the dog 
as we know it, inadvertently resulted in genetic diseases in the dog being 
far from rare. Luckily, public awareness has led to mentality changes and 
with the enormous advances in biotechnology the last decade, the 
prerequisites for improvement are available. As discussed in the 
introduction (Chapter 1), health improvement requires a stepwise approach 
that involves recognition, characterization and prioritization of diseases, the 
planning of remedial measures, execution of these plans and evaluation. 
This dissertation focuses on the first aspects involved in this process.  
The study of genetic diseases starts with the characterization of the 
phenotype. This involves the development of diagnostic criteria, but also 
gaining knowledge on the importance of the disease. As a demonstration 
of some of the difficulties that might arise, we focus in chapter 3 on 
canine hip dysplasia (HD). Typically associated with HD are low 
agreements between assessors and diagnostic tools and prevalence 
estimates that vary widely. 
Deciding which approach should be used to study genetic diseases, 
depends on several factors: the tools that are available, the disease 
characteristics (both within the species studied and in other species), 
previous experiences and the financial resources. Based on the success in 
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human medicine, the attention was drawn towards WES. In chapter 4 and 
5, the development of three WES enrichment designs is discussed and 
their performance is compared. The development of novel wet lab 
techniques often requires the development or optimization of software tools 
to analyze the data as well. In chapter 6, the R-package “Mendelian” is 
discussed. This package was specifically designed to enable heuristic 
filtering of sequencing variants obtained in WES experiments in the dog in 
search for causal genetic variation. As a demonstration of the power of 
WES and “Mendelian”, two coat colour loci in the Labrador Retriever 
were reconfirmed. Non optimal sample selection does not necessarily 
impede the discovery of causal mutations, but optimizing sample selection 
can increase the efficiency tremendously. To provide guidelines on which 
combination of samples is likely to be the most efficient and what can be 
expected in terms of variant filtering, a variety of case-control study 
designs were evaluated and discussed in chapter 7.  
Closely associated with the phenotypical prevalence estimates are the 
DNA tests that can be used to determine the allele frequencies of 
disease-causing mutations in the population. The latter however, are more 
accurate as carriers can be recognized and the blurring environmental 
effects are omitted. This is an important step in disease prioritization and 
in defining the optimal strategy for health improvement. Chapter 8 details 
on the results when DNA tests for nine genetic disorders were performed 
in a population of Belgian, Dutch and German dogs. The breed-specific 
differences in allelic frequencies stress the need for health programs that 
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not only focus on the global dog population, but also consider the health 
issues at the individual breed level.  
The final chapter of this dissertation, chapter 9, provides a discussion 
on the present state of WES in the dog and future prospects. While 
acknowledging the pitfalls, the strength of WES and the potential of 
studying canine diseases for both the dog and their human counterparts 
are discussed in detail. 
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3.1 Abstract 
Although the prevalence of canine hip dysplasia (HD) has been the 
subject of a number of published studies, estimates vary widely. This 
study evaluated several possible causes for these differences. Sixty 
Belgian, Dutch and German veterinarians were asked to submit all hip 
radiographs obtained for screening purposes (irrespective of HD status) 
over a 2-year period, resulting in a database of 583 dogs. Each set of 
radiographs was accompanied by information on the reason for screening 
(breeding soundness examination, clinical complaint, assistance dogs, or 
other reasons), and dog breed, date of birth and age. 
Dog positioning exerted an effect at multiple levels. The agreement 
among different observers regarding correct or incorrect positioning was 
limited and incorrect positioning itself reduced the interobserver agreement 
for radiographic hip conformation. Dysplastic dogs were more commonly 
positioned incorrectly than non-dysplastic dogs. The clinical complaint 
population had a high prevalence of dysplastic dogs (> 70%) compared 
with the breeding population (11%) and the assistance dogs (6%). The 
prevalence of dysplastic dogs varied widely between breeds (16.7 – 
71.4%). Dogs diagnosed with dysplasia were signiﬁcantly older than dogs 
considered healthy (p = 0.001) and dogs classiﬁed as borderline 
dysplastic (p = 0.035). Interobserver agreement for hip conformation was 
moderately low, resulting in > 7% variation in prevalence estimates for 
dysplasia. 
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To assess the potential effect of the referring veterinarian performing 
the radiographic procedure, a second database (the database of the 
National Committee for Inherited Skeletal Disorders) was used. In this 
database, there was a signiﬁcantly lower prevalence of HD among cases 
referred by veterinarians who frequently submitted hip-extended radiographs 
for evaluation (p = 0.002) compared to those who refer less frequently. 
However, this was likely to be selection bias, as radiographs that were 
from dogs suspected to be dysplastic were not submitted by frequent 
senders.  
Chapter 3 
69 
 
3.2 Introduction 
Canine hip dysplasia (HD), ﬁrst described in 1935, is a multifactorial, 
polygenetic disorder mainly characterized by hip joint laxity, which 
eventually leads to degenerative joint disease (DJD)1. This debilitating 
disorder is a common reason for euthanasia in dogs2. 
A broad spectrum of clinical and radiographic techniques can be used 
to diagnose HD3. The most frequently applied technique is the standard 
ventrodorsal (VD) hip-extended radiograph. Three other radiographic 
methods used to identify laxity are the PennHIP distraction index, the 
subluxation index and the dorsolateral subluxation score4–6. 
To reduce the prevalence of this disease, three major pedigree dog 
organizations, the Fédération Cynologique Internationale (FCI), the 
Orthopedic Foundation for Animals (OFA) and the British Veterinary 
Association/Kennel Club (BVA/KC), use VD hip-extended radiographs to 
grade the hips of potential breeding dogs7. In Belgium, canine pelvic 
radiographs are evaluated by the National Committee for Inherited Skeletal 
Disorders (NCISD). For certain breeds, screening for HD is obligatory 
and affected dogs are restricted or prohibited from breeding. To assess 
whether screening has beneﬁcial effects, prevalence must be estimated. 
However, several studies reported variable prevalences across and within 
breeds8–11. 
Radiographic positioning has been shown to affect the appearance of 
anatomical structures12, so it follows that incorrect positioning could perhaps 
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reduce interobserver agreement. Based on clinical experience, we 
hypothesized that dogs with HD would be positioned incorrectly more 
frequently than those without HD. We also hypothesized that the 
prevalence of HD would change depending on the reason for screening 
(breeding soundness examination, clinical complaint, assistance dogs, or 
other reasons), with the highest prevalence found in those dogs presented 
with clinical signs of hip disease. Additionally, selection bias has been 
reported to affect the prevalence of HD when radiographs submitted for 
oﬃcial evaluation are investigated9, and we aimed to determine whether 
the number of radiographs sent by each veterinarian would be an 
independent risk factor for the diagnosis of HD. Dysplastic dogs are older 
than their healthy counterparts13 and there are breed differences in 
prevalence10. Positioning can also affect diagnostic outcome and VD 
radiographs are typically associated with a low interobserver agreement on 
the presence or absence of HD14–16. 
The aim of this study was to evaluate the effect of the following 
parameters, which could potentially inﬂuence estimates of HD prevalence: 
(1) radiographic positioning; (2) the reason for screening; and (3) the 
referring veterinarian. 
3.3 Materials and methods 
Dogs. For the purposes of this study, 60 veterinarians were asked to 
send in every hip radiograph obtained for screening purposes (irrespective 
of HD status) during a 2-year period. This resulted in a sample set of 
583 Belgian, Dutch and German dogs. 
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Approval from the local ethical (Faculty of Veterinary Medicine, Ghent 
University, Belgium) and deontological (Federal Public Service Health, 
Food Chain Safety and Environment, Brussels, Belgium) committees was 
granted (EC2010_171, 28 January 2011 and EC2011_193, 20 January 
2012). 
Radiographic evaluation. Standard VD radiographs (n = 583) were 
independently evaluated by two veterinarians experienced in the ﬁeld of 
HD and ﬁlm reading. The following questions were answered: (1) is the 
dog correctly positioned to assess hip conformation (yes or no)?; (2) 
based on the presence of laxity, incongruency, bony remodelling and/ or 
other degenerative changes on the more severely affected hip, would you 
consider the dog healthy, borderline or dysplastic?17,18; (3) if HD has 
been diagnosed, was the diagnosis based on the presence of degenerative 
joint disease (DJD), laxity (based on sub/luxation) or a combination of 
both, assessed separately for both hips17,18? Positioning was assessed 
according to the OFA, BVA/KC and FCI guidelinesa, which required that 
the pelvis was not tilted, the femurs were parallel and the patellae were 
centered on each femur. Radiographic examples of each subjective 
assessment are provided in Figure 3.1. 
                       
a See: http://www.offa.org/hd_procedures.html, 
http://www.bva.co.uk/uploadedFiles/Content/Canine_Health_Schemes/hip-
dysplasia-scheme-procedure-notes-july-2015.pdf, 
http://www.dkk.dk/xdoc/120/46-2009-annex1.pdf (accessed 27 July 2015) 
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Reason for screening. For each radiograph, veterinarians were asked to 
provide details of the reason for screening (breeding purpose, clinical 
complaint, assistance dogs, other reasons), breed, date of birth and age. 
Referring veterinarians. To assess the potential effect of the referring 
veterinarian performing the radiographic procedure, a second database (the 
database of the National Committee for Inherited Skeletal Disorders) was 
used. This database contains the radiographic results from breeding dogs 
evaluated between January and September 2012 (n = 876). Based on 
the frequency with which radiographs were submitted, two groups were 
created. Frequent senders submitted > 20 radiographs during this period, 
while less frequent senders submitted ≥ 20 radiographs. 
Statistical analysis. Agreement between observers regarding positioning 
(correct/incorrect) and hip conformation (healthy/borderline/dysplastic) 
was evaluated for each radiograph (n = 583) using Cohen’s kappa 
(κ), applying quadratic weighting for hip conformationb. Cut-offs were 
used as initially reported19. Group comparisons were made using chi-
square tests (χ2). 
 
 
                       
b See: http://vassarstats.net/kappa.html (accessed 27 July 2015). 
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Figure 3.1. Radiographic assessment of positioning. (A) Left, correct 
positioning; right, incorrect positioning. (B) Hip conformation. Left, healthy; 
centre, borderline; right, dysplastic. (C) Reasons for the diagnosis of dysplasia. 
Left, DJD; centre, laxity; right, both.
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To investigate the effects of variables rather than observers, only those 
radiographs where both assessors were in agreement were used. Further 
details, including sample sizes, are provided in Figure 3.2. The effect of 
positioning on interobserver agreement for conformation was assessed using 
Cohen’s κ with quadratic weighting (n = 427). The effects of 
conformation were analyzed (n = 341), and the reasons for the 
diagnosis of HD, stratiﬁed by positioning, were assessed (n = 323 for 
DJD, n = 321 for laxity, n = 318 for both; χ2). In correctly positioned 
dogs, the effect of the reason for screening was assessed (n = 215). 
In the NCISD population (n = 876), the effect of the frequent and 
less frequent senders was assessed (χ2). To assess the possible effects 
of positioning, the difference between the right and left Norberg angles 
was calculated and a comparison between the groups of frequent and 
infrequent senders was made (independent Student’s t test). 
Additionally, in correctly positioned dogs from the original population (n 
= 583), the effect of breed was assessed in the ﬁve breeds with the 
highest sample size (n = 161). Age distribution was compared using 
Kruskal–Wallis tests in correctly positioned dogs (n = 268), in the 
reason for screening subgroup (n = 211) and in the breed subgroup (n 
= 145). Post-hoc comparisons were performed using Mann–Whitney U 
tests. For normally distributed data, mean ± standard deviation was 
calculated and for nonparametric data, median and range were calculated. 
Statistical signiﬁcance was set at p < 0.05 using a commercially available 
software package (SPSS version 21, IBM). 
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3.4 Results 
The distributions of hip conformations, as independently assessed by 
each observer, were signiﬁcantly different (p < 0.001; Figure 3.3). The 
general agreement between observers was approximately 80% for 
conformation and approximately 70% for positioning (Table 3.1). The 
interobserver agreement on conformation was higher in correctly positioned 
dogs than in incorrectly positioned dogs (Table 2). A signiﬁcant 
difference in hip conformation was demonstrated when correctly and 
incorrectly positioned dogs were compared (p = 0.003). The prevalence 
of HD in the incorrectly positioned group was 47.2% and 24.3% in 
correctly positioned dogs (Figure 3.4). Only dysplastic dogs with DJD 
were more frequently malpositioned than dogs without DJD (p = 0.014; 
Table 3). No signiﬁcant differences in the frequency of malpositioning 
were found in dogs with DJD and laxity (p = 0.114) or in dogs with 
laxity alone (p = 0.292; Table 3). 
Table 3.1 
Overall interobserver agreement. 
 Agreement κ ± SE 95% CI Strength of agreement 
Conformation – alla,b 0.789 0.827 ± 0.014 0.800–0.854 Almost perfect 
Conformation – agreeda,c 0.799 0.833 ± 0.015 0.804–0.863 Almost perfect 
Positioning 0.732 0.318 ± 0.043 0.233–0.403 Fair 
SE, standard error; CI, conﬁdence interval. 
a    κ with quadratic weighting. 
b    All dogs (n = 583). 
c  Dogs where both assessors agreed on correct or incorrect positioning (n = 427). 
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Based on the reason for screening, the highest prevalence of HD was 
found in the clinical complaint population (n = 42/58, 72%), followed 
by breeding dogs (n = 10/94, 11%) and assistance dogs (n = 4/63, 
6%; Figure 3.5). 
Figure 3.2. Sample sizes used for statistical analysis. 
 
 
Table 3.2 
The effect of radiographic positioning on interobserver agreement. 
 
  Correct positioning    Incorrect positioning   
Agreement κ ± SE 95% CI  Agreement κ ± SE 95% CI 
Conformationa,b 0.825 0.859 ± .008 0.843 - 0.876  0.680 0.718 ± 0.063 0.596 – 841  
SE, standard error; CI, conﬁdence interval. 
a    κ with quadratic weighting. 
b  Dogs where both assessors agreed on correct or incorrect positioning (n = 427). 
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Table 3.3 
Effect of degenerative joint disease (DJD), laxity or both on radiographic 
positioning among dogs for which both observers agreed on positioning and 
radiographic assessment. 
 
 
  Positioning  Total p 
  Incorrect 
n (%) 
Correct 
n (%) 
  
DJD No 42 (87.5) 266 (96.7) 308  
 Yes 6 (12.5) 9 (3.3) 15 0.0141 
 Total 48 275 323  
Laxity No 38 (84.4) 249 (90.2) 287  
 Yes 7 (15.6) 27 (9.8) 34 > 0.052 
 Total 45 276 321  
Both No 37 (86.0) 257 (93.5) 294  
 Yes 6 (14.0) 18 (6.5) 24 > 0.052 
 Total 43 275 318  
1 For dogs with DJD, the proportion positioned incorrectly is signiﬁcantly higher than the proportion positioned 
correctly. 
2 For dogs with laxity alone or laxity and DJD, there was not a statistically significant difference in the proportions 
positioned incorrectly and correctly. 
 
 
In the NCISD population, the prevalence of HD was almost twice as 
high in radiographs from veterinarians who submitted radiographs less 
frequently than those who were frequent senders (p = 0.002; Figure 
3.6). When the difference between left and right Norberg angles was 
compared between the less frequent senders and frequent senders, no 
signiﬁcant differences were found when only healthy and borderline dogs 
were considered (p = 0.171, frequent senders = 1.06 ± 3.34, infrequent 
senders = 0.71 ± 3.66) and when all dogs were considered (p = 
0.122, frequent senders = 1.20 ± 4.28, infrequent senders = 0.74 ± 
4.44), respectively. 
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Figure 3.3. Comparison of hip conformation for both observers (p < 0.001). Of 583 
dogs, assessor 1 determined that 335 dogs were healthy, 62 were borderline and 186 
were dysplastic. Assessor 2 determined that 341 dogs were healthy, 100 were 
borderline and 142 were dysplastic.  
 
 
Figure 3.4. The effect of radiographic positioning on hip conformation (p = 0.003) 
among dogs for which both observers agreed on positioning (n = 341). 
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Figure 3.5. Distribution of healthy, borderline and dysplastic hips in the breeding 
population (BP), assistance dog population (ADP) and clinical complaint population 
(CCP; p < 0.001). 
Figure 3.6. Comparison of the group of frequent senders with the group of less 
frequent senders with respect to hip conformation (p = 0.002). 
Based on breed, prevalence estimates of HD ranged from 16.7% to 
71.4% (Figure 3.7). The highest prevalence was in Bernese mountain 
dogs, while the lowest prevalences were in Golden retrievers and German 
shepherds (Figure 3.7). Dysplastic dogs (median, 2 years 1.6 months; 
range 5.9 months – 11 years 8.8 months) were signiﬁcantly older than 
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healthy dogs (median, 1 year 2.3 months; range 3.7 months – 8 years 
2.3 months; p < 0.001) or borderline dogs (median, 12.9 months; 
range 7.2 months – 5 years 3.5 months; p = 0.035). Assistance dogs 
(median, 12.7 months; range 5.9 months – 2 years 8.7 months) were 
signiﬁcantly younger than the breeding population (median, 1 year 6.1 
months; range 5.2 months – 6 years 9.2 months; p = 0.001) and the 
clinic population (median, 2 years 4.8 months; range 4.2 months – 11 
years 8.7 months; p = 0.006). There was no signiﬁcant difference in 
age between the most common ﬁve breeds (p = 0.227). The median 
age (range) was 1 year 11.8 months (10.4 months – 6 years 1.8 
months) for the Bernese mountain dog, 1 year 2.7 months (4.5 months 
– 6 years 0.4 months) for the Border collie, 1 year 0.6 months (3.7 
months – 11 years 6.5 months) for the German shepherd, 1 year 1.2 
months (5.9 months – 6 years 11.4 months) for the Golden retriever 
and 1 year 0.4 months (8.2 months – 8 years 3.6 months) for the 
Labrador retriever. 
3.5 Discussion 
The three major organizations responsible worldwide for canine HD 
screening (the OFA, BVA/KC and FCI) require that correct positioning is 
used for all radiographs submitted for evaluation. This means that the 
pelvis should not be tilted, the femurs should be parallel and the patellae 
should be centered on each femur. Although these criteria are quite clear, 
the decision to accept or refuse a radiograph is subjective. Good 
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positioning is important, since it can affect the radiographic assessment of 
pelvic anatomical structures12.  
Figure 3.7. Distribution of dysplastic dogs in ﬁve different breeds. 
Our study evaluated this subjective assessment and demonstrated that 
positioning affected prevalence estimates of HD in a number of ways. 
Firstly, correct positioning increased interobserver agreement (Table 3.2), 
conﬁrming the ﬁndings of an earlier report16. Secondly, dogs with HD 
were malpositioned more frequently than dogs without HD (Figure 3.4) 
and this effect was particularly apparent in dogs with DJD (Table 3.3). 
It is possible that if there are clear signs of HD, veterinarians might not 
consider that correct positioning is necessary to make the diagnosis. 
However, our clinical experience supports the claim that dogs with HD 
and especially those with DJD are diﬃcult to position correctly, as they 
have a reduced ability to extend the hip joint completely. A third 
observation was that there was limited interobserver agreement (κ = 
0.32) as to whether or not a dog was correctly positioned (Table 3.1). 
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This ﬁnding is comparable with an earlier report, where agreement was 
unanimous in only 24% of radiographs15 and is probably attributable to the 
subjective nature of the evaluation. The second and third observations 
affect widely quoted HD prevalence estimates reported by NCISD and 
similar organizations worldwide10,11. However, one of the prerequisites for 
the submission of radiographs is correct positioning. Although this is a 
reasonable requirement and should increase interobserver agreement, it is 
a subjective measure that varies between individual observers. This could 
lead to the exclusion of some dysplastic dogs and therefore 
underestimates of the prevalence of HD. We suggest that assessments 
should be performed by at least two experienced observers and an 
objective assessment of positioning should be used, such as the one 
suggested by Verhoeven et al. (2010). Since only correctly positioned 
radiographs should be evaluated, veterinarians should aim for optimal 
positioning, even for dogs with clear signs of HD. 
Our study demonstrated an effect on HD prevalence exerted by the 
reason for screening, which agreed with our expectations. In the clinical 
complaint population, over 70% of dogs had HD, while in breeding and 
assistance dogs HD prevalence was 11% and 6%, respectively (Figure 
3.5). The difference in prevalence between assistance dogs and breeding 
dogs might be attributable to age, since assistance dogs were signiﬁcantly 
younger. However, it could also represent a true difference in prevalence. 
As assistance dogs are screened for performance, the selection of 
breeding stock for assistance dogs might be subject to stringent 
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orthopaedic screening criteria, resulting in a lower prevalence of HD in the 
progeny. 
NCISD and similar committees worldwide often provide data that are 
used to estimate prevalence, although some reports suggest they might 
underestimate the true prevalence of HD9. One possible reason is the 
prerequisite for correct positioning, but a second reason is selection bias, 
as veterinarians tend to withhold radiographs from affected dogs from 
oﬃcial screening9. In our study, we found twice as many dogs in the 
group submitted by less frequent senders were dysplastic, even though 
there were no signiﬁcant differences in positioning between frequent and 
less frequent senders (Figure 3.6). One reason for this could be that 
frequent senders perform pre-screening and withdraw radiographs from 
breeding animals from oﬃcial screening. As this adversely affects 
prevalence estimates, the selective withdrawal of radiographs should be 
discontinued. 
This study examined the effects of age and breed on HD prevalence. 
Older dogs had a signiﬁcantly higher prevalence of HD, which has been 
previously reported and is in agreement with clinical expectations13. In our 
breed analysis, we noticed that the prevalence of HD in German shepherd 
dogs was lower than or equal to that in Labrador retrievers and Golden 
retrievers, respectively (Figure 3.7). This might indicate that German 
shepherd dogs are less commonly affected by HD, although this 
contradicts earlier reports that the German shepherd dog had the highest 
or second highest prevalence of dysplasia10,20. However, our results should 
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be interpreted with care, as they could have been affected by the 
relatively low sample size. Although this study focused on purebred dogs, 
two other studies identiﬁed dysplastic dogs in equal proportions among 
mixed breeds20,21, emphasizing the importance of HD as a problem in the 
general canine population. 
There was at least 7% difference between observers in the number of 
dogs diagnosed as dysplastic in this study (Figure 3.3). This is also 
reﬂected in the moderately low interobserver agreement of 79%, since if 
interobserver agreement was achieved purely by chance, it would occur in 
approximately 33% of cases. In one study of FCI-classiﬁcation, an even 
lower interobserver agreement of 43.6% was found14. 
All results in this study are based on the standard VD view used 
worldwide for oﬃcial HD screening. However, the technique lacks 
sensitivity in the identiﬁcation of laxity in the hip joints, because of the 
positioning necessary for VD views to be obtained22. The dorsolateral 
subluxation score, the subluxation index and the PennHIP distraction index 
are diagnostic techniques that can be used to identify passive hip joint 
laxity. The PennHIP distraction index has been studied extensively and is 
used frequently. Comparisons with both OFA scores and the Norberg 
angle, a measure of laxity on VD radiographs, show that the diagnosis of 
laxity can easily be missed on this view23,24. This suggests that the 
prevalence of HD, based on the standard VD view, could underestimate 
true prevalence. 
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The use of chemical restraint and the drug protocol used can inﬂuence 
hip laxity and thus hip grading25,26. Seasonal variation has also been 
reported to inﬂuence hip score27. When the presence of caudolateral 
curvilinear osteophyte (Morgan Line, ML) was included as an additional 
sign of osteoarthritis in the reading protocol, the prevalence of HD 
increased from 53% to 73% and 41% to 69% in Golden retrievers and 
Rottweilers, respectively9. In this study, in agreement with OFA and FCI 
criteria (G.G. Keller and A.C.C. Criel, personal communication), ML 
alone was not considered to be suﬃcient to declare a dog dysplastic. 
Only the BVA/KC includes the ML in their scoring systems28. This results 
in an effect of scoring system used on the prevalence of HD reported. A 
recent publication compared the OFA scoring system with a Canadian 
system29 (the Ontario Veterinary College Hip Certiﬁcation Program), and 
although agreement between systems was acceptable overall, there were 
variations in categorizations for 4/37 (11%) dogs that underwent 
evaluation, depending on the scoring system used. 
3.6 Conclusions 
The prevalence of HD was diﬃcult to estimate, as numerous factors, 
including the reason for screening, breed and age of dogs, inﬂuenced our 
results. Efforts should be made to correctly position every dog for 
radiographic evaluation and only correctly positioned dogs should be 
included in studies of HD prevalence. Since interobserver agreement in 
this study was only fair, ﬁlm reading by several experienced observers is 
encouraged. There was a signiﬁcantly lower prevalence of HD among 
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cases referred by veterinarians who frequently submitted hip-extended 
radiographs for evaluation compared with those who submitted radiographs 
less frequently. 
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4.1 Abstract 
Whole exome sequencing is a technique that aims to selectively 
sequence all exons of protein-coding genes. A canine whole exome 
sequencing enrichment kit was designed based on the latest canine 
reference genome (build 3.1.72). Its performance was tested by 
sequencing 2 exome captures, each consisting of 4 pre-capture pooled, 
barcoded Illumina libraries on an Illumina HiSeq 2500. At an average 
sequencing depth of 102x, 83 to 86% of the target regions were 
completely sequenced with a minimum coverage of five and 90% of the 
reads mapped on the target regions. Additionally, it is shown that the 
reproducibility within and between captures is high and that pooling four 
samples per capture is a valid option. Overall, we have demonstrated the 
strong performance of this WES enrichment kit and are confident it will be 
a valuable tool in future disease association studies. 
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4.2 Introduction 
Since the first reported study on Whole Exome Sequencing (WES) in 
200711, well over 2000 papers have been published applying this 
technique (PubMed search: “exome sequencing”). WES is a cost-
efficient approach to selectively sequence the coding regions of the 
genome. This approach allows to identify most functional variation without 
the high costs associated with whole genome sequencing (WGS). 
Unfortunately, predesigned and validated kits are only commercially 
available for human and mouse. Scientific reports of WES on other 
animals are scarce2–4. This is unfortunate, as for example the dog is an 
excellent animal model for comparative disease genetics5. To fill the gap, 
we designed a canine exome sequencing kit (based on build 3.1.72) 
and tested its performance using Illumina Sequencing. 
4.3 Results 
Design. We designed a canine whole exome sequencing enrichment kit 
based on the latest canine reference genome (Broad CanFam 3.1.72)6. 
This design was based on the combination of the Ensembl Genes, the 
RefSeq Genes and the mRNA annotation. Additionally, known microRNAs 
were added from miRBase. After merging overlapping regions, the total 
size of the design was 52,876,195 bp (≈ 2% of the genome) divided 
over 203,059 regions. Based on our design, capturing baits were 
developed by Roche Nimblegen to target the specific regions. To avoid 
too much off-target sequencing, the most stringent setting was chosen for 
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the baits design, allowing only unique matches from each bait to the 
reference genome.  
Performance: coverage and specificity. To assess the performance of 
the WES enrichtment kit, two exome captures were done, each consisting 
of four pooled samples. Sequencing depth, coverage of targeted regions 
and targeted bases and specificity were assessed for every sample. The 
results are reported for a minimum coverage of one and five (as five 
was the threshold used for variant calling). Each capture library was 
sequenced in one Illumina HiSeq 2500 lane. The number of raw reads 
generated per sample varied between 74,657,388 and 111,624,766. After 
quality trimming, mapping and duplicate read removal, between 87% and 
90% of the reads were retained (Table 4.1). The average sequencing 
depth overall was 102x and ranged from 82.6x to 125.1x (Table 4.1).  
Table 4.1 
Statistics for exome sequencing eight dogs. 
Sequencing reads 
Sample Total Mapped Duplicate Remaining Remaining 
(%) 
Sequencing  
depth (x) 
1 82,574,410 77,392,469 4,820,648 72,571,821 87.9 93.0 
2 74,657,388 69,542,653 4,518,820 65,023,833 87.1 82.6 
3 90,534,096 83,841,822 4,680,806 79,161,016 87.4 102.0 
4 77,786,110 72,147,586 4,457,341 67,690,245 87.0 87.1 
5 111,624,766 108,781,536 9,882,797 98,898,739 88.6 125.1 
6 96,041,166 93,261,066 8,278,081 84,982,985 88.5 106.9 
7 103,290,412 100,440,603 8,653,736 91,786,867 88.9 116.7 
8 86,094,438 83,226,207 5,926,249 77,299,958 89.8 99.3 
 
Overall, an average of 92% of the regions were covered by at least 
one read and 90% by at least five reads. At a minimum coverage of 
one, 89 to 90% of the regions in our design, were completely covered. 
Chapter 4 
96 
 
83 to 86% of the regions were completely covered when a minimum 
coverage of five was applied (Figure 4.1). A clear relationship exists 
between the percentage of each region being sequenced and the 
proportion of total regions being sequenced (Figure 4.1). On average, a 
minimum coverage of five was not consistently reached throughout the 
entire region for 15% of the regions (Table 4.2). However, for only 8% 
of the regions on average, the maximum coverage never reached five 
(Table 4.2). 
 
Figure 4.1. Relation between the proportion of each region being sequenced and 
the total amount of regions sequenced (%). For each individual region per sample, 
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the percentage of the region being sequenced at a minimum coverage of five, 
was calculated. On average 85% of the regions were completely sequenced. This 
number increased to 87% of the regions being sequenced for at least 90%. 
Around 90% of the regions were being sequenced for at least 60%. 
 
Table 4.2 
Regions with a coverage below 5. 
Sample 
Regions with minimum  
coverage < 5x (%) 
Regions with maximum 
coverage < 5x (%) 
1 31,604 (15.56) 16,330 (8.04) 
2 33,167 (16.33) 17,042 (8.39) 
3 30,122 (14.83) 15,800 (7.78) 
4 34,655 (17.07) 17,831 (8.78) 
5 28,250 (13.91) 14,733 (7.26) 
6 28,979 (14.27) 14,824 (7.30) 
7 28,487 (14.03) 14,696 (7.24) 
8 30,224 (14.88) 15,465 (7.62) 
 
Table 4.3 
Coverage of targeted base pairs. 
 
 
Sample % of target bp covered (> 1x) % of target bp covered (> 5x) 
1 93.15 89.96 
2 92.90 89.54 
3 93.22 90.24 
4 92.82 89.15 
5 93.52 90.63 
6 93.66 90.71 
7 93.53 90.63 
8 93.56 90.53 
The second and third column show the percentage of base pairs from the design of 52,876,195 basepairs with a coverage of at least one and five, 
respectively, within each sample.  
 
When looking at the coverage of targeted bases instead of regions, 
93 to 94% ( 49 Mb) of the targeted bases ( 53 Mb) were 
covered at least once and 89 to 91% were covered at least five times 
(Table 4.3). We also assessed the specificity (reads on target/total 
number of reads). With an average overall specificity of 90%, off-target 
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sequencing is rather small and comparable with earlier reports7. The 
specificity was also assessed in every single sample per chromosome. For 
all eight samples, results were similar, with the highest specificity on 
average found on chromosome nine (94.05%) and the lowest specificity 
found on average on chromosome 22 (84.09%). Per chromosome 
specificity is available in Supplementary Table S4.1.  
Performance: reproducibility. The reproducibility within and between 
captures was checked by comparing the amount of targeted bases and 
regions that are sequenced at least once and five times in every single 
sample. Overall, from the  53 Mb target base pairs, 48,141,464 base 
pairs (91.0%) were sequenced at least once in all eight samples. We 
also assessed how many base pairs were never sequenced. Overall, 
2,313,892 base pairs (4.4%) were never covered. Overall, the remaining 
4.6% of the total target base pairs are being sequenced variably. 
Comparing the four samples within each capture, we found that 
48,333,432 (91.4%) or 48,663,244 (92.0%) base pairs were common 
and 2,816,548 (5.3%) or 2,553,759 (4.8%) base pairs were never 
sequenced. A similar analysis was conducted for a coverage of five. For 
all eight samples, 46,236,131 base pairs (87.4%) were sequenced 
consistently with a minimum coverage of five and 4,078,886 base pairs 
(7.7%) never reached a coverage of five. 46,439,217 (87.8%) or 
47,102,104 (89.1%) and 4,572,396 (8.6%) or 4,216,408 (8.0%) 
base pairs were common within each pool reaching a coverage of at least 
five or never reaching a coverage of five, respectively.  
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The regions in common were also assessed for a coverage of 1 and 
five. From the 203,059 regions, overall, 4,791 (2.4%) regions were 
never sequenced and 176,645 (87,0%) were consistently covered at 
least once. Within each pool, 177,664 (87.5%) or 179,463 (88.4%) 
regions were common and 6,620 (3.3%) or 5,722 (2.8%) regions 
were never sequenced. For a coverage of five, 11,691 regions (5.8%) 
were consistently not sequenced sufficiently and 160,366 (79.0%) regions 
were. This results in 31,002 (15.3%) of the regions being variably 
sequenced. Within each pool for a coverage of five, 162,312 (79.9%) or 
167,830 (82.7%) reqions were sequenced and 13,484 (6.6%) or 
12192 (6.0%) regions were not. The non-covered base pairs and 
regions are probably a consequence of the chosen stringency when baits 
were designed as only unique matches were allowed. A table containing 
these annotated 11,691 regions is available on request. 
Sample pooling. Pooling several samples together prior to capturing is 
common practice, mainly to reduce cost. Of course, pre-capture pooling 
should only be done when it does not significantly decrease the 
enrichment performance. To check the effect of pre-capture pooling, we 
created subsets containing 25% randomly chosen reads out of the total 
number of reads in the combined output of the four samples per capture. 
The rationale is to simulate samples as if they were not barcoded and as 
if the DNA strands presented to the capture baits are from one sample. 
A random subset of 25% needs to be taken to reduce the total number 
of reads to a number comparable to the number of reads in the 
individual barcoded samples. Per pool, ten subsets were created, resulting 
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in a total of twenty new samples. Comparing the number of regions that 
are completely covered at least once in the subsets and the original 
samples, an average of 687 and 684 additional regions ( 0.3%) were 
covered in the subsets of pool one and two, respectively. An average of 
119,097 and 131,774 additional target base pairs were covered at least 
once in the respective subsets, which represents 0.2% of the  53 Mb 
design. At a minimum sequencing depth of five, an average of 1,705 
(0.8%) and 1,468 (0.7%) additional completely covered regions and an 
additional 174,070 (0.3%) and 164,522 (0.3%) base pairs were 
covered for pool one and two, respectively. The average specificity 
increased from 90.85% to 91.48% and from 89.86% to 90.73% in both 
pools, respectively. Based on these results, we conclude that pre-capture 
pooling of samples is a valid option as the effect on the different 
performance parameters is minimal. The exact number of samples that can 
be pooled, depends on a cost-benefit assessment. 
Variant calling. Finally, we also called variants using a probabilistic 
variant caller. The number of non-reference variants called per sample, 
ranged from 55,683 to 60,576 and from 62,117 to 67,890 with the 
“require presence in both forward and reverse reads” setting being applied 
or not, respectively (Supplementary Table S4.2). Applying this setting 
might exclude variants at the boundaries of the targeted regions, however 
it decreases the amount of erroneous variants8.  
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4.4 Discussion 
This study is the first to report on the performance of an exome kit 
designed for the dog on the latest annotation (CanFam 3.1.72). With on 
average 90% of the regions and 90% of the bases covered five times, a 
high amount of the targeted regions is captured, without too much off-
target sequencing as the specificity is 90%. The reproducibility within and 
between captures is high. Additionally, the results indicate that pooling four 
samples per capture is a valid option as it has only a very limited effect 
on the performance, but substantially reduces the costs. This makes WES 
even more affordable (compared with WGS). Finally, it is demonstrated 
that WES is capable to detect variants within the coding regions. Overall, 
we have demonstrated the strong performance of this WES enrichment kit 
and are confident it will be a valuable tool in future disease association 
studies. 
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4.5 Methods 
Sample collection. Eight blood samples were obtained from a canine 
blood bank available at Ghent University to study genetic disorders9. 
Approval was granted by the local ethical (Faculty of Veterinary Medicine, 
Ghent University, Belgium) and deontological (Federal Public Service 
Health, Food Chain Safety and Environment, Brussels, Belgium) 
committees (EC2013_193).  
Design. The data needed to design the exome kit was downloaded 
from the University Of California Santa Cruz (UCSC) 
(http://genome.ucsc.edu/) table browser (Dog, CanFam3.1)10. From the 
Genes and Gene prediction tracks, RefSeq Genes and Ensembl Genes 
were selected. The output format was a BED file with the setting “exons 
(plus 0 bases at each end)”. From the mRNA and EST Tracks, Dog 
mRNAs and all_mrna were selected respectively. The output format was 
also a BED file with the “blocks plus 0 bases at each end” setting. 
MicroRNA sequence positions were downloaded from miRBase11. Regions 
were merged using bedtools version v2.17.0. The total size of the design 
was 52,876,195 Mb (≈ 2% of the genome) divided over 203,059 
regions. The BED file is available on request.  
Roche Nimblegen WES enrichment kit. Our design was processed by 
the Roche Nimblegen custom design group (Madison, USA). Using an 
SSAHA algorithm, capturing baits were developed based on our design 
and the reference genome of the dog (Canis Familiaris 3.1). Design 
settings for the baits allowed five or fewer single-base insertions, deletions 
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or substitutions between the baits and the genome. Each bait itself was 
only allowed to match one location in the genome to avoid too much off 
target sequencing. Regions under 100 bp were padded to 100 bp to 
increase capturing efficiency. After approval, the baits were generated and 
provided as SeqCap Developer Library. 
DNA extraction. Genomic DNA was extracted with the DNeasy Blood & 
Tissue Kit (QIAGEN) with 100 µl of blood as input. The standard 
protocol was followed with the exception of the final elution step: instead 
of using 200 µl of Buffer AE, only 50 µl was used. The eluate was 
used again to elute a second and third time to increase the 
concentration. The DNA yield was measured with Quant-iTTM Picogreen® 
dsDNA Assay (Life Technologies). 
Sample preparation and sequencing. Extracted DNA was fragmented on 
a Covaris S2 System in a 50µl volume (aim: 300 bp fragments, 
settings: duty cycle: 10%, intensity: 5, cycles per burst: 200, time: 
50s). After shearing, another picogreen assay was performed. Around one 
µg of the fragmented DNA was used as input for the library preparation. 
Samples were end repaired, A-tailed and ligated with TruSeq adapters 
using the reagents from the NEBNext DNA Library Prep Master mix set 
for Illumina (New England Biolabs) according to the manufacturer’s 
protocol. AMPure XP beads (Beckman Coulter) were used for selection 
of fragments with an insert size around 300 bp. One µl of the ligated 
product was subsequently amplified in an enrichment PCR (10 cycles) for 
library quality assessment as recommended in the ‘SeqCap EZ Library SR 
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User’s Guide’ (Nimblegen, Roche). Thereafter, the pre-capture LM-PCR 
was performed on the samples for 8 cycles as prescribed in the SeqCap 
EZ library protocol. The concentration of each PCR product was 
determined using Quant-iTTM Picogreen® dsDNA Assay (Life 
Technologies). Two times four samples were equimolarly pooled to obtain 
a total DNA input of 1250 ng. The pooled library was hybridized for 67-
68 hours with the baits (SeqCap Developer Library). The hybridized 
library was washed and the captured and pooled DNA was recovered. 
After a final amplification (LM-PCR, 18 cycles), the quality of the library 
was checked using the High Sensitivity DNA chip (Agilent).  
QPCR. To check the fold enrichment after capturing, a qPCR is 
performed as a final quality control step before sequencing. We chose to 
test five loci. Primer one is the standard primer provided by Roche 
Nimblegen (NSC-0237). The other four primers were designed using 
NCBI Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/)12. 
Sequences are available in Supplementary Table S4.3. The amplification 
efficiency of each primer was determined by qPCR. One µl of the 
following template DNA quantities were added to each reaction: 20 ng, 10 
ng, 5 ng, 2.5 ng and 1.25 ng. Each reaction was performed in triplicate. 
Efficiencies E were calculated with the following formula: E = 10(–1/slope of 
standard curve) and are mentioned in Supplementary Table S4.3. To assess 
the fold enrichment for both pools of four samples, a qPCR was 
performed according to the instructions from Roche Nimblegen. Fold 
enrichment was calculated using the following formula: (Edelta-Ct) with 
delta-Ct being the difference in threshold cycle between the library prior 
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and post capturing. The average fold enrichment was well over the tenfold 
threshold suggested by Roche Nimblegen.  
Sequencing. The two pools were sequenced on two different lanes in 
two different runs on a HiSeq 2500 PE 100 bp.  
Data-analysis. Data-analysis was performed using the CLC Genomics 
Workbench (Version 6.5.1, CLC Bio, Aarhus, Denmark). Data was 
trimmed with the following settings: ambiguous trim = no, quality trim = 
yes, quality limit = 0.05, use colourspace = no, create report = yes, 
also search on reversed sequence = yes, save discarded sequences = 
yes, remove 5’ terminal nucleotides = no, discard short reads = no, 
remove 3’ terminal nucleotides = no, trim adapter list = adapter list 
Illumina, discard long reads = no, save broken pairs = yes. The 
reference genome was downloaded from the UCSC genome browser6. For 
read mapping, the following parameters were used: mismatch cost = 2, 
insertion and deletion cost = 3, length fraction: 0.5, similarity fraction = 
0.8, global alignment = no, auto-detect paired distances = yes, non-
specific match handling = ignore, output mode = create reads track, 
create report = yes, collect un-mapped reads = yes. Duplicated reads 
were removed with the Duplicate Mapped Reads Removal (Version 1.0 
beta 5) plugin (setting: maximum representation of minority sequence 
(percent) to 20.0). Reads were locally realigned with the following 
settings: realign unaligned ends = yes, multi-pass realignment = 3, 
guidance-variant track = not set, output mode = create reads track, 
output track of realigned regions = yes. Variants were called twice using 
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probability variant detection with the following settings: ignore non-specific 
matches = yes, ignore broken pairs = yes, minimum coverage = 5, 
variant probability = 90.0, required variant count = 2, ignore variants in 
non-specific regions = yes, filter 454/Ion homopolymer indels = no, 
maximum expected variants = 2, genetic code = 1 standard , create track 
= yes, create annotated table = yes. The first variants were called with 
the “require presence in both forward and reverse reads = yes”, the 
second call was run without this setting. 
Effect of pooling. Forward and reverse reads from each pool were 
combined in two large pools. From each pool, ten random subsets were 
created using seqtk version 1.0-r31. Data was analysed using the same 
settings as the real samples.  
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4.7 Supplementary material 
 
Supplementary Table S4.1 
Per sample per chromosome specificity (calculated as mapped reads on target/total number of mapped reads). 
 Specificity per sample (%) 
Chr 1 2 3 4 5 6 7 8 
1 92.23 91.96 92.57 92.26 91.65 91.3 91.20 91.79 
2 91.59 91.29 92.02 91.71 91.01 90.66 90.52 91.10 
3 89.48 89.41 89.96 89.78 88.43 88.17 87.83 88.59 
4 90.26 90.12 90.64 90.53 89.43 89.05 88.75 89.46 
5 92.82 92.55 93.17 92.8 92.32 91.91 91.82 92.38 
6 92.68 92.46 93.13 92.74 92.26 91.8 91.75 92.44 
7 91.95 91.67 92.24 92.13 91.37 90.92 90.82 91.39 
8 90.28 90.10 90.80 90.44 89.63 89.31 89.12 89.86 
9 94.19 93.88 94.53 94.17 94.22 93.66 93.66 94.11 
10 91.45 91.26 91.88 91.61 90.84 90.49 90.36 90.96 
11 91.06 90.88 91.36 91.19 90.43 90.07 89.88 90.46 
12 91.73 91.53 92.16 91.89 91.17 90.86 90.69 91.35 
13 89.63 89.63 90.18 90.14 88.60 88.50 88.09 88.80 
14 89.98 89.81 90.37 90.29 88.99 88.75 88.42 89.05 
15 91.03 90.83 91.47 91.28 90.31 90.01 89.80 90.40 
16 89.82 89.33 90.31 89.89 88.66 88.59 88.71 89.20 
17 91.99 91.74 92.38 92.12 91.50 91.07 91.00 91.50 
18 92.91 92.63 93.28 92.80 92.44 92.12 92.07 92.66 
19 85.92 86.31 86.69 86.73 84.87 84.63 83.91 84.78 
20 93.36 93.01 93.69 93.12 93.12 92.70 92.74 93.30 
21 91.15 90.93 91.46 91.12 90.43 90.09 90.03 90.54 
22 84.69 84.86 85.38 85.35 83.18 83.21 82.59 83.44 
23 90.41 90.34 90.78 90.77 89.64 89.27 88.96 89.58 
24 92.08 91.89 92.44 92.05 91.55 91.14 91.06 91.68 
25 90.81 90.68 91.29 91.11 90.07 89.85 89.62 90.25 
26 92.22 91.96 92.55 92.19 91.95 91.53 91.34 92.02 
27 92.33 92.01 92.65 92.37 91.98 91.54 91.50 92.06 
28 91.64 91.47 92.02 91.93 91.26 90.77 90.60 91.03 
29 88.01 87.98 88.57 88.75 86.75 86.59 85.97 86.70 
30 92.91 92.66 93.22 93.06 92.70 92.28 92.03 92.57 
31 86.13 86.18 86.75 86.23 84.99 84.57 84.36 85.40 
32 88.97 88.81 89.37 89.57 88.30 88.08 87.72 88.19 
33 91.77 91.67 92.05 92.13 91.20 90.76 90.61 91.05 
34 88.89 88.71 89.31 89.08 87.74 87.52 87.12 87.96 
35 89.14 89.03 89.53 89.41 88.07 87.84 87.42 88.21 
36 92.80 92.67 93.20 93.30 92.20 91.95 91.73 92.04 
37 91.20 91.10 91.62 91.57 90.66 90.26 90.00 90.58 
38 91.20 90.98 91.70 91.16 90.46 90.16 89.97 90.63 
X 87.85 87.88 88.53 87.99 87.74 87.62 87.26 87.89 
 
 
 
 
Chapter 4 
110 
 
Supplementary Table S4.2 
Non-reference variants detected on target per sample. 
Sample Variants (bidirectional) Variants 
1 57,827 65,060 
2 56,401 63,491 
3 58,769 66,639 
4 57,623 64,793 
5 60,444 67,222 
6 60,576 67,890 
7 55,683 62,117 
8 58,615 65,967 
The second and third column show the number of variants being called with and without “the “require presence in both forward and reverse 
reads” setting being applied, respectively. 
 
Supplementary Table S4.3  
Primers (and their efficiencies) used to assess fold enrichment. 
Primer Forward Reverse E Chr 
1 5'-CGCATTCCTCATCCCAGTATG-3' 5'-AAAGGACTTGGTGCAGAGTTCAG-3' 1.60 12 
2 5'-GTAGTGAGGCGAGTGGCTTT-3' 5'-CCGACAGCACTACATGGGTT-3' 2.06 36 
3 5'-CTCCTGGGGCACAAATGAGT-3' 5'-AGGGAGAATATGGCCCACCT-3' 1.81 30 
4 5'-TCTGTGAGGGTGGCTTTTCC-3' 5'-TCTCTGGGGCATCTGTGAGA-3' 1.75 17 
5 5'-TCGCTGACGTGTTCAAAGGA-3' 5'-AGAACCCACGCCTGAAGATG-3' 1.67 3 
The second and third column contain the sequences of all five primers. Primer one is the standard primer provided by Nimblegen (NSC-0237). 
The fourth column contains the efficiency of amplification (E) as calculated with the following formula: E = 10(–1/slope of standard curve). The 
chromosome on which the control locus is located is mentioned in the fifth column.  
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5.1 Abstract 
By limiting sequencing to those sequences transcribed as mRNA, whole 
exome sequencing is a cost-efficient technique often used in disease-
association studies. We developed two target enrichment designs based on 
the recently released annotation of the canine genome: the exome-plus 
design and the exome-CDS design. The exome-plus design combines the 
exons of the CanFam 3.1 Ensembl annotation, more recently discovered 
protein-coding exons and a variety of non-coding RNA regions 
(microRNAs, long non-coding RNAs and antisense transcripts), leading to 
a total size of ≈ 152 Mb. The exome-CDS was designed as a subset of 
the exome-plus by omitting all 3’ and 5’ untranslated regions. This 
reduced the size of the exome-CDS to ≈ 71 Mb. To test the capturing 
performance, four exome-plus captures were sequenced on a NextSeq 
500 with each capture containing four pre-capture pooled, barcoded 
samples. At an average sequencing depth of 68.3x, 80% of the regions 
and well over 90% of the targeted base pairs were completely covered at 
least five times with high reproducibility. Based on the performance of the 
exome-plus, we estimated the performance of the exome-CDS. Overall, 
these designs provide flexible solutions for a variety of research questions 
and are likely to be reliable tools in disease studies. 
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5.2 Introduction 
In 2014, the first report detailing the design and performance of a 
whole exome sequencing (WES) enrichment assay for the dog was 
published by our group1. Aiming to selectively sequence all the regions 
that are transcribed to mRNA, WES is a reliable tool used to identify 
disease-causing or predisposing mutations at a fraction of the price of 
whole genome sequencing (WGS) studies. A limitation of WES is that it 
is based on our current knowledge of the annotation of the genome and 
that many disease causing mutations are likely to fall outside protein-
coding regions. With new information becoming available, updates and 
extensions are required. Recently, an improved annotation for the dog 
genome has been published and new data on non-protein coding genes 
has been obtained2. Based on this data, two new target enrichment 
designs for dogs, called the exome-plus and the exome-CDS, were 
developed. The exome-plus offers the most comprehensive design. The 
exome-CDS is a subset of the exome-plus, focusing on the coding DNA 
sequences (CDS) by excluding the 3’ and 5’ untranslated regions 
(UTRs). These two designs offer flexible solutions for a variety of 
research questions associated with targeted dog exome resequencing. Our 
current study describes the development of the new designs and the 
performance of the exome-plus. Based on the results of the exome-plus, 
we estimate the performance of the exome-CDS. In addition, we provide 
an in-depth comparison with the previously published exome-1.01. 
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5.3 Results and discussion 
Design. Commercially available target enrichment technologies are able 
to capture up to 200 Mb, which is around 10% of the dog genome. The 
choice of which regions to include can therefore be based on practical 
and theoretical considerations, instead of technical limitations. A smaller 
design does not necessarily result in a cheaper target capture assay, as 
most commercial custom target capture design tools will increase the tiling 
density of the baits when the target region size decreases and thus a 
similar amount of baits are produced. This increased tiling density might 
increase the capture efficiency. The main cost difference between smaller 
and bigger designs lies in the increased sequencing cost: more sequence 
reads will need to be generated to achieve the same sequencing depth 
on a bigger target compared to a smaller captured region of interest. With 
these considerations in mind, two separate designs were developed.  
The first design, called the exome-plus, has a total size of 
151,698,592 bp (≈ 6% of the genome) divided over 242,914 regions. 
The exome-plus contains both protein-coding genes and their UTRs and 
specific non-coding genes. The protein-coding regions contain the exons 
from the Ensembl annotation (Canis familiaris, CanFam 3.1) and newly 
discovered protein-coding exons recently identified by RNA-sequencing2. 
The non-coding genes are a combination of the microRNAs from 
miRBase3, experimentally characterized long non-coding RNA2 and 
antisense transcripts2.  
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The second design, the exome-CDS, was designed to be a subset of 
the exome-plus, containing only the CDS from both the Ensembl 
annotation and the newly discovered protein-coding genes. The 3’ and 5’ 
UTRs were thus excluded. Candidate CDS within transcript sequences 
were identified through TransDecoder4. Interestingly, this bioinformatics tool 
discovered a small number of additional exons and CDS, adding a total 
of 115,044 bp (0.16% of the size exome-CDS) that were not shared 
with the exome-plus. Overall, the exome-CDS targets 71,254,801 bp (≈ 
3% of the genome) spread over 244,543 regions. 
Based on these designs, capturing baits were developed by Roche 
Nimblegen to target specific regions. When the baits were designed, the 
regions on the mitochondrial DNA were omitted to avoid overcapturing and 
oversequencing of the mitochondrial DNA compared with the nuclear DNA5. 
If mitochondrial DNA sequencing is required, one of the options would be 
to design baits separately and to spike them in at a low concentration. 
Sequencing. In total, 16 canine Labrador Retriever DNA samples were 
sequenced using the exome-plus design. To assess performance, four 
separate captures were performed, each consisting of four different pre-
capture pooled and indexed samples. Each pool was sequenced in a 
separate run on a NextSeq 500 Illumina sequencing system. These results 
were also used to estimate the coverage performance for the exome-CDS, 
which is a subset of the exome-plus. On average, 243 million reads 
were generated per sample (Table 5.1). Following quality trimming, 
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mapping and duplicate reads removal, 87.2% of the reads were retained 
on average. This result is comparable with previous reports1,6. 
Performance of the exome-plus: coverage. The on target sequencing 
depth for the exome-plus varied from 42.6x to 93.9x and was on 
average 68.3x (Table 5.1). To assess the regions and base pairs 
covered, a cut-off sequencing depth of 5x was used as this is the 
threshold applied usually for variant calling.  
Table 5.1  
Statistics for exome sequencing sixteen dogs. 
Sample Pool Total reads Mapped reads Duplicate 
reads 
Remaining 
reads 
Remaining 
(%) 
Sequencing 
depth (x) 
1 1 284,357,886 264,735,195 9,414,179 255,321,016 89.8 85.8 
2 1 281,522,490 261,170,320 9,366,318 251,804,002 89.4 84.3 
3 1 249,659,670 231,433,861 7,819,714 223,614,147 89.6 75.4 
4 1 181,728,820 168,679,105 4,382,284 164,296,821 90.4 55.5 
5 2 266,996,086 251,028,902 17,002,907 234,025,995 87.7 75.3 
6 2 187,857,302 176,207,940 12,226,544 163,981,396 87.3 53.9 
7 2 233,403,500 216,361,182 13,330,685 203,030,497 87.0 65.0 
8 2 314,005,584 289,641,450 23,514,154 266,127,296 84.8 82.9 
9 3 262,726,150 246,019,167 14,919,187 231,099,980 88.0 74.8 
10 3 181,120,464 169,294,819 10,140,076 159,154,743 87.9 51.6 
11 3 269,017,896 247,287,291 16,377,215 230,910,076 85.8 73.1 
12 3 243,350,554 227,421,662 12,820,659 214,601,003 88.2 69.5 
13 4 154,004,914 142,631,944 9,095,086 133,536,858 86.7 42.6 
14 4 193,942,804 175,552,484 13,670,936 161,881,548 83.5 50.1 
15 4 221,094,842 204,380,382 15,086,795 189,293,587 85.6 59.5 
16 4 364,079,702 337,983,155 31,679,889 306,303,266 84.1 93.9 
 
From the total of 242,914 targeted regions of the exome-plus, on 
average 193,722 regions (79.7%) were completely covered with a depth 
of at least five reads. The number of partially sequenced target regions 
with a minimal percentage covered, increases when the minimal required 
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percentage of coverage is lowered: e.g. 88% of the regions are covered 
at least 90%. For on average 9192 regions (3.8%), the maximum 
sequencing depth reached was four reads. An overview can be found in 
Table 5.2. The relation between the number of regions with a minimal 
coverage and the percentage minimally covered is visualized in Figure 5.1.  
Table 5.2 
Regions with a sequencing depth below 5x. 
Sample Pool Regions with minimum  
sequencing depth < 5x (%) 
Regions with maximum 
 sequencing depth < 5x (%) 
1 1 42,705 (17.6) 6,977 (2.9) 
2 1 42,749 (17.6) 6,980 (2.9) 
3 1 45,739 (18.8) 7,307 (3.0) 
4 1 55,643 (22.9) 9,346 (3.8) 
5 2 41,798 (17.2) 8,502 (3.5) 
6 2 54,390 (22.4) 10,953 (4.5) 
7 2 50,032 (20.6) 10,439 (4.3) 
8 2 40,793 (16.8) 8,238 (3.4) 
9 3 44,312 (18.2) 8,884 (3.7) 
10 3 57,615 (23.7) 11,185 (4.6) 
11 3 44,956 (18.5) 8,698 (3.6) 
12 3 46,948 (19.3) 9,125 (3.8) 
13 4 66,381 (27.3) 12,380 (5.1) 
14 4 57,903 (23.8) 10,446 (4.3) 
15 4 41,031 (16.9) 7,457 (3.1) 
16 4 54,075 (22.3) 10,156 (4.2) 
 
In terms of covered base pairs, on average 95.1% of the targeted 
bases pairs reach a minimum sequencing depth of five (Table 5.3). 
Overall, these results are similar to commercially available human exome 
sequencing kits6. 
Performance of the exome-plus: percentage reads on target. The 
percentage (%) reads on target is calculated as the number of reads on 
target, divided by the total number of reads. This parameter informs us of 
the enrichment efficiency. Overall, the average % reads on target (for all 
chromosomes and samples) is 75.8%. The lowest average chromosome 
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% reads on target is 63.3% for chromosome X, the highest is 82.2% for 
chromosome 9. Only a small difference on the % reads on target for 
chromosome X was noticed when the two sexes were compared: the 
average % reads on target was 62.6% for males (n = 8) and 63.8% 
for females (n = 8). Detailed results are provided in Supplementary 
Table S5.1. The obtained percentages were similar in the sequenced 
samples.  
 
Figure 5.1. Relation between the minimal percentage covered of each region (%) 
and the percentage of the total number of regions (%). For each individual region, 
Chapter 5 
120 
 
the proportion of the region covered at a minimum sequencing depth of 5x, was 
calculated. 
Table 5.3  
Coverage of targeted base pairs (≥ 5x). 
Sample Pool base pairs exome-plus (%) base pairs exome-CDS (%) 
1 1 145,066,553 (95.6) 67,225,626 (94.3) 
2 1 145,081,909 (95.6) 67,250,020 (94.4) 
3 1 144,607,207 (95.3) 67,007,231 (94.0) 
4 1 143,036,351 (94.3) 66,060,290 (92.7) 
5 2 145,147,282 (95.7) 67,070,797 (94.1) 
6 2 143,617,018 (94.7) 66,121,333 (92.8) 
7 2 144,051,293 (95.0) 66,351,108 (93.1) 
8 2 145,267,122 (95.8) 67,097,056 (94.2) 
9 3 144,802,496 (95.5) 66,904,165 (93.9) 
10 3 143,126,270 (94.3) 65,865,667 (92.4) 
11 3 144,861,681 (95.5) 66,904,165 (93.9) 
12 3 144,585,713 (95.3) 66,786,409 (93.7) 
13 4 142,170,547 (93.7) 65,328,731 (91.7) 
14 4 143,170,286 (94.4) 66,018,207 (92.7) 
15 4 145,360,509 (95.8) 67,273,067 (94.4) 
16 4 143,449,544 (94.6) 66,120,048 (92.8) 
Performance of the exome-plus: reproducibility. We determined the 
overall reproducibility for both the targeted regions and the targeted base 
pairs. For all 16 samples, 154,318 regions (63.5%) were completely 
covered at a minimum sequencing depth of 5x in every single sample. 
For 4,220 (1.7%) of the regions the maximum sequencing depth reached 
was four reads for all 16 samples. In terms of base pairs, 137,071,014 
base pairs (90.4%) are consistently sequenced at least five times and 
3,642,390 base pairs (2.4%) never reach a sequencing depth of 5x.  
Assessment of possible reasons for differences in sequencing depth 
between regions. It seems that the regions can be divided in three 
categories based on their sequencing performance. Group 1 contains the 
154,318 regions that were completely covered in all sixteen samples at a 
minimum sequencing depth of 5x. Group 2 contains the 84,376 regions 
that at least partially did not reach a minimum sequencing depth of 5x in 
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all 16 samples. The last group, group 3, contains the 4,220 regions with 
a maximum sequencing depth of 4x for all sixteen samples. We evaluated 
whether differences in GC content and bait design could be linked to the 
obtained sequencing performance of these regions. It has been reported 
that a low sequencing depth can be caused by a high or low GC 
content6–8. Initially, we compared the GC content per region (% GC) for 
all three groups, resulting in median % GC values of 46.7%, 54.9% and 
76.8% for group 1, 2 and 3, respectively (Figure 5.2, yellow boxes). 
Sharp drops of sequencing depth have been reported with % GC above 
60.0% and below 40.0%6. As all the regions in group 1 were completely 
covered, we considered that group to be a reliable reference and used 
the 2.5th and 97.5th percentile of that group as cut-off values for a 
sequenceable % GC. Based on these cut-offs (which were 32.0% and 
64.5%, respectively), we determined for each group the proportion of 
regions with a more extreme % GC. The proportion of regions with a 
more extreme value were 4.9%, 24.4% and 75.2% for group 1, group 2 
and group 3, respectively. Based on these results, especially group 3 has 
a relatively large group of extreme % GCs.  
Roche Nimblegen does not design baits in regions with low complexity 
or regions that are highly repetitive to avoid off-target sequencing (called 
the “repeats” from now on). In addition, for a small number of regions 
in the canine genome, the exact nucleotide composition is unknown 
(called the “Ns” from now on), making bait design difficult. Our next 
step was to determine if any group contained more of these regions. 
Upon request, Roche Nimblegen provided us with two BED files containing 
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the regions with no baits directly designed for due to repeats and due to 
Ns, respectively. For group 3, 275 regions (6.5%) contained Ns and 90 
regions (2.1%) repeats. Overall, this results in 364 of the regions 
(8.6%) being (at least partially) excluded for bait design. For group 2, 
1,210 regions (1.4%) have Ns and 17,119 regions (20.3%) contained 
repeats. Overall, this results in 18,136 of the regions (21.5%) being (at 
least partially) excluded for bait design. For group 1, no regions 
contained Ns and 1,798 (1.2%) contained repeats. Overall, group 2 
contains the largest proportion of regions (partially) excluded from bait 
design. As some regions in group 1 were consistently sequenced but were 
at least partially excluded from bait design, it seems that some regions 
could still be sequenced efficiently due to the presence of neighboring 
baits. During the designing process, Roche Nimblegen tries to predict this 
as well and provided an additional BED file that identifies regions that are 
predicted not to be sequenced. These regions are a subset of the repeat 
and Ns regions. We compared their estimates with our results and this 
showed that 0.1%, 7.2% and 1.6% of the regions in group 1, group 2 
and group 3, respectively were predicted not to be sequenced by Roche. 
For group 1, this result seems to be close to correct. Group 2 contained 
again the largest proportion of difficult regions.  
We also compared the % GC of the remaining regions after 1) 
exclusion of the regions that Roche Nimblegen predicted not to be 
sequenced and 2) exclusion of all regions that were at least partially 
excluded from bait design due to Ns and/or repeats (Figure 5.2, green 
and red boxes, respectively). This allows us to check whether the % GC 
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of the remaining regions in each group differs from the overall % GC in 
each group. For group 1, the median % GC of 46.7% remained identical 
and the proportion of regions with an extreme % GC remained nearly the 
same (from 4.9% over 4.9% to 5.0%). For group 2, the median % GC 
increased from 54.9% over 56.0% to 57.9%. The proportion of regions 
with an extreme % GC increased likewise from 24.4% over 26.0% to 
29.5%. For group 3, the median value and proportion of regions with an 
extreme % GC only increased slightly (from 76.8% over 77.0% to 77.3% 
and 75.2% over 75.4% to 76.0%, respectively). It seems that in the 
second group, the remaining regions tend to have slightly higher % GCs, 
which might negatively influence sequencing.  
In the end, we combined the criteria for the % GC (with 32.0% and 
64.5% as cut-offs) and the bait design results to determine the total 
proportion of regions in each group considered to be at risk for reduced 
sequencing. Due to extreme % GC and/or regions excluded due to 
Ns/repeats, 6.1%, 44.6% and 78.1% of the regions for group 1, group 2 
and group 3, respectively, were identified to be at risk for reduced 
performance. Due to extreme % GC and/or regions that were predicted 
not to be sequenced, 5.0%, 31.4% and 75.8% of the regions for group 
1, group 2 and group 3, respectively, were identified to be at risk.  
Overall, our criteria seem to be relatively correct as they classify the 
largest proportion of regions at risk in group 3, the second largest in 
group 2 and only a small amount in group 1. Specifically for group 3, 
the majority of the regions seems to be insufficiently covered due to 
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extreme % GC. For group 2, the results seem to be a more balanced 
combination of extreme % GC and bait design. 
Figure 5.2. Comparison of the GC content per region (% GC) for the completely 
covered regions with a minimum sequencing depth of 5x (= group 1), the regions with 
a varying sequencing depth (= group 2) and the regions with a maximum sequencing 
depth of 4x (= group 3). Each box represents the 25th (Q1), median (Q2) and 
the 75th (Q3) quartile, the whiskers represent 1.5 times the interquartile range 
(Q3–Q1). Outliers are represented as circles. Vertical lines represent the cutoffs 
at 32.0% GC and 64.5% GC. The yellow boxes represent the values for all the 
regions in a group. The green boxes represent the values for the remaining 
regions after exclusion of the regions that Roche Nimblegen predicted to not 
being sequenced. The red boxes represent the values for the remaining regions 
after exclusion of all the regions with repeats and Ns. 
Chapter 5 
125 
 
Estimating the coverage for the exome-CDS. Although all samples were 
sequenced with the exome-plus, we believe we can reliably estimate the 
performance of the exome-CDS with respect to coverage and 
reproducibility. This is due to the fact that the exome-CDS is (almost 
entirely) a subset of the exome-plus. We might underestimate the 
performance a little bit for the exome-CDS due to the constant number of 
target baits in each capturing assay. Each target enrichment sequencing 
assay contains 2.1 million baits. As the exome-CDS is half the size of 
the exome-plus, twice the number of baits can be used per region. 
Taking these considerations into account, the following coverage results 
might be conservative. From the 244,543 regions in the exome-CDS, on 
average 208,950 regions (85.4%) are estimated to have a sequencing 
depth of at least 5x throughout the entire region. For on average 9,031 
regions (3.7%), the maximum sequencing depth estimated was 4x. In 
terms of base pairs, we estimate that on average 93.4% (66,586,495 
base pairs) of the targeted base pairs are sequenced at least five times. 
As for the reproducibility, we estimated that in all 16 samples 174,667 
regions (71.4%) would be completely sequenced at a minimal sequencing 
depth of 5x and for 4138 regions (1.7%) the maximum sequencing 
depth reached would be 4x. In terms of base pairs, 62,455,013 
(87.7%) of the base pairs were estimated to be covered consistently in 
all samples and 2,438,559 (3.4%) base pairs consistently not. The % 
on target of the exome-CDS was not assessed as a part of the off-
target reads for the exome-CDS would actually be on-target reads based 
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on the exome-plus. Including these in the calculation would lead to an 
underestimation of the % on target. 
Variant calling. As WES is often used in disease-association studies, 
variant detection is an essential part9. Overall, between 250,196 and 
278,688 non-reference variants were detected inside the targeted regions 
of the exome-plus (Table 5.4). Filtering for those variants inside the 
exome-CDS, reduces this number to 110,047 to 122,429 variants (Table 
5.4).  
Table 5.4  
Variants called inside the target regions. 
Sample Pool Exome-plus (n) Exome-CDS (n) 
1 1 266,334 118,686 
2 1 267,695 119,322 
3 1 259,499 115,874 
4 1 250,196 110,047 
5 2 271,834 118,987 
6 2 269,445 117,882 
7 2 269,995 118,085 
8 2 273,081 119,495 
9 3 278,462 122,429 
10 3 274,222 119,880 
11 3 278,688 122,285 
12 3 262,793 116,038 
13 4 254,919 111,805 
14 4 260,454 114,874 
15 4 269,313 118,527 
16 4 262,786 114,849 
 
Comparison with the exome-1.0: design. A visual comparison between 
the exome-plus, the exome-CDS and the exome-1.0 can be found in 
Figure 5.3. Overall, 34.77 Mb are shared between all three designs. 
Although the vast majority is targeted by the exome-plus, a small number 
of base pairs is targeted uniquely by the exome-1.0 (0.09 Mb) and the 
exome-CDS (0.12 Mb).  
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Figure 5.3. Venn diagram showing the overlap between the exome-1.0 (= 53 Mb), 
exome-CDS (= 71 Mb) and the exome-plus (= 152 Mb). The depicted numbers 
represent the size in Mb for the various intersections. Overall, 34.77 Mb is 
shared by all designs. Inside the target space of the exome-plus, the exome-1.0 
targets 17.57 Mb more than the exome-CDS and the exome-CDS targets 36.37 
Mb more than the exome-1.0. Finally, 0.09 Mb, 0.12 Mb and 62.99 Mb are 
targeted uniquely by the exome-1.0, the exome-CDS and the exome-plus, 
respectively. 
The difference between the exome-1.0 and exome-plus is attributable 
to a small number of genes not being shared by Ensembl Genes and the 
RefSeq Genes and/or mRNA database. The difference between the 
exome-CDS and the exome-plus is caused by a small number of 
additional exons and CDS identified by TransDecoder, as described in the 
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design section. Inside the target space of the exome-plus (152 Mb), the 
exome-plus and the exome-CDS contain respectively 62.99 Mb and 
36.37 Mb more compared with the exome-1.0. For the exome-plus, 
these differences are attributable to the inclusion of all the new protein-
coding genes and the non-protein coding regions that were not available 
when the exome-1.0 was designed. For the exome-CDS, this difference 
is smaller due to the exclusion of UTRs from the newly discovered 
proteins. Finally, besides the 0.09 Mb already mentioned, the exome-1.0 
contains an additional 17.57 Mb that is not shared with the exome-CDS. 
This difference is caused by the exclusion of the UTRs from the Ensembl 
Genes in the exome-CDS. These UTRs are incorporated in the exome-
1.0.  
Comparison with the exome-1.0: performance. An overall comparison of 
the average performance parameters of the exome-plus, the exome-CDS 
and the exome-1.0 can be found in table 5.5. The exome-plus has the 
lowest scores for the completely covered regions and the region 
reproducibility. This is attributable to the average size of each individual 
region. For the exome-plus, ≈ 152 Mb is divided over 242,914 regions, 
leading to an average size of each region of 624 base pairs. For the 
exome-1.0, similar calculations lead to an average region size of only 
260 nucleotides. If for even one nucleotide in a region, a sequencing 
depth of 5x is not reached, this region is not covered completely. 
Theoretically, we can assume that the probability for this to happen is 
much more likely when the region size increases. This is in agreement 
with the experimental results: we divided the target regions in those with 
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a length < 260 and ≥ 260 bp. Next, we compared in each subgroup 
the proportion of regions that were completely covered, with the total 
number of regions in this subgroup. On average, 25.0% more regions 
were completely sequenced if the region size was under 260 bp.  
Table 5.5 
Performance parameters of the exome-plus, the exome-CDS and the exome-1.0. 
 exome-plus exome-CDS exome-1.0 
fully covered regions (%) 79.7 85.4 84.9 
base pairs covered (%) 95.1 93.4 90.2 
% on target (%) 75.8 - 90.4 
reproducibility regions (%) 63.5 71.4 79.9 
reproducibility base pairs (%) 90.4 87.7 87.4 
non-reference variants (n) 266,857 117,442 61,820 
The exome-plus scores highest in terms of base pairs covered and 
base pair reproducibility. At the same time, the % reads on target is 
lower in the exome-plus compared with the exome-1.0. These results are 
explained by the settings applied when the baits were designed. For the 
exome-1.0, only unique baits were allowed, i.e. baits that only match 
one location. This is in contrast with the exome-plus that allowed up to 
20 matches for each bait. This increases the number of target regions 
and target base pairs being sequenced at the expense of a lower % 
reads on target.  
The contrasting results of regions and base pairs are due to the 
combination of the increased region size and the “more matches allowed” 
bait design settings. Overall, this leads to more regions (and base pairs) 
being covered for a relatively large proportion, but not completely (Figure 
5.1). Compared with the exome-1.0, the exome-plus covers 0.9% 
regions more for 90%1. 
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Intended use and user-specific customization options. With the 
development of the exome-plus and the exome-CDS, three WES 
enrichment assays are available for use. The exome-1.0 contains the core 
set of protein coding genes. As both the exome-plus and the exome-
CDS contain many regulatory regions, they are especially valuable in 
complex disease studies where mutations influencing expression are more 
likely to be involved2. The exome-plus is the design of choice when one 
needs the most comprehensive capture based on the most recent 
annotation of the dog genome, including virtually all transcribed regions. 
The exome-CDS balances completeness and cost-efficiency. 
An additional advantage of all three designs, is the ease of 
customization. Even in the exome-plus there is still room for ≈ 50 Mb of 
target regions to be added. For example, the few non-targeted RefSeq 
Genes and/or mRNA regions mentioned earlier or a new update in the 
non-coding RNA repertoire might be of interest. The regions uniquely 
identified by TransDecoder might also be added. BED files containing 
these regions are available on request. 
5.4 Discussion 
This study describes the development of two new target enrichment 
designs and the performance of the exome-plus. At a minimum 
sequencing depth of five, around 80% of the regions were covered 
completely and well over 90% of the base pairs were covered with a 
high reproducibility. In addition, a large number of variants were detected. 
Based on the results of the exome-plus, we estimate the performance of 
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the exome-CDS. Together with the exome-1.0, these designs provide 
flexible solutions for a variety of research questions. 
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5.5 Methods 
Sample collection. Sixteen canine Labrador Retriever blood samples 
were obtained from a canine blood bank available at Ghent University to 
study genetic disorders10. Approval was granted by the local ethical 
(Faculty of Veterinary Medicine, Ghent University, Belgium) and 
deontological (Federal Public Service Health, Food Chain Safety and 
Environment, Brussels, Belgium) committees (EC2013_193). All 
experiments were carried out in accordance with the approved guidelines. 
Design. For the exome-plus, from the University Of California Santa 
Cruz (UCSC) (http://genome.ucsc.edu/) table browser (Dog, 
CanFam3.1), the Ensembl Genes were selected from the Genes and 
Gene prediction tracks11,12. The output format was a BED file with the 
setting “exons (plus 0 bases at each end)”. MicroRNA sequence 
positions were downloaded from miRBase3. These files were combined with 
the protein coding genes, antisense transcripts and long non-coding 
transcripts2,13. Regions were merged using bedtools version v2.17.0. The 
total size of the design was 151,698,592 bp (≈ 6% of the genome) 
divided over 242,914 regions. For the exome-CDS, all files were identical 
except for the Ensembl Genes and the protein coding genes. From these 
2 files, the CDS were predicted with TransDecoder4 and selected. The 
total size of the exome-CDS is 71,254,801 bp (≈ 3% of the genome) 
divided over 244,543 regions. Both BED files are available on request. 
Roche Nimblegen WES enrichment assay. Our design was processed by 
the Roche Nimblegen custom design group (Madison, USA). Using an 
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SSAHA algorithm, capturing baits were developed based on our design 
and the reference genome of the dog (Canis familiaris 3.1). Design 
settings for the baits allowed five or fewer single-base insertions, deletions 
or substitutions between the baits and the genome. Each bait was allowed 
to match at maximum up to 20 close matches in the genome. Regions 
under 100 bp were padded to 100 bp to increase capturing efficiency. 
After approval, the baits were generated and provided as SeqCap 
Developer Library. 
DNA extraction. Genomic DNA was extracted with the DNeasy Blood & 
Tissue Kit (QIAGEN) with 100 µl of blood as input. The standard 
protocol was followed (including the RNAse A step) with the exception of 
the final elution step: instead of using 200 µl of Buffer AE, only 100 µl 
was used. The eluate was used again to elute a second and third time 
to increase the concentration. The DNA yield was measured with Quant-
iTTM Picogreen® dsDNA Assay (Life Technologies). 
Sample preparation and sequencing. Extracted DNA was fragmented on 
a Covaris S2 System in a 130 µl volume (aim: 400 bp fragments, 
settings: duty cycle: 10%, intensity: 4, cycles per burst: 200, time: 
55s). After shearing, another picogreen assay was performed. Depending 
on the yield after DNA-extraction, between 500 ng and 1 µg of the 
fragmented DNA was used as input for the library preparation. Samples 
were end repaired, A-tailed and ligated with TruSeq adapters using the 
reagents from the NEBNext Ultra DNA Library Prep Master mix set for 
Illumina (New England Biolabs) according to the manufacturer’s protocol. 
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Size selection was performed on a 2% E-Gel (Invitrogen Life 
Technologies) (G4010-02), fragments were selected with an insert size 
around 300 bp. One µl of the ligated product was subsequently amplified 
in an enrichment PCR (10 cycles) for library quality assessment as 
recommended in the ‘SeqCap EZ Library SR User’s Guide’ (Nimblegen, 
Roche). Thereafter, the pre-capture LM-PCR was performed on the 
samples for 8 cycles as prescribed in the SeqCap EZ library protocol. 
The concentration of each PCR product was determined using Quant-iTTM 
Picogreen® dsDNA Assay (Life Technologies). Four times four samples 
were equimolarly pooled to obtain a total DNA input of 1250 ng. The 
pooled library was hybridized for 67-68 hours with the baits (SeqCap 
Developer Library). The hybridized library was washed and the captured 
and pooled DNA was recovered. After a final amplification (LM-PCR, 18 
cycles), the quality of the library was checked using the High Sensitivity 
DNA chip (Agilent).  
QPCR. To check the fold enrichment after capturing, a qPCR is 
performed as a quality control step before sequencing. Five primer pairs 
were used, as described previously1. An additional qPCR was performed 
to determine the quantity of the library to ensure optimal cluster densities. 
Sequencing. Each pool was sequenced in a separate run on the 
NextSeq 500 PE 75 bp.  
Data-analysis. Data-analysis was performed using the CLC Genomics 
Workbench (Version 7.5.1, CLC Bio, Aarhus, Denmark). Data were 
trimmed with the following settings: ambiguous trim = no, quality trim = 
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yes, quality limit = 0.05, use colourspace = no, create report = yes, 
also search on reversed sequence = yes, save discarded sequences = 
yes, remove 5’ terminal nucleotides = no, discard short reads = no, 
discard long reads = no, remove 3’ terminal nucleotides = no, trim 
adapter list = adapter list Illumina, save broken pairs = yes. The 
reference genome was downloaded from the UCSC genome browser12. For 
read mapping, the following parameters were used: mismatch cost = 2, 
insertion and deletion cost = 3, length fraction: 0.5, similarity fraction = 
0.8, global alignment = no, auto-detect paired distances = yes, non-
specific match handling = ignore, output mode = create reads track, 
create report = yes, collect un-mapped reads = yes, colour space 
alignment = no, masking mode = no masking. Duplicated reads were 
removed with the Duplicate Mapped Reads Removal (Version 1.0 beta 
6) plugin (setting: maximum representation of minority sequence 
(percent) to 20.0), create a second output file to save the removed 
reads = yes. Reads were locally realigned with the following settings: 
realign unaligned ends = yes, multi-pass realignment = 3, guidance-
variant track = not set, force realignment to guidance variants = no, 
output mode = create reads track, output track of realigned regions = 
yes. Variants were called using fixed ploidy variant detection with the 
following settings: ploidy = 2, required variant probability = 90.0, ignore 
positions with coverage above = 100000, minimum coverage = 5, 
minimum count = 2, minimum frequency = 20.0%, restrict calling to target 
regions = no, ignore broken pairs = yes, ignore non-specific matches = 
reads, minimum read length = 20, base quality filter = no, relative read 
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direction filter = yes (significance 1.0%), remove pyro-error variants = 
no, create track = yes, create table = yes, variant report = yes. 
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5.7 Supplementary material 
Supplementary Table S5.1 
Per sample per chromosome percentage reads on target (calculated as mapped reads on target/total number of mapped reads). 
Chr 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
1 81.0 80.6 80.8 81.0 77.6 77.4 76.9 77.4 77.5 77.7 77.2 77.2 77.1 77.1 78.0 77.7 
2 80.5 80.1 80.2 80.1 76.7 76.6 76.0 76.8 77.1 77.0 76.8 76.7 76.4 76.6 77.6 77.2 
3 78.2 77.9 78.2 78.1 74.4 74.2 73.5 74.1 74.3 74.4 73.9 74.0 73.8 73.5 74.6 74.4 
4 80.5 80.2 80.5 80.3 77.2 76.9 76.3 77.0 77.1 77.3 76.8 76.7 76.6 76.5 77.7 77.3 
5 82.0 82.0 82.3 82.1 79.2 78.8 78.1 79.1 79.2 79.2 79.1 79.0 78.7 78.6 79.8 79.3 
6 81.1 80.8 81.2 80.9 77.3 77.1 76.4 77.0 77.2 77.1 76.8 77.1 76.8 76.7 77.8 77.4 
7 80.7 80.9 82.0 79.6 76.5 76.0 74.9 76.0 75.8 76.2 76.0 76.2 75.2 74.8 76.6 75.7 
8 79.5 79.3 79.6 79.3 76.2 75.8 74.9 75.8 75.9 76.0 75.7 75.9 75.6 75.4 76.5 76.3 
9 84.5 84.2 84.6 84.4 81.4 81.0 80.6 81.5 81.5 81.5 81.3 81.4 81.2 81.5 82.4 82.0 
10 81.9 81.6 81.9 81.7 78.7 78.4 77.7 78.5 78.7 78.8 78.4 78.4 78.2 78.3 79.3 78.9 
11 79.4 79.2 79.4 79.5 76.2 75.9 75.2 75.9 76.2 76.2 75.8 75.9 75.7 75.6 76.7 76.3 
12 80.2 79.9 80.2 80.0 76.7 76.5 75.6 76.4 76.6 76.8 76.2 76.3 76.1 76.2 77.1 76.8 
13 75.3 75.0 74.9 77.8 74.3 74.1 73.2 74.1 74.2 74.2 73.9 73.9 73.7 73.6 74.8 74.4 
14 78.3 78.0 78.5 78.1 74.6 74.3 73.5 74.2 74.4 74.5 73.9 74.0 73.7 73.7 74.8 74.6 
15 80.6 80.3 80.6 80.4 76.9 76.6 75.9 76.8 77.0 77.1 76.6 76.6 76.3 76.3 77.6 77.2 
16 74.9 74.6 74.6 74.7 71.1 70.8 70.0 71.0 71.3 70.9 70.5 70.7 70.9 70.6 71.8 70.6 
17 80.9 80.9 80.6 80.4 77.4 77.0 76.5 77.2 77.7 77.7 77.2 77.2 77.0 77.1 78.2 77.5 
18 80.2 80.0 80.3 79.8 77.1 76.6 75.8 76.6 76.8 76.9 76.5 76.6 76.5 76.6 77.3 77.0 
19 72.0 71.3 72.4 71.7 68.4 68.3 66.6 67.7 67.5 67.8 67.5 67.4 67.2 66.5 68.4 67.9 
20 82.7 82.4 82.7 82.4 79.6 79.2 78.4 79.4 79.5 79.7 79.3 79.5 79.2 79.5 80.1 79.7 
21 78.0 77.6 77.6 77.3 74.4 74.0 73.4 74.2 74.4 74.5 74.2 74.3 73.8 73.7 74.8 73.5 
22 73.8 73.4 73.8 73.6 70.0 70.0 69.1 69.4 69.6 69.9 69.1 69.4 69.2 68.9 69.9 69.7 
23 80.2 80.0 80.3 80.0 76.6 76.2 75.6 76.3 76.5 76.7 76.2 76.3 76.0 75.9 77.0 76.6 
24 81.1 81.0 81.4 81.2 77.7 77.5 77.0 77.7 77.9 78.2 77.7 77.8 77.7 77.8 78.8 78.3 
25 79.1 78.9 79.3 79.1 75.7 75.4 74.7 75.5 75.7 75.8 75.5 75.4 74.9 74.9 76.1 75.7 
26 81.3 80.9 81.3 81.1 77.7 77.5 77.1 77.8 77.8 78.0 77.8 77.8 77.7 77.5 78.6 78.2 
27 81.4 81.1 81.3 81.0 77.5 77.1 76.5 77.3 77.5 77.5 77.2 77.2 77.1 77.2 78.2 77.8 
28 81.4 81.0 81.4 81.1 77.7 77.3 76.8 77.7 77.7 77.8 77.6 77.5 77.0 77.1 78.6 78.0 
29 76.5 76.1 76.4 76.3 72.3 72.0 71.3 72.1 72.1 72.3 71.6 71.7 71.5 71.2 72.5 72.5 
30 82.4 82.1 82.6 82.1 78.6 78.1 77.6 78.4 78.7 78.7 78.3 78.3 78.1 78.3 79.5 79.0 
31 70.3 69.8 69.6 69.4 65.3 65.1 64.4 64.8 64.9 64.9 64.2 63.5 64.5 63.8 64.8 64.4 
32 70.7 69.8 70.3 69.6 62.6 62.7 63.4 63.4 63.2 62.1 62.4 60.5 60.9 59.4 62.9 62.9 
33 80.6 80.4 80.7 80.4 76.9 76.5 75.8 76.7 76.8 76.8 76.5 76.5 76.1 76.2 77.6 77.1 
34 77.7 77.4 77.6 77.4 73.4 73.2 72.7 73.2 73.2 73.2 72.9 72.8 72.5 72.0 73.6 73.2 
35 80.5 80.2 80.4 80.4 77.1 77.0 76.3 76.9 77.1 77.1 76.8 76.9 76.4 76.4 77.4 77.1 
36 80.6 80.3 80.7 80.3 76.7 76.2 75.5 76.7 76.7 76.7 76.4 76.2 75.8 76.2 77.7 77.1 
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37 80.3 80.0 80.2 79.9 75.8 75.5 74.9 75.5 75.3 75.5 75.1 75.3 75.2 75.0 76.2 75.9 
38 78.3 77.9 78.2 78.0 74.9 74.5 73.3 74.1 74.5 74.5 74.0 74.2 73.8 74.2 74.6 74.4 
X 66.5 66.1 67.8 67.7 63.0 62.9 60.8 61.7 61.9 62.0 62.5 61.6 61.1 61.2 62.6 62.7 
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6.1 Abstract 
Background: Identification of one or several disease causing variant(s) 
from the large collection of variants present in an individual is often 
achieved by the sequential use of heuristic filters. The recent development 
of whole exome sequencing enrichment designs for several non-model 
species created the need for a species-independent, fast and versatile 
analysis tool, capable of tackling a wide variety of standard and more 
complex inheritance models. With this aim, we developed “Mendelian”, an 
R-package that can be used for heuristic variant filtering.  
Results: the R-package Mendelian offers fast and convenient filters to 
analyze putative variants for both recessive and dominant models of 
inheritance, with variable degrees of penetrance and detectance. Analysis 
of trios is supported. Filtering against variant databases and annotation of 
variants is also included. This package is not species specific and 
supports parallel computation. We validated this package by reanalyzing 
data from a whole exome sequencing experiment on intellectual disability 
in humans. In a second example, we identified the mutations responsible 
for coat colour in the dog. This is the first example of whole exome 
sequencing without prior mapping in the dog.  
Conclusion: We developed an R-package that enables the identification 
of disease-causing variants from the long list of variants called in 
sequencing experiments. The software and a detailed manual are available 
at https://github.com/BartBroeckx/Mendelian. 
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6.2 Background 
The identification of genetic variation responsible for a phenotype, is 
one of the key aims in the field of genetics. This field has been 
revolutionized with the introduction of next generation sequencing 
technologies and is continuously evolving. Although several sequencing 
platforms exist, the analysis of sequencing data generated in disease-
association studies is virtually identical: the platform-specific raw data is 
used for base-calling and subsequently for mapping and variant calling 
against a reference genome. These variants can subsequently be used to 
perform a disease-association analysis, where the typical aim is to identify 
one or several disease causing variant(s) from the large collection of 
variants present in an individual. This can be achieved by the sequential 
application of several heuristic filters1.  
As genetic diseases are heterogeneous, a wide range of filters is 
required. Compared to complex disorders, it is more straightforward to 
identify disease causing variants in Mendelian disorders. However, even in 
this subgroup of Mendelian disorders, a variety of factors might complicate 
the analysis: different inheritance models (dominant, recessive), de novo 
mutations, allelic or locus heterogeneity, reduced penetrance, phenocopies, 
etcetera1.  
Due to the recent development of whole exome sequencing (WES) 
enrichment designs for several non-model species, these species are likely 
to be sequenced more often2–5. To be of practical use, heuristic filtering 
software should thus be capable to deal with all the aforementioned 
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situations for both model and non-model species. At this point however, 
most tools are specifically intended for human analyses (e.g. they only 
allow processing of files that can be linked to human-specific databases 
or annotation) and/or only allow the most basic filtering. This limits the 
broad application of sequencing based approaches as it requires access to 
bioinformaticians that have to write custom scripts for the analysis at 
hand. To avoid a constant reinvention of the wheel and to fulfil the need 
for a species-independent, fast and versatile analysis tool, capable of 
tackling a wide variety of inheritance models and complicating factors, we 
developed the R-package “Mendelian”. It allows the analysis of several 
types of variants, including single nucleotide polymorphisms, insertion-
deletions and structural variants.  
We demonstrate its use with two practical examples. In the first 
example, we reanalyze the data of a human WES experiment that 
identified a de novo mutation responsible for intellectual disability6. The 
second example demonstrates the power of the combination of the 
exome-plus, a novel WES design in the dog, and Mendelian by 
revalidating the recessively inherited yellow and brown coat colour 
phenotypes in the Labrador Retriever5,7–9. This second analysis is also the 
first to use WES without prior mapping in the dog. The combination of 
WES and “Mendelian” will likely aid future disease-association studies.  
6.3 Implementation 
Flexibility of the applied software tool is an important aspect in 
disease-association studies as the species and phenotype studied might 
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significantly alter the analysis process. For example, filtering steps might 
be omitted (e.g. when a variant database is not available for the studied 
species), the proposed inheritance model might be dominant or recessive 
and genetic heterogeneity might be present. An overview of the features 
of the tool is provided below. In addition, a detailed vignette is available 
together with the software package at 
https://github.com/BartBroeckx/Mendelian. 
Input. “Mendelian” allows for the use of the standard variant call 
format (VCF). In addition, specific .txt output from the commercial 
platform CLC Genomics Workbench is also supported. If necessary, variant 
files can be annotated using .bed or .gtf files. The variants can be 
assigned to a variety of units from standard databases, e.g. an exon or 
a gene. User-specific custom annotations can also be used. 
Filtering against variant databases. Often, the first step in filtering called 
variants consists of the removal of previously identified variants present in 
public databases such as dbSNP. This significantly reduces the number of 
putative variants. Depending on the disease studied, one can choose to 
use all the variants present in a database or to use only those variants 
that have a certain minor allele frequency (MAF). This step can be 
skipped if a dbSNP is not available for the species studied. 
Filtering sequencing variants. There are four variant filters to support 
both dominant and recessive modes of inheritance, filtering at the 
nucleotide level or at a user-defined level (often an exon or a gene). 
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They can be applied on one or more affected individuals at once and 
allow for the inclusion of one or several unaffected control individuals.  
The two (dominant and recessive) functions for filtering at the 
nucleotide level, consider individual variants at a single nucleotide position 
in the genome. Under a dominant mode of inheritance, no zygosity 
assumptions are made: every variant called in an affected individual is a 
putative disease causing variant. Every variant called in unaffected 
individuals can be used to filter the variants in affected individuals.  
Under a recessive mode of inheritance, putative causal variants are 
assumed to be in a homozygous state. Only homozygous variants in 
unaffected individuals are used to filter variants in affected individuals. 
The two functions for filtering at a user-specified level, consider the 
variants in a unit (e.g. an exon or a gene) together. This allows for 
allelic heterogeneity, which implies that different variants within one unit 
might be disease causing.  
Under a recessive mode of inheritance, putative causal variants can 
both be homozygous and/or compound heterozygous. Compound 
heterozygosity means that an individual expresses a phenotype due to two 
different heterozygous alleles within a particular unit. Every unit with at 
least one homozygous variant or that is compound heterozygous, is 
retained. If several cases are available, the filter identifies shared units 
instead of shared nucleotides. Variants called in unaffected individuals are 
used to filter variants in cases in two consecutive steps. First, 
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homozygous variants in controls are used for filtering. Next, all compound 
heterozygous variants within a unit are used for filtering. 
Under a dominant mode of inheritance, no zygosity assumptions are 
made, resulting in every unit with at least one variant being retained in 
affected individuals. Every variant present in a control is used for filtering. 
Detectance and penetrance. All four filters allow for a reduced 
penetrance and reduced detectance. Penetrance is defined as the 
probability of seeing a certain phenotype, given the genotype. Detectance 
is defined as the probability of identifying a certain genotype, given the 
phenotype. A 100% detectance and penetrance is often assumed. Under a 
reduced detectance, a causal variant can be identified, even under locus 
heterogeneity or when phenocopies are present. Under reduced penetrance, 
a causal variant can be present in an individual without the expression of 
the associated phenotype. 
These theoretical definitions are translated into practice by Mendelian in 
two sequential steps. First, Mendelian calculates the possible detectance 
and penetrance levels using the following formulas:  
𝑝𝑒𝑛𝑒𝑡𝑟𝑎𝑛𝑐𝑒 =
𝑛𝑐
𝑛𝑐 + 𝑐𝑔
 
𝑑𝑒𝑡𝑒𝑐𝑡𝑎𝑛𝑐𝑒 =  
𝑛𝑐
𝑛𝑐 + 𝑛𝑑
 
With for the phenotypically affected individuals:  
ns = {phenotypically “sick” animals (called “cases”)}; nc 
={phenotypically “sick” individuals with a shared (= “common”) genetic 
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cause}; nd ={ phenotypically “sick” individuals with a different genetic 
cause or phenocopies} and nc + nd = ns.  
and for the phenotypically unaffected individuals: 
c = {phenotypically “healthy” animals (called “controls”)}, cg = 
{phenotypically “healthy” animals with “sick” genotype}, cc = 
{phenotypically “healthy” animals with “healthy” genotype} and cg + cc = 
c. The relation between these abbreviations is depicted in detail in Table 
6.1. By varying cg (restrictions: 0 ≤ cg ≤ c) for the penetrance and nd 
(restrictions: 0 ≤ nd < ns) for the detectance over all the possible 
values, the different options are calculated and provided to the user to 
choose from.  
Table 6.1  
Relation between a genotype and a phenotype. 
Genotype Phenotype 
 Affected Healthy 
Affected nc cg 
Healthy nd cc 
Total ns c 
cg reflects the number of animals that have a reduced penetrance. nd is the number of animals that have a different genetic cause and/or 
that are phenocopies. nc are the animals that share a genetic cause and are phenotypically affected. cc are the animals that are both genetically 
and phenotypically healthy. A priori, only ns and c are known. 
After the user has chosen the appropriate levels of detectance and 
penetrance, cg and nc are calculated by rearranging both formulas: 
𝑐𝑔 =
𝑛𝑐
𝑝𝑒𝑛𝑒𝑡𝑟𝑎𝑛𝑐𝑒
− 𝑛𝑐 
And  
𝑛𝑐 = 𝑑𝑒𝑡𝑒𝑐𝑡𝑎𝑛𝑐𝑒 . 𝑛𝑠 
Practically, Mendelian assumes that under reduced penetrance a variant 
is allowed to be present in at most cg phenotypical controls and that 
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under reduced detectance the variant has to be present in at least nc 
cases. The chosen penetrance and detectance levels are thus the lower 
limits, all variants with levels of penetrance and detectance at least as 
high will be returned by default. This can be adapted, if needed. 
6.4 Results and discussion 
The output of the heuristic filters is a data frame that for each variant 
contains the chromosome, the exact location, the allele and the number of 
samples with that allele. To show the possibilities of “Mendelian”, we 
performed two separate analyses. All R commands used in this analysis 
are included (see supplementary file 1). All the data reanalyzed in this 
study was obtained from published studies that were approved by the 
institution’s ethical committees. 
Example 1: human intellectual disability. As a starting point, we 
reanalyzed WES data from a study on intellectual disability6. A trio of one 
affected child and two healthy parents was sequenced and a de novo 
mutation was expected. Trio sequencing has the benefit that the vast 
majority of variants in the child will be present in at least one of the 
parents and with a de novo mutation, one can additionally assume that 
the variant has to be heterozygous in the affected child. This allows for 
an enormous reduction of variants, even though only three samples are 
sequenced. Two sequential filters were used in our analysis: after 
preprocessing, the VCF file containing the variants of the patient (patient 
#3 in the original study) was filtered against a human variant database. 
In agreement with the original study, the dbSNP135 was used with a 
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MAF of 0% (i.e. every variant in the database can be used for 
filtering). This already reduced the number of variants with 72.1%. In the 
second filtering step the standard dominant filtering at the nucleotide level 
function was used, but with the “family” option specified. By specifying 
the “family” option, the parental variants were used to further reduce the 
number of variants, but with the additional assumption that the putative 
variant has to be heterozygous in the child. At this point, 99.99% of the 
variants were excluded and only 5 variants remained. The original de 
novo mutation on chromosome 17 (chr17:72341086G>A) was one of 
these 5. In the original paper, the number of variants was further reduced 
by filtering against a second control population and a Sanger sequencing 
step. An overview of the analysis is provided in Figure 6.1.  
Figure 6.1. Consecutive filtering steps in the identification of putative causal 
variants for intellectual disability. 
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Two remarks have to be made when the “family” option is being used. 
First of all, each family should be analyzed separately. In addition, 
unrelated controls should not be included with the “family” option specified 
as the function would consider them to be parents. This would result in 
additional variants being filtered, based on assumptions that might not be 
valid. 
Example 2: coat colour in the Labrador Retriever. In contrast with human 
studies, WES is not used frequently in domestic species. One of the 
reasons is likely the limited availability of WES capturing designs. For the 
dog, the first report on a WES design was published in 2014. The 
development of new WES designs, are likely to boost disease-association 
studies in these species. To demonstrate the power of WES studies 
combined with “Mendelian”, we revalidated the mutations responsible for 
the black, brown and yellow coat colour in the Labrador Retriever7–9. For 
this analysis, variant data of 16 dogs that were sequenced to validate the 
exome-plus design, were used5. The analysis is detailed in Figure 6.2. 
Based on previous reports and the available pedigree data (see 
supplementary file 2) of the sequenced dogs, it is known that both 
brown and yellow are inherited recessively as opposed to black7–9. For 
both yellow to black and brown to black, two separate analyses were 
conducted in parallel. The first step was simple recessive filtering, 
assuming 100% detectance and 100% penetrance. The analysis was 
continued by two filtering steps based on annotation: at first, only variants 
that were inside a gene were retained, followed by a second filtering to 
retain only those variants within known exons. In the final step, only 
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non-synonymous variants were retained. At this point, only one putative 
variant remained in the comparison of yellow versus black. For the brown 
versus black analysis, 27 unique putative variants remained and one of 
them fell within the exon boundaries of both the Ensembl Genes and the 
RefSeq genes annotation. Further checking learned that both annotations 
actually referred to the same gene and that the effect on the protein 
sequence was identical. The two annotations for that specific variant were 
thus treated as one. 
To further prioritize the putative variants, the analysis was followed by 
an assessment of the potential effect of the variant at the protein level 
with Provean10. Finally, the variant responsible for the yellow coat colour 
was identified to be a highly deleterious (Provean score of -25.589) 
mutation (chr5:63694334G>A) introducing a premature stop codon 
(R306_W317del in MC1R). For the brown coat colour, the variant which 
corresponds with the known mutation, was predicted to be the most 
deleterious (Provean score of -376.444). This mutation 
(chr11:33326685C>T) also results in the introduction of a premature stop 
codon and removes more than 200 amino-acids from the protein 
(Q331_V537del in TYRP1). None of the other mutations associated with 
yellow and brown colour in the MC1R and TYRP1 genes were present in 
any of the dogs11.  
Even with a limited number of dogs, it was possible to identify the 
mutations responsible for the yellow coat colour and almost to identify the 
causal mutation for brown coat colour. Importantly, this analysis does not 
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demonstrate the full power of WES for several reasons. First of all, this 
analysis was conducted without prior filtering to a variant database. For 
rare disease phenotypes, it is relatively safe to assume that the putative 
variant has a low MAF in such a database. For a common phenotype 
such as coat colours, this assumption is not valid and determining an 
appropriate MAF cut-off will be difficult. In addition, the sequenced dogs, 
were selected to study orthopedic disorders, not coat colour. Therefore, 
the case/control selection was not optimized for our analysis. For 
example, it is much more interesting to include two full siblings with 
opposite phenotypes than two siblings with the same phenotype (additional 
variant reduction of 27.6%, chapter 7). Finally, the yellow versus black 
analysis was somewhat overpowered. A simulation where we gradually 
included dogs, showed that with 5 yellow dogs and 4 black dogs, we 
still would have retained the same unique variant (see supplementary file 
2).  
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Figure 6.2. Sequence of heuristic filters to identify causal mutations for coat 
colours in the Labrador Retriever. The two analysis (yellow (n = 7) versus black 
(n = 6) and brown (n = 3) versus black (n = 6)) were performed 
separately. The annotation steps were split for the Ensembl Genes (a) and the 
RefSeq genes (b). The potential effect on the protein was predicted with 
Provean. The default threshold of -2.5 was used as the cut-off value. * = the 
causal mutations for brown and yellow coat colours, synon. = synonymous, Nov. 
g. = novel gene (ENSCAFG00000030103).  
Chapter 6 
156 
 
As the attention shifts towards complex disorders, the question is 
whether Mendelian can be used for those disorders as well. Complex 
disorders are in essence no more than a combination of genetic and 
environmental factors that lead to a reduced penetrance and detectance. 
As Mendelian allows both reduced penetrance and/or detectance, it should 
be possible technically. However, lowering the thresholds will also result in 
less variants being filtered. Overall, the power of Mendelian for complex 
disorders will probably be lower compared to simple disorders. 
6.5 Comparison with existing software 
A limited number of different software packages that deal with similar 
problems are available. Examples are VCFtools12 and GEMINI13. Inside R 
Bioconductor, the packages VariantFiltering and VariantTools can be used. 
Compared with these tools, Mendelian has several advantages. GEMINI 
and VariantFiltering were developed specifically for humans only, which is 
a disadvantage since WES becomes increasingly popular in a variety of 
non-model species2–5. VariantFiltering does not support multi-allelic variants 
(variants with more than one alternate allele). Simple analysis tools such 
as VCFtools and VariantTools only allow for basic analysis (e.g. 
intersections or complements) and do not support various modes of 
inheritance12. Mendelian is the only package that allows the analysis of 
variants under reduced penetrance and detectance. To give an idea on 
the time required when analyzing variant data with Mendelian, some 
simulations on a standard desktop were added [Additional file 3]. 
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6.6 Conclusions 
The identification of one or several causal variant(s) from the vast 
amount of variant data generated in sequencing experiments, is often 
based on the sequential use of various filter steps. This software package 
was designed to provide a species-independent, fast and versatile analysis 
tool, capable of tackling a wide variety of inheritance models and 
complicating factors such as genetic heterogeneity and reduced penetrance. 
We demonstrated its possibilities by reanalyzing a dataset on human 
intellectual disability and were the first to use WES for the coat colour 
phenotype in the Labrador Retriever without prior mapping. Overall, this 
package is a valuable tool for causal variant identification in sequencing 
studies, especially in non-human species were the alternatives are very 
limited. 
6.7 Availability and requirements 
Project name: Mendelian 
Project home page: https://github.com/BartBroeckx/Mendelian 
Operating system(s): Platform independent 
Programming language: R 
Other requirements: R version 3.1.0 or higher 
License: GPL-2 
Any restrictions to use by non-academics: none 
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6.9 Supplementary material 
Supplementary file 1: command line used for example 1 and 2: 
Installation of “Mendelian” in R: 
devtools::install_github("BartBroeckx/Mendelian", build_vignettes=TRUE) 
By setting build_vignettes to TRUE, the vignette (= manual) is 
downloaded as well. The vignette can be accessed by typing: 
vignette("Mendelian-vignette") 
Example 1: 
Input: example of reading in the .vcf files in R: 
patient1 <- read.table("a") 
parent1 <- read.table("b") 
parent2 <- read.table("c") 
Preparing the .vcf files for further processing with a filtering to retain 
only those variants that passed the quality filters of the GATK pipeline.  
patient1proc <- VCFfile(patient1, "V10", filter=TRUE, "PASS") 
parent1proc <- VCFfile(parent1, "V10", filter=TRUE, "PASS") 
parent2proc <- VCFfile(parent2, "V10", filter=TRUE, "PASS") 
Reading in the dbSNP data: 
dbSNP <- read.table("dbSNP135", header=TRUE, sep="\t") 
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Preparing the dbSNP for filtering: 
a. Deciding how many processors are allowed to be used to 
prepare the dbSNP: 
library(doParallel) 
registerDoParallel() 
nproc <- getDoParWorkers() 
b. The actual filtering against a variant database with the MAF 
unspecified: 
dbSNPfilter <- prepvarpar(dbSNP,,”refNCBI”, nproc) 
Remark: an unspecified MAF gives the same result as setting MAF = 
0, e.g.:  
dbSNPfilter <- prepvarpar(dbSNP,0,”refNCBI”, nproc) 
Removing all the variants present in the dbSNP from the variants in 
the patient:  
filtered <- varfilter(patient1proc,dbSNPfilter)  
Trio filtering: 
nDom("filtered", c("parent1proc", "parent2proc"), "Ps-F") 
 
Example 2: 
Input: example of reading in of one .txt output file from CLC 
Genomcics Workbench in R: 
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a <- read.table("a", header=TRUE, sep="\t") 
Standard recessive filtering (with three cases and three controls): 
b <- nRec(c("a", "b", "c”), c("d", "e", "f")) 
Annotation:  
reading in the RefSeq Genes annotation as downloaded from the 
UCSC table browser: 
RefBED <- read.table("bed", sep="\t", header=FALSE) 
the actual annotation process with removal of all variants that do not 
fall inside the RefSeq regions 
out <- annot(a,RefBED, type="BED", nomatch=FALSE, CLC=TRUE) 
 
Additional examples for each function are provided together with the 
installation of the R-package. They can be accessed by combining “?” 
with the function you require information for: 
Example: 
?annot 
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Supplementary file 6.2. pedigree data of the dogs used in the coat 
colour analysis. In this figure, the familial relation between the dogs used 
in the analysis, is shown. The colour of the squares and circles 
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corresponds with the coat colour of the dog (yellow, brown or black). If 
the coat colour is not known, an empty black circle or square was used. 
□ = male, ○ = female, # the dogs used in the general analyses, * the 
5 yellow dogs and 4 black dogs needed to retain only one variant. 
 
  
 
Supplementary file 3. Time duration required for processing a variable 
number of cases and controls with the dominant (Dom) and recessive 
(Rec) filter (at the nucleotide level) used in example 1 and 2. Even 
though each dog had well over 250000 variants, the analysis only took 
at most around 30 seconds on a standard desktop (Intel(R) Core(TM) 
i3-2100 CPU @ 3.10GHz, 4.00 GB RAM, 32-bit Windows 7). The 
inclusion of controls decreases the computing time through a reduction of 
the number of variants in the cases. The recessive filter outperforms the 
dominant filter here as the size of the data frames is reduced by the 
exclusion of heterozygous variants. 
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7.1 Abstract 
With the recent development of whole exome sequencing enrichment 
designs for the dog, a novel tool for disease-association studies became 
available. The aim of disease-association studies is to identify one or a 
very limited number of putative causal variants or genes from the large 
pool of genetic variation. To maximize the efficiency of these studies and 
to provide some directions of what to expect, we evaluated the effect on 
variant reduction for various combinations of cases and controls for both 
dominant and recessive types of inheritance assuming variable degrees of 
penetrance and detectance. In this study, variant data of 14 dogs (13 
Labrador Retrievers and 1 Dogue de Bordeaux) obtained by whole exome 
sequencing, were analyzed. In the filtering process, we found that 
unrelated dogs from the same breed share up to 70% of their variants, 
which is likely a consequence of the breeding history of the dog. For the 
designs tested with unrelated dogs, combining 2 cases and 2 controls 
gave the best result. These results were improved further by adding 
closely related dogs. Reduced penetrance and/or detectance has a drastic 
effect on the efficiency and is likely to have a profound effect on the 
sample size needed to elucidate the causal variant. Overall, we 
demonstrated that sequencing a small number of dogs, results in a 
marked reduction of variants that is likely sufficient to pinpoint causal 
variants or genes. 
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7.2 Introduction 
The development of a technique that enables selective capturing of 
exons in 2007, announced the era of whole exome sequencing (WES)1. 
The practical use of this technique was soon demonstrated by the 
discovery of a mutation responsible for Miller syndrome2. Since then, WES 
has been widely used in disease-association studies in the human 
population. Gradually, WES designs also became available for several 
domestic species like the mouse and the pig3,4. In 2014, the first report 
on a WES design, called the exome-1.0, in the dog was published5. 
Typically, WES aims to selectively sequence all the regions that are 
transcribed to mRNA. However, many disease causing mutations are likely 
to fall outside these protein-coding regions. This was at least partially 
resolved by the recent development of two novel canine WES designs, the 
exome-plus and the exome-CDS. In addition to novel protein-coding 
regions, these designs target microRNAs, long non-coding RNAs and 
antisense transcripts from the recently published improved annotation6,7 
Although WES is much cheaper compared to whole-genome 
sequencing, it remains relatively expensive. A priori selecting the optimal 
combination of samples is likely to improve variant reduction, increase 
cost-efficiency and thus the overall chance of successfully identifying 
causal mutation(s) in disease-association studies. This study evaluates 
various combinations of cases and controls, inheritance types and familial 
relatedness to determine the most efficient design for sample sizes up to 
4 and can be used as a guideline for WES studies in the dog. As the 
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goal in disease-association studies is filtering genetic variation until only 
one or a very limited number of putative causal variants or genes 
remains, we compared the efficiency of each design in terms of the 
proportion of variants from the case(s) that could be excluded. The most 
efficient designs are those where the smallest amount of variants were 
retained. 
7.3 Materials and Methods 
Animal selection. Dogs were selected from two prior whole-exome 
sequencing experiments5,7. Inclusion criteria were 1) the presence of a 
pedigree (at least up to four generations), 2) besides the familial 
degrees studied (parent – progeny, full sibs, half sibs) no additional 
ancestors were allowed to be shared to avoid bias due to relatedness. So 
called “unrelated dogs” did not share any ancestor in the four generation 
pedigree. 
Exome-enrichment and data-analysis. Fourteen dogs were selected 
based on their known familial relationships (Figure 7.1). Details of the 
library preparation, sequencing and data-analysis are provided in the 
original papers5,7. Briefly, after shearing, samples were end repaired, A-
tailed and ligated according to the manufacturer’s protocol. Prior to each 
enrichment, four samples were equimolarly pooled. Each exome-1.0 pool 
(target size ≈ 53 Mb, CanFam 3.1) was sequenced in one lane on a 
HiSeq 2500 (PE 100 bp) whereas each exome-plus pool (target size 
≈ 152 Mb, CanFam 3.1 and updated annotation) was sequenced in a 
separate run on the NextSeq 500 PE 75 bp. The data-analysis was 
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performed with the CLC Genomics Workbench and consisted out of quality 
filtering, read mapping, duplicate read removal, local realignment and 
probabilistic variant calling (minimum coverage = 5). The average 
coverage for the eight samples sequenced with the exome-1.0 was 102x 
and 70x for the six samples sequenced with the exome-plus. Detailed 
sequencing statistics are available in Table S7.1. 
Filtering. In concordance with standard practices, only the autosomal, 
non-synonymous variants were retained from each animal8. Mitochondrial 
variants and variants on the X chromosome were thus removed. The 
number of variants and functional units for each animal prior to filtering 
are shown in Figure 7.1. The filtering was performed with the R-package 
“Mendelian” (Chapter 6). The assumptions for each filter are detailed in 
Table 7.1. Four different filters have been used: two of them filter at the 
nucleotide level, the other two filter at the level of a unit. The two 
(dominant and recessive) functions for filtering at the nucleotide level, 
consider individual variants in the genome. Under a dominant mode of 
inheritance, every variant called in an affected individual is a putative 
disease causing variant whereas the recessive filter assumes that causal 
variants are homozygous in cases. All the variants called in controls or 
only those that are homozygous are used to remove variants in cases for 
the dominant and recessive filters, respectively. 
Filtering units instead of individual variants allows the presence of 
allelic heterogeneity (different variants within one unit might be disease 
causing). As mentioned, non-synonymous variants were the starting point 
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for the analysis. This means that, based on the known annotation, the 
effect of a variant at the protein level was determined. A logical choice 
for the functional unit is thus the protein: a functional unit is only retained 
if case(s) have variant(s) with an effect on the amino-acid sequence 
of the same protein. Under a dominant mode of inheritance, every unit 
with at least one variant is being retained in cases. Under a recessive 
mode of inheritance, every unit with at least one homozygous variant or 
that is compound heterozygous, is retained. If several cases are available, 
the filter identifies shared units instead of shared nucleotides. All variants 
called in controls are used to remove variants in cases when the 
dominant filter is used. When the recessive filter is used, the variants in 
controls are used in two consecutive steps. First, homozygous variants in 
controls are used for filtering. Next, all compound heterozygous variants 
within a unit are used for filtering. 
Table 7.1  
Assumptions during heuristic filtering under a dominant and recessive mode of inheritance for single variants (= no allelic heterogeneity) and 
for functional units (= allelic heterogeneity allowed). In this study, a protein is the functional unit of choice. 
filter retained when shared by cases which variants called in control(s) can be used 
to remove variants from case(s) 
Dominant  
variants every variant every variant 
proteins every protein ≥ 1 variant every variant 
Recessive  
variants homozygous variants homozygous variants 
proteins every protein ≥1 homozygous variant and/or 
≥1 compound heterozygous 
homozygous variants and/or pairwise 
combination of heterozygous variants in each 
protein  
Instead of the actual number of variants that were retained, we 
calculated the proportionate reduction for each case. The rationale is that 
the number of variants retained will vary considerably depending on the 
number of variants initially obtained, whereas the proportionate reduction is 
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expected to give more generally applicable results. This proportionate 
reduction was termed efficiency and is calculated as: 
 
1
𝑛 × 𝑝
 ∑ ∑(1 −
𝑛𝑣𝑎𝑟𝑖𝑗1
𝑛𝑣𝑎𝑟𝑖𝑗0
)
𝑛
𝑖=1
𝑝
𝑗=1
 
with:  
- nvarij0/1 = the number of variants for case i in permutation j after 
filtering (1) and before filtering (0) 
- n = the number of cases 
- p = the number of possible permutations  
A stepwise approach was applied. In the baseline analysis, only 
unrelated animals were selected. To avoid any bias due to relatedness, 
one individual from every family was selected randomly for all comparisons 
(Figure 7.1, individuals with *). All possible permutations were used to 
evaluate the efficiency. In the second analysis, various familial designs 
were evaluated. The third analysis combined the most efficient design for 
a sample size of three and four, as identified in the first analysis, with 
the most efficient familial combinations from the second analysis. Finally, 
one of the most efficient designs overall was used to assess the effect of 
reduced penetrance and detectance. Penetrance and detectance are defined 
respectively in literature, as8:  
P (phenotype | genotype) 
P (genotype | phenotype) 
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In theory, detectance and penetrance can vary between 0 and 100%. 
When having sequenced a number of individuals, this continuous variable 
turns into a discrete variable with a limited number of thresholds, based 
on the following formulas: 
𝑝𝑒𝑛𝑒𝑡𝑟𝑎𝑛𝑐𝑒 =
𝑛𝑐
𝑛𝑐 + 𝑐𝑔
 
𝑑𝑒𝑡𝑒𝑐𝑡𝑎𝑛𝑐𝑒 =  
𝑛𝑐
𝑛𝑐 + 𝑛𝑑
 
With for the phenotypically affected individuals:  
ns = {phenotypically “sick” animals (called “cases”)}; nc 
={phenotypically “sick” individuals with a shared (= “common”) genetic 
cause}; nd ={ phenotypically “sick” individuals with a different genetic 
cause or phenocopies} and nc + nd = ns.  
and for the phenotypically unaffected individuals: 
c = {phenotypically “healthy” animals (called “controls”)}, cg = 
{phenotypically “healthy” animals with “sick” genotype}, cc = 
{phenotypically “healthy” animals with “healthy” genotype} and cg + cc = 
c. Only ns and c are known a priori. Depending on the chosen 
detectance and penetrance levels, the other variables vary within the 
restrictions mentioned. 
For analysis 2-4, the samples were permutated taking the familial 
relatedness into account. Throughout the manuscript, all comparisons are 
presented as x vs y with x the number of cases and y the number of 
controls.  
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Figure 7.1. Pedigree detailing the relationship for the 14 dogs (# of variants; # of 
proteins). Dog I to VIII were sequenced using the exome-1.0, dog IX to XIV with the 
exome-plus. * denotes the dogs selected in the unrelated dogs analysis; ** is the 
only Dogue de Bordeaux, the other ones are Labrador Retrievers; □ = male, ○ = 
female. 
7.4 Results 
A total of 14 dogs were selected based on their known familial 
relationships (Figure 7.1). Thirteen of these fourteen dogs were Labrador 
Retrievers, one dog was a Dogue de Bordeaux. 
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The baseline: increasing the sample size by including unrelated 
individuals. The effect of the following parameters was assessed in 
unrelated individuals: the sample size, the proposed type of inheritance, 
the functional unit of choice (a single variant or a protein) and the 
choice to include additional case(s) or control(s) (Table 7.2A and B). 
Overall, an increase in sample size always results in less (albeit a single 
mutation or proteins) being retained. For all sample sizes, recessive 
inheritance is more efficient compared to dominant inheritance and the 
assumption of one identical variant being shared is more efficient than 
assuming a shared protein. A balanced design (with equal number(s) of 
case(s) and control(s)) outperforms all the other designs, but is 
followed closely by designs with several cases and one control. 
For a sample size of two and three, we compared the exome-1.0 
and the exome-plus enrichment designs directly. In general, the results 
are similar, with the maximum difference being 7.1% for the variants (2 
vs 0, 62.3% for the exome-1.0 versus 69.4% for the exome-plus) and 
8.5% for the proteins (1 vs 2, 73.7% for the exome-1.0 versus 65.2% 
for the exome-plus). For both the exome-1.0 and the exome-plus 
enrichment designs, the same combinations of cases and controls are 
designated as being the most efficient (for n = 2, 1 vs 1; for n = 3, 2 
vs 1; for n = 4, 2 vs 2). 
The effect of familial relatedness on variant reduction. The effect of the 
inclusion of individuals with a variable degree of familial relatedness was 
assessed next (Table 7.3). The more closely related the individual, the 
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more pronounced the effect is in terms of variant reduction if the included 
individual is a control (1 vs 1). If the individual is a case as well, less 
related individuals have the benefit (2 vs 0). The most extreme example 
of unrelatedness in this study is the inclusion of a dog from a different 
breed (a Dogue de Bordeaux). Combining dogs from two different breeds 
results in the highest reduction if both dogs are cases (2 vs 0, e.g. 
40.3% > 26.4% > 20.6%) and the lowest reduction if one of them is 
a control and one of them is a case (1 vs 1, e.g. 58.9% < 73.6% < 
80.6% < 86.8%). 
Table 7.2 
The average efficiency for reduction of variants and proteins for various combinations of cases and controls (x vs y) from one breed. All animals were 
unrelated up to four generations. Two exome designs were used: the exome-1.0 (= 1.0) and the exome-plus (= plus). 
A n = 2 n = 3 
2 vs 0 1 vs 1 3 vs 0 2 vs 1 1 vs 2 
Dominant 1.0 Plus 1.0 Plus 1.0 Plus 1.0 Plus 1.0 Plus 
variants 31,3 35,8 68,7 64,2 43,5 47,7 87,8 88,2 80,9 76,0 
proteins 21,2 22,4 59,7 51,9 30,8 31,9 79,8 76,0 73,7 65,2 
           
Recessive   
variants 62,3 69,4 80,1 84,5 69,3 74,8 93,0 94,7 87,1 89,7 
proteins 42,1 45,3 65,4 64,7 49,5 52,2 82,5 81,5 76,0 74,1 
 B n = 4 
 4 vs 0 3 vs 1 2 vs 2 1 vs 3 
Dominant Plus Plus Plus Plus 
variants 54,1 93,5 94,6 81,4 
proteins 37,5 84,2 86,4 71,8 
     
Recessive  
variants 77,7 97,1 97,6 92,3 
proteins 56,3 87,4 89,0 78,9 
Combining related and unrelated individuals. Based on the first two 
analyses, the most efficient designs are likely to be those with a closely 
related family member as a control and an unrelated individual as an 
additional case. Based on these results, additional designs were evaluated 
further (Table 7.4). 
For a sample size of three, the most efficient combination was a 2 
vs 1 design. Three combinations were evaluated: a combination of two full 
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sibs (two cases) with one parent (control), two full sibs (one case, 
one control) and an unrelated case, one descendant (case) with one 
parent (control) and an additional unrelated case. The results for all 
three designs were comparable with the maximum difference being only 
2.4% (2 vs 1, Fsa, U vs Pa = 94.7% and Fs1a, U vs Fs2a = 92.3%).  
Table 7.3 
The average efficiency for reduction of variants and proteins for various combinations of cases and controls (x vs y) for varying degrees of 
familial relatedness. Two exome designs were used: the exome-1.0 (= 1.0) and the exome-plus (= plus). Parents were included as a 
control only, not as a case. 
 progeny 
-  
parent 
full sibs half sibs unrelated dog 
1 vs 1 2 vs 0 1 vs 1 2 vs 0 1 vs 1 2 vs 0 1 vs 1 
Dominant 1.0 1.0 Plus 1.0 plus 1.0 1.0 1.0 1.0 
variants 86,8 20,6 24,0 80,6 76,0 26,4 73,6 40,3 58,9 
proteins 77,0 12,5 14,7 74,5 65,4 17,6 65,9 28,2 47,7 
     
Recessive     
variants 91,6 55,8 63,0 87,3 90,6 61,6 83,3 66,5 75,5 
proteins 76,8 35,1 38,9 77,2 74,4 41,1 69,6 48,1 57,3 
 
For a sample size of four, the most efficient combination was a 2 vs 
2 design. We evaluated two combinations: two pairs of full sibs, with one 
individual of each pair as a control and the other one as a case and 
one pair of full sibs with one parent and one descendant were evaluated. 
Overall, these designs were the most efficient in terms of variant reduction 
with almost no variants/proteins being retained. 
Complicating factors: reduced penetrance and detectance. The 2 vs 2 
design with a combination of 2 pairs of full sibs (one individual of each 
pair being a control, the other one being a case) was used to evaluate 
the effect of reduced penetrance and reduced detectance (Table 7.5). 
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For the detectance, two cut-offs can be evaluated in this design: 50 and 
100%. A detectance of 50% means that a variant/protein present in at 
least one of the two cases is putatively causal. As the formula for 
penetrance takes nc into account, the calculated percent penetrance 
depends on the choice of the detectance level. For a detectance of 
100%, three cut-offs can be evaluated for penetrance: 100%, 67% and 
50%. For a detectance of 50%, the three cut-offs are 100%, 50% and 
33%. Practically however, the result is the same: reducing the penetrance 
one level, means that a putative causal variant/protein shared is also  
allowed to be present in up to one of the two controls. Dropping it 
two levels means the putative variant/protein is allowed in both controls. 
The baseline to compare these results is 100% detectance and 100% 
penetrance (Table 7.4). Incomplete penetrance or detectance has a large 
effect on the efficiency. Reducing either one of them with one step, 
Table 7.4 
The average efficiency for reduction of variants and proteins for a 2 cases vs 2 controls (2 vs 2) and a 2 cases vs 1 control (2 vs 1) design by  
combining individuals with varying degrees of familial relatedness. Two exome designs were used: the exome-1.0 (= 1.0) and the exome-plus  
(= plus). For each design, an example is given. Abbreviations: Fs1/2a/b = full sib pair with the respective individual 1 or 2 from family a or 
 family b; Pa = parent of individual Fsa in family a; U = unrelated dog from the same breed. 
 2 vs 2 2 vs 1 
Fsa,Fs1b 
vs 
Pa,Fs2b 
Fs1a,Fs1b 
vs 
Fs2a,Fs2b 
Fsa,U 
vs 
Pa 
Fs1a,Fs2a 
vs 
Pa 
Fs1a,U 
vs 
Fs2a 
Dominant 1.0 1.0 plus 1.0 1.0 1.0 Plus 
variants 98,9 98,1 97,8 94,7 93,7 92,3 93,0 
proteins 96,2 96,0 92,0 88,2 87,1 86,5 83,0 
      
Recessive      
variants 99,4 98,6 99,1 97,3 96,3 95,9 97,1 
proteins 95,7 95,5 93,5 88,7 87,7 88,6 87,0 
example IV,I 
vs  
VI,II 
IV,II 
vs 
V,I 
IV,II  
vs 
VI 
IV,V 
vs 
VI 
IV,II 
vs 
V 
Chapter 7 
181 
 
reduces the efficiency at its best to the same level of a 2 vs 1 design 
of unrelated individuals. The most extreme case is a penetrance of 33% 
and detectance of 50% under a dominant inheritance: with every 
variant/protein being putative disease causing for each case and no 
variant/protein in a control that can be used for filtering, we end up with 
more than we initially started. 
Table 7.5 
The effect of reduced penetrance (P) and/or detectance (D) on the average efficiency of reduction of variants and proteins for the 2 cases vs 2 
controls design with two pairs of full sibs, where one individual of each pair is a control and the other one a case. Two exome designs were 
used: the exome-1.0 (= 1.0) and the exome-plus (= plus). 
 100% D 100% P Reduced D and P 
67% P 50% P 50% D 50% P, 50% D 33% P, 50% D 
Dominant 1.0 plus 1.0 plus 1.0 plus 1.0 plus 1.0 plus 
variants 86,8 88,1 33,3 38,5 78,3 68,2 31,1 20,7 -33,6 -38,6 
proteins 75,4 71,3 22,8 23,6 71,3 55,5 23,0 13,1 -23,0 -23,6 
           
Recessive           
variants 93,2 95,1 63,9 70,1 84,0 87,8 56,9 65,8 22,2 36,8 
proteins 75,6 75,3 43,4 46,0 72,4 67,5 34,1 36,0 5,3 11,3 
7.5 Discussion 
This study evaluates the effect of various combinations of individuals 
for different sample sizes, types of inheritance, functional units, familial 
relatedness and penetrance and detectance levels in the dog. A baseline 
to compare the other designs with was established by comparing the 
effect of the inclusion of several unrelated individuals from one dog breed, 
the Labrador Retriever. As the general dog population went through 
several bottlenecks (domestication and breed creation), a high degree of 
shared variants was expected9,10. For the Labrador Retriever, this resulted 
in close to 70% of the variants being shared between two unrelated dogs 
(Table 7.2). These results are likely to vary between breeds as they 
reflect among other the population history. Even within one breed, our 
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results will vary somewhat. These differences are likely due to differences 
between the dogs. The analysis pipeline, the choice for whole exome or 
whole genome sequencing and the exome capturing design used, are not 
likely to affect the proportionate reduction. However, they do influence the 
exact number of variants being retained eventually. To provide some 
guidance to what variation one might expect, we analyzed two different 
sets of Labrador Retrievers with two different exome designs (exome-1.0 
and exome-plus) with two different analysis pipelines. As the results for 
both analyses are rather similar, these estimates can be considered 
relatively reliable. A remark is that the difference between the two 
analyses is sometimes larger than the difference between designs (e.g. 2 
vs 1 and 1 vs 2 in Table 7.2). However, inside each analysis, the 
same combination of cases and controls was the most efficient. If one 
has a choice, choosing the most optimal design for a certain sample size 
will always pay off. A joint analysis of exome-1.0 and exome-plus 
sequenced dogs was not conducted here, even though it would have 
given us the chance to analyze designs with n > 4. The reason is that, 
as the exome-plus and exome-1.0 WES enrichment designs are not the 
same, neither in size, nor in targets, mingling them would affect the 
variant count and the proportionate reduction: e.g. filtering a case 
sequenced with the exome-plus, using a control sequenced with the 
exome-1.0, will always result in at least 5377 variants and 1734 proteins 
being retained as this is the average difference in variants/proteins at the 
start. In general, combining different enrichment designs should always be 
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done with caution and it is best to decide beforehand what is likely to be 
the most appropriate enrichment design. 
The majority of the presented analyses were conducted in one breed, 
the Labrador Retriever. The question is whether the presented results can 
be extrapolated directly to these other breeds. As each breed has its own 
population history, the baseline and thus the other efficiency numbers will 
vary between breeds. However, the trends that were observed when the 
different combinations of cases and controls were compared, will remain. 
The reason is that for all the analyses conducted in one breed, the 
breed-specific genetic background remained the same. The observed 
differences between the various case-control designs originated thus from 
the parameters that were varied and not from the breed. A design that is 
more efficient in the Labrador Retriever will thus also be more efficient in 
other breeds, but the exact proportionate reduction will differ. In general, 
we expect the results presented here to be rather conservative (i.e. 
underestimated) as the population size of the Labrador Retriever is 
relatively big compared to other breeds9,10. 
It is generally accepted that disease-association studies for recessive 
diseases are more likely to be successful compared with the dominant 
ones8,11. The advantage of recessive inheritance lies in the fact that 
homozygous variants are easier to detect compared to heterozygous 
variants and the a priori exclusion of variants or functional units that are 
not homozygous and/or compound heterozygous in cases. In general, this 
trend is confirmed here, although with increasing sample sizes and more 
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efficient combinations of cases and controls, the difference tends to 
diminish. We did identify three exceptions in this study where dominant 
was more efficient than recessive: the 1 vs 1 design (parent – progeny, 
Table 7.3), and the 2 vs 2 design for parent-progeny and full-sibs 
(Table 7.4). These differences are very small with the maximum 
difference being only 0.5%. It can be expected however that at some 
point, with increasing numbers of cases and controls, the dominant model 
of inheritance will reduce variants more efficiently than the recessive 
model. This will not be the case if only affected individuals are included, 
but it will occur when controls are included. The reason is that when 
assuming recessive inheritance, only homozygous or compound 
heterozygous variants present in controls can be used to filter variants in 
cases. For a dominant type of inheritance, every variant present in 
controls can be used for filtering. The balance favoring recessive 
inheritance, is thus likely to tilt towards dominant inheritance when several 
cases and controls are combined. Overall, the difference became negligible 
in the most efficient 2 vs 2 designs (Table 7.4).  
Due to the high relatedness of “unrelated” dogs from one breed, 
designs including one control are always preferred over designs with the 
same sample size but with cases only. Even the most extreme case of 
unrelatedness presented in this study (= a dog from a different and 
relatively distinct breed) favors inclusion as a control instead of an 
additional case. Considering that even unrelated dogs are highly similar 
and favor inclusion as a control, the inclusion of more closely related 
individuals should result in a more efficient variant reduction. This trend is 
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visible in Table 7.3. Although full sibs and one parent vs a descendant 
are mathematically expected to be equally related, the inclusion of at least 
one parent has some additional benefits. Under a recessive mode of 
inheritance with no genetic heterogeneity and with healthy parents, you 
can assume additionally that the parent has to be heterozygous for the 
causal mutation. Under the same conditions, but for a dominant mode of 
inheritance, it can be assumed that the causal mutation is heterozygous in 
the affected descendant. Under these assumptions, including a parent is 
preferred over a full sib. If allelic heterogeneity is present, the advantage 
of parents over full sibs is non-existent. This is confirmed by our 
experiments (Table 7.3).  
One downside of this study is that we did not have access to two 
parents, so no results for “trio sequencing” (a combination of a healthy 
mother, healthy father and an affected child) could be provided. Trio 
sequencing is a very efficient design due to the additional assumptions of 
a mutation to be de novo under a dominant mode of inheritance or the 
requirement of heterozygosity in both parents under a recessive mode of 
inheritance. Based on previous studies, we estimate the number of 
retained variants to be between ten and three hundred depending on the 
amount of prior filtering and additional assumptions made12,13. If these 
numbers are directly transferred to our data, this would mean a reduction 
between 98.2% and 99.9%. This would make trio sequencing the most 
efficient design for a sample size of 3 and at least as efficient as the 
other designs tested here with a sample size of 4.  
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The 2 vs 2 design is the most efficient one, especially if closely 
related individuals are combined (Table 7.2 and 7.4). In our study, up 
to 99% of the variants and 96% of the proteins were removed with only 
4 samples, which is the usual number of samples pooled prior to 
capturing5,7. An important remark is that these results were obtained 
without prior filtering to a variant database and without additional filtering 
based on predicted deleteriousness by tools as PolyPhen and Provean14,15. 
These steps were omitted here to avoid retaining no single variant or 
protein as this would make comparisons on the efficiency impossible. 
However, these steps are standard in most disease-association studies8. 
Therefore, it is likely that a sample size of 4 is sufficient in standard 
studies, if detectance and penetrance are 100%.  
The effect of reduced penetrance and detectance was evaluated for the 
2 vs 2 design of 2 pairs of full sibs as this was one of the most 
efficient designs until now (Table 7.5). Reducing either of them 
immediately decreases efficiency. The most extreme design (33% 
penetrance and 50% detectance under a dominant mode of inheritance) 
results in even more variants and proteins being retained, since all the 
variants from all the affected individuals are just added together and no 
filtering occurs. Under these assumptions, proceeding to sequencing would 
be futile. For a recessive mode of inheritance, this extreme design still 
results in a limited reduction. This is a consequence of the assumption of 
compound heterozygosity and/or homozygosity in the individual affected 
cases. These results demonstrate that a reduced penetrance and/or 
detectance requires a dramatic increase of the sample size. Unfortunately, 
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it is not unlikely for this situation to occur. Reduced penetrance is 
reported quite often. Some common examples in the dog are the 
environmentally influenced exercise-induced collapse (affected by physical 
activity) and the age-dependent reduced penetrance of degenerative 
myelopathy16,17. Reduced detectance has been reported less often, but was 
necessary to identify the disease-causing mutations for Kabuki syndrome in 
humans18. Reduced detectance enables the presence of phenocopies and 
genetic heterogeneity (albeit locus or allelic heterogeneity). This might be 
important if dogs from several breeds are combined. For some diseases, 
the disease-causing mutation is the same in a wide range of breeds 
(e.g. the c.118G>A mutation in the SOD1 gene for degenerative 
myelopathy)16,19. However, for other diseases, several genes and mutations 
are known to be disease-causing with some being unique for individual 
breeds. One example in the dog is the group of progressive retinal 
atrophies (PRA)20. In this group of conditions, a mutation in the PRCD 
gene is shared by several breeds, but in the Golden Retriever at least 
two other genes are also linked to PRA and even phenocopies have been 
reported20–25.  
Overall, these results have various consequences. As dogs from two 
distinct different breeds share up to 60% of their variants and unrelated 
dogs within a breed up to 70%, it is likely that sequencing experiments 
with a limited sample size will be successful, even without access to a 
(large) variant database. This efficiency for low sample sizes has already 
been demonstrated for genome-wide association studies in the dog10. Due 
to the relatively large litter size and the frequent use of the same 
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breeding dogs, it should be fairly easy to obtain related animals, as 
opposed to human studies. Although genetic heterogeneity has of course 
been reported in the dog, it is still less extensive compared with the 
human population23. Due to the population bottlenecks and the high 
degree of relatedness, it is not unlikely that complex diseases are 
relatively easy to study in the dog. Therefore, the dog is likely to be a 
good animal model to study disorders in the human population, as 
demonstrated for Retinitis Pigmentosa, the human variant of PRA, and 
narcolepsy21,26. 
This is the first study evaluating the effect of various parameters in 
disease-association studies in the dog. We demonstrated that, with a 
small sample size, a large reduction can be achieved, with recessive 
inheritance in general being more efficient than dominant inheritance. A 
balanced combination of cases and controls should be preferred and, if 
available, closely related family members should be selected. Reduced 
detectance and/or penetrance are likely to have a profound effect on the 
sample size needed to elucidate the variant responsible for a genetic 
disease.
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7.7 Supplementary material 
Supplementary Table S7.1  
General sequencing statistics. 
Sample Total Reads Mapped Reads Duplicate Reads Remaining Reads (%) Sequencing depth (x) 
Exome-1.0 (HiSeq 2500 PE 100 bp) 
I 96,041,166 93,261,066 8,278,081 84,982,985 (88.5) 106.9 
II 90,534,096 83,841,822 4,680,806 79,161,016 (87.4) 102.0 
III 77,786,110 72,147,586 4,457,341 67,690,245 (87.0) 87.1 
IV 82,574,410 77,392,469 4,820,648 72,571,821 (87.9) 93.0 
V 74,657,388 69,542,653 4,518,820 65,023,833 (87.1) 82.6 
VI 111,624,766 108,781,536 9,882,797 98,898,739 (88.6) 125.1 
VII 86,094,438 83,226,207 5,926,249 77,299,958 (89.8) 99.3 
VIII 103,290,412 100,440,603 8,653,736 91,786,867 (88.9) 116.7 
Exome-plus (NextSeq 500 PE 75 bp) 
IX 266,996,086 251,028,902 17,002,907 234,025,995 (87.7) 75.3 
X 187,857,302 176,207,940 12,226,544 163,981,396 (87.3) 53.9 
XI 284,357,886 264,735,195 9,414,179 255,321,016 (89.8) 85.8 
XII 281,522,490 261,170,320 9,366,318 251,804,002 (89.4) 84.3 
XIII 233,403,500 216,361,182 13,330,685 203,030,497 (87.0) 65.0 
XIV 181,728,820 168,679,105 4,382,284 164,296,821 (90.4) 55.5 
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8.1 Abstract 
The objective of this study was to screen a dog population from 
Belgium, the Netherlands and Germany for the presence of mutant alleles 
associated with hip dysplasia (HD), degenerative myelopathy (DM), 
exercise-induced collapse (EIC), neuronal ceroid lipofuscinosis 4A 
(NCL), centronuclear myopathy (HMLR), mucopolysaccharidosis VII 
(MPS VII), myotonia congenita (MG), gangliosidosis (GM1) and 
muscular dystrophy (Duchenne type) (GRMD). Blood samples 
(K3EDTA) were collected for genotyping with Kompetitive Allele Specific 
PCR (n = 476). Allele and genotype frequencies were calculated in 
those breeds with at least 12 samples (n = 8). Hardy-Weinberg 
equilibrium was tested. Genetic variation was identified for 4 out of 9 
disorders: mutant alleles were found in 49, 15, 3 and 2 breeds for HD, 
DM, EIC and NCL respectively. Additionally, mutant alleles were identified 
in crossbreeds for both HD and EIC. For HD, DM, EIC and NCL mutant 
alleles were newly discovered in 43, 13, 2 and 1 breed(s), respectively. 
In 9, 2 and 1 breed(s) for DM, EIC and NCL respectively, the mutant 
allele was detected, but the respective disorder has not been reported in 
those breeds. For 5 disorders (HMLR, MPS VII, MG, GM1, GRMD), the 
mutant allele could not be identified in our population. For the other 4 
disorders (HD, DM, EIC, NCL), prevalence of associated mutant alleles 
seems strongly breed dependent. Surprisingly, mutant alleles were found in 
many breeds where the disorder has not been reported to date. 
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8.2 Background 
The reduction of genetic disorders remains an important goal for both 
veterinarians and breeders1. It is the responsibility of the scientific 
community to provide detailed information regarding the existence, 
application and importance of diagnostic genetic tests that have been 
developed1–3. An important step in this process is to evaluate the 
prevalence of disorders and mutant alleles in the population. This 
information is needed to provide proper breeding advice. So far, only a 
few studies have been conducted to identify allele frequencies in a canine 
population3–6. The presence of mutant alleles in different breeds with each 
having their specific genetic background, might provide interesting 
(clinical) information for both the animal and human population as many 
canine disorders are animal models for human genetic disorders. 
This study reports on the prevalence of mutant alleles associated with 
9 canine genetic disorders (Table 8.1) that influence the neuronal and/or 
musculoskeletal system: hip dysplasia (HD), degenerative myelopathy 
(DM), exercise-induced collapse (EIC), neuronal ceroid lipofuscinosis 4A 
(NCL), centronuclear myopathy (HMLR), mucopolysaccharidosis VII 
(MPS VII), myotonia congenita (MG), gangliosidosis (GM1) and 
muscular dystrophy (Duchenne type) (GRMD). The tests were performed 
in a dog population from Belgium, the Netherlands and Germany. Eight 
out of these 9 disorders are animal models for similar conditions in 
humans. The mutations predicted to cause HD, DM, EIC and NCL, were 
detected in a wide variety of breeds. 
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Table 8.1 
Overview of 9 disorders tested with their corresponding chromosome number, the mutation, the effect, the inheritance, the breeds where the mutation has been reported before and the animal model. CFA = chromosome number; AR = 
autosomal recessive, XR = X-linked recessive, MP = multifactorial; MS = missense, SP = splice variant, FS = frame shift, ES = exon skipping, SINE = short interspersed element, SNP = single nucleotide polymorphism; 1 leading to premature 
termination, 2 reduced penetrance. 
Disorder Gene CFA Mutation 
 
Effect inheritance 
Breeds with mutation 
reported so far Similar human disease Ref 
Hip dysplasia (HD) 
Fibrillin 2 (FBN2) (Gene ID: 
481491) 
11 
intronic (3 
SNPs + 
deletion) 
GAT 
> 
AGC 
? MP 
Labrador Retriever, Border 
Collie, German Shepherd 
Dog, Golden Retriever, 
Newfoundland, Rottweiler, 
Great Dane 
Congenital Contractural 
Arachnodactyly 
7 
Degenerative 
myelopathy (DM) 
Superoxide dismutase 1 (SOD1) 
(Gene ID: 403559) 
31 
exon (1 
SNP) 
G > 
A 
MS AR2 
German Shepherd Dog, 
Boxer, Rhodesian Ridgeback, 
Chesapeake Bay Retriever, 
Pembroke Welsh Corgi 
Amyotrophic lateral sclerosis 8 
Exercise-induced 
collapse (EIC) 
Dynamin 1 (DNM1) (Gene ID: 
491319) 
9 
exon (1 
SNP) 
G > 
T 
MS AR2 
Labrador Retriever, 
Chesapeake Bay Retriever, 
Curly-coated Retriever, 
Boykin Spaniel, Pembroke 
Welsh Corgi 
- 9 
Neuronal ceroid 
lipofuscinosis 4A (NCL) 
Arylsulfatase G (ARSG) (Gene ID: 
480460) 
9 
exon (1 
SNP) 
G > 
A 
MS AR2 
American Staffordshire 
Terrier 
Kufs disease 10 
Centronuclear 
myopathy (HMLR) 
Protein tyrosine phosphatase-like 
(PTPLA) (Gene ID: 574011) 
2 exon (SINE) SINE MS AR Labrador Retriever 
Human centronuclear 
myopathy 
11 
Mucopolysaccharidosis 
VII (MPS VII) 
Beta-glucuronidase (GUSB) (Gene 
ID: 403831) 
6 
exon (1 
SNP) 
G>A MS AR German Shepherd Dog Mucopolysaccharidosis VII 12 
 
Beta-glucuronidase (GUSB) (Gene 
ID: 403831) 
6 
exon (1 
SNP) 
C>T MS AR Brazilian Terrier Mucopolysaccharidosis VII 13 
Myotonia congenita 
(MG) 
Chloride channel, voltage sensitive 
1 (CLCN1) (Gene ID: 403723) 
16 
exon (1 
SNP) 
C>T MS AR Miniature Schnauzer 
Generalized myotonia (Beckers 
disease) 
14 
Gangliosidosis (GM1) 
Beta-galactosidase (GLB1) (Gene 
ID: 403873) 
23 
exon 
(deletion) 
C FS1 AR Shiba Gangliosidosis 15 
Muscular dystrophy 
(Duchenne) (GRMD) 
Dystrophin (DMD) (Gene ID: 
606758) 
X 
intron (1 
SNP) 
A>G ES XR Golden Retriever Duchenne Muscular Dystrophy 16 
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8.3 Materials and methods 
Ethics Statement. Approval from the local ethical (Faculty of Veterinary 
Medicine, Ghent University, Belgium) and deontological (Federal Public 
Service Health, Food Chain Safety and Environment, Brussels, Belgium) 
committees was granted (EC2010_171 and EC2011_193). All efforts were 
made to minimize suffering. Informed consent was obtained from owners of 
dogs before enrollment in the study. 
Sample Collection. Blood samples (K3EDTA) were collected for a 
genetic database to study HD. Veterinarians from Belgium, the Netherlands 
and Germany were asked to take a blood sample from every dog that 
had a hip radiograph taken. Reasons for performing the procedure varied 
from screening purposes (breeding and assistance dogs) to dogs with 
clinical complaints (with HD in the differential diagnosis). No prerequisites 
were made regarding breed, sex and age. 
Irrespective of breed, samples (n = 476) were tested for the 
presence of mutations associated with 9 disorders (HD, DM, EIC, NCL, 
HMLR, MPS VII, MG, GM1 and GRMD). Breeds where the mutant allele 
has already been reported, can be found in Table 8.1. A summary of 
breeds and samples per breed can be found in Table 8.2. Additionally, a 
mixed breed group of 28 dogs was tested. 
Genotyping. Genomic DNA was isolated using routine procedures. For 
blood samples, 10 µl of blood was washed 3 times with 150 µl of a 
Tris-HCL based buffer. The procedure was performed with the use of  
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Table 8.2  
Breed and samples per breed tested. a = not specified whether English or Welsh Springer Spaniel. 
Breed n % Breed n % 
Airedale Terrier 2 0.4 Gordon Setter 1 0.2 
Akita 1 0.2 Great Dane 1 0.2 
American Bulldog 1 0.2 Hovawart 1 0.2 
American Cocker Spaniel 1 0.2 Hungarian Vizsla 7 1.5 
American Staffordshire Terrier 18 3.8 Jack Russell Terrier 2 0.4 
Anatolian Shepherd Dog 2 0.4 Labrador Retriever 75 15.8 
Appenzeller Sennenhund 1 0.2 Laekenois 1 0.2 
Australian Kelpie 1 0.2 Large Munsterlander 1 0.2 
Australian Shepherd 6 1.3 Leonberger 4 0.8 
Basset Hound 1 0.2 Malinois 7 1.5 
Berger de Picardie 2 0.4 Maltese 1 0.2 
Bernese Mountain Dog 20 4.2 Mastino Napoletano 1 0.2 
Blue Picardy Spaniel 1 0.2 Miniature Pinscher 1 0.2 
Boerboel 1 0.2 Munsterlander 1 0.2 
Border Collie 29 6.1 Nederlandse Schapendoes 1 0.2 
Bouvier des Flandres 3 0.6 Newfoundland 4 0.8 
Boxer 15 3.2 Nova Scotia Duck Tolling Retriever 3 0.6 
Briard 1 0.2 Rhodesian Ridgeback 1 0.2 
Bull Terrier 1 0.2 Rottweiler 7 1.5 
Cavalier King Charles Spaniel 4 0.8 Saarlooswolfhond 2 0.4 
Collie Rough 2 0.4 Saint Bernard Dog 3 0.6 
Dalmatian 2 0.4 Samoyed 1 0.2 
Dobermann 2 0.4 Shar Pei 4 0.8 
Dogo Argentino 1 0.2 Shetland Sheepdog 1 0.2 
Dogue de Bordeaux 5 1.1 Shiba 3 0.6 
Dwergschnauzer 1 0.2 Siberian Husky 2 0.4 
English Bulldog 4 0.8 Spanish Water Dog 12 2.5 
English Cocker Spaniel 2 0.4 Springer Spaniela 1 0.2 
English Setter 2 0.4 Stabyhoun 3 0.6 
English Springer Spaniel 1 0.2 Standard Poodle 2 0.4 
Epagneul Breton 2 0.4 Tervueren 2 0.4 
Flat Coated Retriever 8 1.7 Tibetan Mastiff 1 0.2 
French Bulldog 3 0.6 Weimaraner 4 0.8 
German Shepherd Dog 73 15.3 White Swiss Shepherd Dog 5 1.1 
Golden Retriever 62 13.0 Wire-Haired Pointing Griffon Korthals 1 0.2 
   Total 476 
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robotic equipment. The cell pellet was lysed with Proteinase K (0.5 units 
for 45 minutes at 56°C followed by heat inactivation at 95°C for 5 
minutes). 
Genotyping was conducted using KASP 
(http://www.kbioscience.co.uk), a competitive allele specific polymerase 
chain reaction system, according to the manufacturer’s instructions. Primer 
sequences were based on literature (see Table 8.1) and transformed to 
be compatible with KASP. All tests are routinely run at the dr. Van 
Haeringen Laboratorium (Wageningen, the Netherlands). 
Statistical Analysis. Breed specific prevalence was analyzed in 8 breeds 
for which at least 12 samples were available (German Shepherd Dog, 
Labrador Retriever, Golden Retriever, Border Collie, Bernese Mountain 
Dog, American Staffordshire Terrier, Boxer, Spanish Water Dog). Hardy – 
Weinberg equilibrium (HWE) was tested with an online calculator 
(www.tufts.edu/~mcourt01/Documents). Data are available on request. 
8.4 Results 
No variation was found in any of the breeds for the mutations 
putatively responsible for 5 of the 9 disorders (HMLR, MPS VII, MG, 
GM1, GRMD). The mutations predicted to cause HD, DM, EIC and NCL, 
were observed in a wide variety of breeds (49, 15, 3 and 2 breeds, 
respectively). Breeds where mutant alleles were found are listed in Tables 
8.3, 8.4, 8.5 and 8.6 for HD, DM, EIC and NCL, respectively. For HD, 
DM, EIC and NCL mutant alleles were newly discovered in 43, 13, 2 
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and 1 breed(s), respectively. The mutant alleles for HD and EIC were 
also identified in mixed breed dogs. For 25 of the 28 crossbreds, the 
parental breeds were known and we have shown these breeds to possess 
the respective mutant allele. 
For 8 breeds, breed specific prevalence of alleles were reported 
(Table 8.3–8.6). Comparisons with previous reports could only be made 
for EIC in the Labrador Retriever: our population contained a very high 
number of genetically affected dogs (Table 8.7)6. HWE could be tested 
for HD in the German Shepherd Dog and the Golden Retriever (no 
significant deviation). For the Labrador Retriever, genotype frequencies for 
HD and EIC both deviated significantly from HWE (p ≤ 0.001). The 
other breeds and disorders were not tested due to low number of 
samples and/or absence of variation. 
8.5 Discussion 
Since its first report in 1935, intensive research has focused on hip 
dysplasia (HD), one of the most frequent orthopedic disorder in dogs17. 
HD can be found in a wide variety of breeds18,19. Recently, a haplotype 
in the Fibrillin 2 (FBN2) gene has been reported to be associated with 
this highly prevalent, multifactorial disorder7. Fibrillins are components of 
extracellular microfibrils and have both a structural and a regulatory 
function20. The mutant AGC haplotype was identified in 49 different breeds 
in the population under study (Table 8.3). In 44 breeds, this mutant 
allele was reported for the first time. We identified the AGC haplotype as 
the only allele in 10 breeds (Cavalier King Charles Spaniel (n = 4), 
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English Setter (n = 2), English Springer Spaniel (n = 1), Gordon 
Setter (n = 1), Laekenois (n = 1), Mastino Napoletano (n = 1), 
Rhodesian Ridgeback (n = 1), Saarlooswolfhond (n = 2), Siberian 
Husky (n = 2), Standard Poodle (n = 2)), however few conclusions 
can be made as the sample count is low (n = 17 overall). One 
additional dog was homozygous for the mutant allele, but as the breed 
was not correctly specified (Springer Spaniel without mentioning English or 
Welsh Springer Spaniel), this sample was excluded. 
Table 8.3  
Breeds where mutant alleles for hip dysplasia were found and breed specific prevalence for breeds with at least 12 samples. 
 NN NA AA Total HWE q (%) 
 n (%) n (%) n (%) n (%) P-
value 
 
American Staffordshire 
Terrier 
4 (24) 9 (53) 4 (24) 17 (100) - 50 
Bernese Mountain Dog 7 (35) 12 (60) 1 (5) 20 (100) - 35 
Border Collie 25 (89) 3 (11) 0 (0) 28 (100) - 5 
Boxer 15 (100) 0 (0) 0 (0) 15 (100) - 0 
German Shepherd Dog 34 (47) 34 (47) 4 (6) 72 (100) 0.225 29 
Golden Retriever 10 (16) 31 (51) 20 (33) 61 (100) 0.728 58 
Labrador Retriever 32 (45) 21 (30) 18 (25) 71 (100) 0.001 40 
Spanish Water Dog 4 (33) 8 (67) 0 (0) 12 (100) - 33 
Others: 
 
Airedale Terrier, Appenzeller Sennenhund, Australian Shepherd, Blue Picardy 
Spaniel, Boerboel, Bouvier des Flanders, Briard, Bull Terrier, Cavalier King Charles 
Spaniel, Collie Rough, Dalmatian, Dobermann, Dogo Argentino, Dogue de 
Bordeaux, English Bulldog, English Cocker Spaniel, English Setter, English Springer 
Spaniel, Epagneul Breton, Flat Coated Retriever, Gordon Setter, Hovawart, 
Hungarian Vizsla, Laekenois, Large Munsterlander, Leonberger, Malinois, Maltese, 
Mastino Napoletano, Miniature Pinscher, Newfoundland, Nova Scotia Duck Tolling 
Retriever, Rhodesian Ridgeback, Rottweiler, Saarlooswolfhond, Saint Bernard Dog, 
Shetland Sheepdog, Siberian Husky, Springer Spaniela, Stabyhoun, Standard 
Poodle, Weimaraner, White Swiss Shepherd Dog 
NN = 2 normal alleles, NA = heterozygous, AA = 2 mutant alleles, HWE = Hardy-Weinberg equilibrium, q = mutant allele frequency, % = 
percent of dogs belonging to specific category, - = not applicable, a = not specified whether English or Welsh Springer Spaniel. 
Degenerative myelopathy (DM) is characterized by progressive ataxia 
and upper motor neuron spastic paresis. The majority of dogs with DM 
start to develop symptoms from 5 years of age21. Diagnosis is not 
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straightforward when patients are alive. Based on clinical symptoms and 
exclusion of other disorders (for example intervertebral disc disease, spinal 
cord neoplasia), DM can be the most likely etiology, but formal diagnosis 
can only be achieved post-mortem on histopathology21. Only for a subset 
of those breeds in which DM has been reported clinically, this disorder 
has been confirmed on histopathology. In 2009, a causal mutation was 
discovered in the superoxide dismutase 1 (SOD1) gene for 5 breeds 
(Table 8.1) with an age-dependent incomplete penetrance8. This gene 
encodes a free radical scavenger21. We identified the causal mutation in 
15 breeds. In 2 breeds (Standard Poodle and Bernese Mountain Dog) 
the disorder was confirmed both clinically and on histopathology while in 
another 2 breeds (Border Collie and Collie Rough) the diagnosis of DM 
was made only on clinical examination21. We report the presence of the 
mutant allele in these 4 breeds and in an additional 9 breeds, in which 
the disorder has not yet been reported. We also confirmed the presence 
of the mutant allele in the German Shepherd Dog and Boxer (Table 
8.4). DM has been clinically reported in the Labrador Retriever and 
confirmed by histopathology in the Golden Retriever, but the mutation has 
not yet been reported in these breeds21. In our population of respectively 
74 and 62 individuals, we also did not identify the SOD1 mutation. The 
mutant allele might be infrequently present in the population or a different 
mutation might be responsible for the same disorder, as recently 
reported22. 
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Table 8.4  
Breeds where mutant alleles for degenerative myelopathy were found and breed specific prevalence for breeds with at least 12 samples. 
 NN NA AA Total HWE q (%) 
 n (%) n (%) n (%) n (%) P-
value 
 
American Staffordshire 
Terrier 
18 (100) 0 (0) 0 (0) 18 (100) - 0 
Bernese Mountain Dog 12 (60) 7 (35) 1 (5) 20 (100) - 23 
Border Collie 27 (96) 1 (4) 0 (0) 28 (100) - 2 
Boxer 13 (87) 2 (13) 0 (0) 15 (100) - 7 
German Shepherd Dog 53 (73) 18 (25) 2 (3) 73 (100) - 15 
Golden Retriever 62 (100) 0 (0) 0 (0) 62 (100) - 0 
Labrador Retriever 74 (100) 0 (0) 0 (0) 74 (100) - 0 
Spanish Water Dog 12 (100) 0 (0) 0 (0) 12 (100) - 0 
Others: Airedale Terrier, Australian Shepherd, Cavalier King Charles Spaniel, Collie Rough, 
Dobermann, Dogo Argentino, Saarlooswolfhond, Shetland Sheepdog, Stabyhoun, 
Standard Poodle, White Swiss Shepherd Dog 
NN = 2 normal alleles, NA = heterozygous, AA = 2 mutant alleles, HWE = Hardy-Weinberg equilibrium, q = mutant allele frequency, % = 
percent of dogs belonging to specific category, - = not applicable. 
Dogs with exercise-induced collapse (EIC) develop incoordination of 
the hind limbs, paraparesis and/or tetraparesis and have an increased 
body temperature after strenuous exercise. A mutation in the dynamin 1 
(DNM1) gene was found to be responsible for this disorder and an 
incomplete penetrance (influenced by the level of physical activity) was 
suggested9. DNM1 is important in neuronal synaptic vesicle recycling, 
especially during high levels of activity23. This disorder is reported mainly 
in Labrador Retrievers, but presence of the mutant allele has also been 
reported in other retriever breeds6,9. We report on the presence of the 
mutant allele for the first time in one English Cocker Spaniel and one 
Hungarian Vizsla (Table 8.5). The prevalence of EIC in our Labrador 
population was higher than in a previous report (Table 8.7)6. The 
sample source seems to affect the percentage of affected dogs: when 
samples were collected from Labrador Retrievers in dog shows, field trials 
and from local pet owners in Canada and the United States, the 
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prevalence of affected dogs was relatively low and in agreement with 
HWE expectations6. The opposite was true for dogs that were specifically 
tested for EIC and those results were in agreement with the results from 
our study, although we did not specifically select for those dogs. In our 
population of Labrador Retrievers, genotype frequencies for both HD and 
EIC deviate significantly from HWE. This might be a reflection of non-
random sampling or selection4. For HD, non-random sampling can be 
expected since our dogs were initially collected to study this disorder. For 
EIC, the reason for rejection of the HWE is not clear. For both HD and 
EIC, our results tend to overestimate the number of affected dogs based 
on HWE. A similar result was found in the pet population in a previous 
study (26.9 versus 29.2%)6. 
NN = 2 normal alleles, NA = heterozygous, AA = 2 mutant alleles, HWE = Hardy-Weinberg equilibrium, q = mutant allele frequency, % = percent 
of dogs belonging to specific category, - = not applicable. 
Neuronal ceroid lipofuscinosis 4A (NCL) has been reported in 
American Staffordshire Terriers with progressive ataxia24. The causal 
mutation was discovered in 2010 in the Arylsulfatase G (ARSG) gene 
Table 8.5  
Breeds where mutant alleles for exercise-induced collapse were found and breed specific prevalence for breeds with at least 12 samples. 
 NN NA AA Total HWE q (%) 
 n (%) n (%) n (%) n (%) P-value  
American Staffordshire 
Terrier 
18 (100) 0 (0) 0 (0) 18 (100) - 0 
Bernese Mountain Dog 18 (100) 0 (0) 0 (0) 18 (100) - 0 
Border Collie 25 (100) 0 (0) 0 (0) 25 (100) - 0 
Boxer 12 (100) 0 (0) 0 (0) 12 (100) - 0 
German Shepherd Dog 69 (100) 0 (0) 0 (0) 69 (100) - 0 
Golden Retriever 51 (100) 0 (0) 0 (0) 51 (100) - 0 
Labrador Retriever 30 (46) 16 (25) 19 (29) 65 (100) < 0.001 42 
Spanish Water Dog 12 (100) 0 (0) 0 (0) 12 (100) - 0 
Others: Hungarian Vizsla, English Cocker Spaniel 
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and an incomplete penetrance was suggested10. ARSG encodes for a 
lysosomal enzyme25. The mutant allele has a prevalence of approximately 
9% in our 17 American Staffordshire Terriers which is less than the 
frequency expected based on a previous study24. We report the presence 
of the same mutation in the Bull Terrier, a breed where NCL has not 
been reported (Table 8.6). No dogs were homozygous for the mutant 
allele in the population studied. 
Table 8.6  
Breeds where mutant alleles for neuronal ceroid lipofuscinosis 4A were found and breed specific prevalence for breeds with at least 12 samples. 
 
NN NA AA Total HWE q (%) 
 
n (%) n (%) n (%) n (%) 
P-value 
 
American Staffordshire Terrier 14 (82) 3 (18) 0 (0) 17 (100) - 9 
Bernese Mountain Dog 19 (100) 0 (0) 0 (0) 19 (100) - 0 
Border Collie 26 (100) 0 (0) 0 (0) 26 (100) - 0 
Boxer 13 (100) 0 (0) 0 (0) 13 (100) - 0 
German Shepherd Dog 71 (100) 0 (0) 0 (0) 71 (100) - 0 
Golden Retriever 57 (100) 0 (0) 0 (0) 57 (100) - 0 
Labrador Retriever 70 (100) 0 (0) 0 (0) 70 (100) - 0 
Spanish Water Dog 12 (100) 0 (0) 0 (0) 12 (100) - 0 
Others: Bull Terrier 
NN = 2 normal alleles, NA = heterozygous, AA = 2 mutant alleles, HWE = Hardy-Weinberg equilibrium, q = mutant allele frequency, % = 
percent of dogs belonging to specific category, - = not applicable. 
For the other 5 disorders (HMLR, MPS VII, MG, GM1, GRMD) the 
mutant alleles were not detected in our population. Non-detection of the 
mutant allele might indicate that the allele is absent, that it is present but 
at a low frequency and that the number of samples tested was too low. 
For HMLR (Labrador Retriever, n = 66) and MPS VII (German 
Shepherd Dog, n = 67), we had, with the numbers of animals tested, a 
99% chance of detecting every allele with a minor allele frequency 
(MAF) of at least 3.5%26. For GRMD (Golden Retriever, n = 19), we 
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had a 99% chance of detecting alleles with a frequency of at least 
11.5%26. For MG, GM1 and MPS VII (in the Brazilian Terrier), the 
sample size was too small to make any conclusions regarding the 
absence of the mutant allele26. The allele frequency for HMLR has 
previously been investigated4. In that study, the mutant allele frequency 
was very low (1.8% or 0.47%). To be able to detect all alleles with a 
MAF of 1% with a 99.9% probability, 344 samples would be needed. 
Since our sample count was much lower, it cannot be concluded that any 
of these 5 mutant alleles are completely absent. 
Table 8.7  
Comparisons of genotype frequencies for exercise-induced collapse in the Labrador Retriever. 
   Reference populations6 
Predicted 
Phenotype 
Our population Est. Freq (HWE) Source: Public Source: researchers 
 % (n) % (n) % (n) % (n) 
Healthy (homo) 46.2 (30) 34.2 (22.2) 52.9 (4826) 59.2 (509) 
Healthy (hetero) 24.6 (16) 48.6 (31.6) 37.2 (3392) 34.5 (297) 
Affected 29.2 (19) 17.2 (11.2) 9.9 (907) 6.3 (54) 
Total 100 (65) 100 (65) 100 (9125) 100 (860) 
The reference population consists of 2 different subsets based on collection method. Source: Public = based on request by the owner to 
perform genetic testing for EIC, Soure: researchers = researchers went to several competitions and took samples from every dog. Est. Freq 
(HWE) = estimated frequencies under Hardy-Weinberg equilibrium. 
For DM, EIC and NCL breeding advice can be given based on our 
population study. For some disorders, the mutant allele frequency is quite 
high in certain breeds (> 40% in Labrador Retriever for EIC). However, 
because of their recessive nature, a relatively fast reduction of both the 
mutant allele frequency and affected dogs can be achieved based on 
genetic tests. We propose to exclude certain genotypic combinations of 
dogs from mating, rather than excluding individuals, especially if high 
mutant allele frequencies are found. For autosomal recessive diseases, 
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dogs homozygous for the mutant allele should not be combined with each 
other or with heterozygous dogs. However, they can still be used for 
breeding, but require a mating combination involving only homozygous wild 
type animals to reduce the number of affected dogs. As heterozygous 
dogs can be used the same way, no dogs need to be excluded. As 
essentially every dog can still be used for breeding, the clinical outcome 
of disorders can be prevented without excessive exclusion of carriers or 
genetically affected dogs from the breeding population. Reduction of the 
prevalence of HD based only on FBN2 will be more difficult since it is a 
multifactorial polygenetic disorder. 
Surprisingly, mutant alleles for 3 autosomal recessive disorders (DM, 
EIC and NCL) were found in 9, 2 and 1 breed(s) respectively where 
the disorder has not been clinically reported. The most plausible 
explanation might be that the disorder just has not been recognized in 
those breeds. A second explanation is the influence of the breed specific 
genetic background: the effect of mutations might be different in different 
breeds. This has been reported in Drosophila and the mouse27,28. In a 
meta-analysis in humans where studies on a wide variety of diseases and 
genes were compared, opposite effects between races were found, but 
none of them significant29. To the authors’ knowledge, this phenomenon 
has not yet been reported in dogs for the diseases studied here. 
This study reports on the presence of mutant alleles for 9 disorders in 
a wide variety of dog breeds. Veterinarians and dog breeders should be 
aware that mutations are present in breeds even where the disorder has 
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not been reported. Dogs from non-suspected breeds that show comparable 
symptoms to the disorders reported in this and other studies should be 
genotyped and results should be reported in order to create a reliable 
database. Ideally, phenotypical information for every disorder should be 
included in this database. As this is not available for all diseases in our 
database, this is a major limitation to this study.  
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9 Discussion: the promises of whole exome sequencing in canine 
genetics 
 
This chapter can be divided into two parts. The first, more general 
part (9.1 to 9.4) starts with a discussion of the phenotypical issues 
encountered when studying HD and briefly states the consequences for 
screening. This is followed by a demonstration of the practical use of 
DNA testing, using DM as an example. Difficulties in estimating disease 
prevalence with either DNA tests or phenotypically are discussed as is the 
importance of the dog as an animal model. Although some of these 
topics might be considered evidentiary or outside the scope of this 
dissertation, these topics were included to situate our research within the 
larger picture of canine genetics. This dissertation is a result from a 
fruitful collaboration with a wide range of professionals: veterinarians, dog 
breeders, assistance and rescue dogs federations and individual dog 
owners. We are indebted to all participants, for which this research is of 
utmost importance. The second part (9.5 to 9.7) focuses on WES and 
“Mendelian” as tools for mutation identification in genetic research and 
discusses future expectations. 
9.1 Phenotypical problems: the issue with HD 
The importance of correct phenotyping cannot be stressed enough. HD 
is a perfect disorder to demonstrate potential sources for phenotypical 
misclassification. Worldwide, the standard VD is the technique used in 
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screening programs. However, it has been demonstrated that this technique 
lacks sensitivity to diagnose laxity in the hip joint1,2. Besides at the level 
of the technique that is used, several factors have been reported to 
influence the diagnosis. In chapter 3, we demonstrated a clear effect of 
the evaluating assessor and the positioning of the dog on the radiographic 
diagnosis of HD. Additional factors that interfere with the diagnosis are 
age of the dog and whether the dog is anesthetized or not; even the 
choice of sedatives has been reported to influence the diagnosis3–7. 
All these factors increase the environmental noise relative to the 
genetic contribution and it is the combination of both that results in a 
complex phenotype such as HD. If not handled correctly, these factors will 
decrease the effectiveness of screening programs and of genetic studies 
that aim to discover disease-contributing variants. Based on literature and 
our results, we propose the following improvements for radiographic HD 
screening: 
- Define clear measurable quality criteria for radiographs (e.g. 
maximum amount of rotation of the pelvis around the longitudinal 
axis) 
- Add a laxity based radiographical technique and, if this is not 
possible, increase the age of screening  
- Standardize the anesthesia protocol 
The assessment by multiple observers, familiar with the HD enigma, 
should be continued.  
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9.2 Underneath the (phenotypical) surface: the genotype 
It is clear that, because of the complexity of complex disorders, 
reduction of disease prevalence purely based on the phenotype will be 
difficult. However, also for simple disorders, DNA testing offers a 
tremendous advantage. We demonstrate the practical use of DNA testing 
based on the results of chapter 8. DM is a recessive disorder with 
incomplete penetrance. Assuming that penetrance is complete (which is a 
simplification of reality), DM would be seen in 3% of the studied German 
Shepherd population. By excluding all dogs that are phenotypically affected 
(genotype = aa), only dogs with genotype Aa and AA will remain for 
breeding. As long as at least one AA dog is used in every mating, no 
phenotypically affected dogs will be born. However, if Aa dogs are mated, 
on average 25% will be phenotypically affected. Without knowing the 
genotype, these matings cannot be avoided and affected individuals will be 
born. DNA tests can completely remove phenotypical DM from the 
population in one generation. This is achieved by only allowing aa x AA 
and Aa x AA matings. In addition, no animals have to be excluded from 
breeding when a DNA test is used, as even aa animals (that are 
phenotypically affected) combined with AA animals will not result in 
affected progeny. Thus, aside from the more efficient elimination of 
disease, DNA tests increase the population size of breeding dogs which is 
beneficiary for the overall population health.  
An additional point of consideration is that in reality, phenotypical 
selection is even less efficient: due to the reduced penetrance, even 
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genetically affected animals that did not (yet?) express DM, would be 
used for breeding from time to time. Based on these results, it is clear 
that DNA tests can speed up health improvement. 
9.3 Disease prioritization 
In reality, health improvement is not an issue of one disease only. As 
the canine population suffers from several diseases, it is likely that some 
form of disease prioritization will be necessary in order to maintain a 
sufficiently large population for breeding. Disease prioritization requires an 
assessment of the impact of the disease on the health of the dog, aside 
from a determination of the prevalence of the disorder8–10. Knowledge on 
the prevalence of diseases is also important to define the optimal strategy 
for health improvement. The results from chapter 3 and chapter 8 are two 
examples of studying disease prevalence based on either the phenotype or 
a genetic test. As detailed in the previous section, DNA tests are 
preferred, but unfortunately, are not available for every disorder.  
Based on the results from chapter 3, reliable disease estimates are 
difficult to obtain. Aside from the previously discussed factors that influence 
prevalence indirectly by adding noise to the phenotype, two factors 
influence the prevalence directly. Firstly, the selection bias in radiograph 
submission decreases the disease prevalence overall and also tends to 
reduce the differences in disease prevalence between breeds. The second 
point is that the sampling population should reliably represent the true 
population. It is clear that the orthopedic clinical complaint dog population 
is probably (hopefully) not a reliable representation of the general dog 
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population with over 70% of the dogs having HD. However, the breeding 
population is also not representative due to the selection bias.  
The results of the DNA tests from chapter 8 demonstrate that the 
disease prevalence is highly variable between breeds (from absent to 
30% genetically affected individuals) and that the carrier frequency can be 
high (up to 35%). As shown by the rejection of HWE for two tests in 
the Labrador Retriever, an accurate selection of the test population is also 
important for DNA tests. 
Overall, obtaining reliable disease prevalence estimates is important, but 
not easy. Estimating disease prevalence requires the collaboration of all 
parties involved in animal breeding. All factors that contribute to 
underidentification of a disease should be addressed because decision 
makers base their plans on these results.  
9.4 Why do we study the dog? 
Based on the previous sections, genetic research on canine diseases 
will likely improve their health. In addition to being an enjoyable pet, the 
dog is a good animal model and thus beneficial for biomedical research. 
Compared to established laboratory animals, such as mice, dogs have 
several advantages. Here is an overview of why the dog has so much 
potential as an animal model: 
Phenotype. The dog population has a remarkable phenotypical diversity 
and a high frequency of spontaneously occurring genetic diseases. 
Frequently occurring spontaneous diseases reduce the need to establish 
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and maintain research colonies as the pet population itself can be used 
directly. In addition, the willingness of individual owners to participate in 
research studies is often considerable. With litters of sometimes 10 
puppies or more, the collection of closely related cases and controls is 
often relatively easy. With the health care standard close to that of 
human medicine, the majority of specialized diagnostical and therapeutical 
techniques are available for the dog, resulting in improved phenotypical 
characterization11. A large number of diseases share clinical and laboratory 
abnormalities in humans and dog and at this moment, well over 50% of 
the genetic diseases in the dog are considered to be potential models for 
human diseases11,12. Especially for complex diseases, spontaneous models 
have the benefit over induced models as the latter often are simplified 
models that knock out only one gene13. Both in size and structure, the 
anatomy of several organs of the dog resembles the human anatomy 
more than routinely used laboratory animals14,15. As companions, dogs 
share the world of their owners, resulting also in a shared environment 
that may influence the pathogenesis of disease. Extrapolation of results 
and studying of the bigger picture of interactions between genes and 
environment will certainly be more realistic than in the typical laboratory 
animal environment14.  
Genetic constitution. The creation of the dog as we know it, has 
clearly left its marks on the dog genome. The large haplotype blocks and 
low genetic heterogeneity have already been reported13,16. The practical 
advantage this has for WES has only recently been demonstrated 
(chapter 7). The same processes that caused the high prevalence of 
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spontaneous diseases can be put to good use now because they will 
likely limit the number of animals necessary to identify causal mutations13,17 
(chapter 7). Additional advantages are that the dog genome is less 
diverged from the human than the mouse genome18. With the recent 
release of WES designs, several modern tools to study diseases are now 
available. Especially for complex diseases, the combination of high disease 
prevalence, genetic population isolation due to the pedigree barrier and 
sequencing based approaches is promising11,19. 
Translation to human diseases. Knowledge of disease-causing mutations 
in the dog has already led to the identification of several disease-causing 
mutations in humans. The identification of a mutation in the PRCB gene, 
responsible for progressive rod-cone degeneration in the dog, led to the 
subsequent discovery of that identical mutation in a woman with autosomal 
recessive Retinitis Pigmentosa20. Two other examples are the identification 
of mutations in the hypocretin receptor 2 gene and the preprohypocretin 
gene, responsible for canine narcolepsy and an autosomal dominant early 
onset narcolepsy in a human patient, respectively and the association 
between PNPLA1 mutations and canine and human ichthyosis21–23. 
Promises for treatment. Aside from the importance for breeding to 
improve health in future generations, knowledge of the causal mutation 
also holds the promise of improvement of the health of affected 
individuals14. Especially for eye diseases, the dog has been a valuable 
partner. Congenital stationary night blindness or retinal dystrophy is the 
spontaneously occurring canine homologue of Leber congenital amaurosis24. 
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Upon identification of the causal mutation, gene therapy with a 
recombinant adeno-associated virus successfully restored vision in the 
dog24. It was only after this success that gene therapy studies were 
conducted in the mouse, which subsequently led to clinical trials with 
promising results in humans14,15,25. For other diseases such as 
achromatopsia and hereditary nephropathies, results obtained by gene 
therapy in the dog are also promising14,15.  
All these examples illustrate that the relationship between dogs and 
humans is a relationship that benefits both species and proves again that 
the dog really is “man’s best friend”. 
9.5 Additional resources for the toolbox: WES 
Currently, the majority of genetic studies conducted in the dog rely on 
GWAS. However, the transition from the indirect GWAS to direct 
sequencing is being made, as demonstrated on the latest Canine and 
Feline genomics conference (Cambridge, UK, 2015). In human genetics 
however, sequencing-based approaches such as WES are already being 
used for several years26. Possible reasons are the cost (GWAS is less 
expensive than WES), the success of GWAS (“never change a winning 
team”) and the limited availability of WES designs for the dog27. As 
sequencing costs are plummeting, the difference in costs between GWAS 
and WES will decrease26,28. With the recent release of several WES 
designs (chapter 4 and 5), availability will be less of an issue from 
now on.  
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As already mentioned in chapter 5, the three available designs differ 
mainly in terms of: whether or not to target (3’ and 5’) UTRs and 
whether the focus should be almost exclusively on protein-coding regions 
or whether a large non-protein coding catalogue is to be targeted as 
well. Especially in cancer research and complex diseases, extending the 
focus beyond the protein-coding regions is advisable29–31. However for 
Mendelian disorders, the majority of causal variants are located in protein-
coding regions32,33. Choosing the smallest design, the exome-1.0, for 
these disorders is the most cost-efficient option32,33.  
In comparison with human WES designs, two aspects are to be 
highlighted. First of all, with the availability of three canine WES designs, 
the same flexibility as commercial WES designs for humans is guaranteed. 
The flexibility is increased further as up to 200 Mb can be targeted 
nowadays, so additional regions of interest can be easily added. A 
second remark is that none of the human designs offer the combination 
of all the non-protein coding regions, all the UTRs and all the protein-
coding regions in one design. Thus, the exome-plus is superior in terms 
of completeness.  
9.5.1 Potential limitations 
Just like GWAS, it is important to realize that WES is a tool and as 
with every other tool, it has its limitations. 
One of the most important points of consideration, is that WES is only 
as strong as the quality of the annotation it is based on. If the 
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annotation misses some genes, WES designs will not target them, unless 
there is overlap with other targets by coincidence. Actually, one of the 
reasons for the extended WES designs (exome-CDS and exome-plus), 
was the release of an updated annotation30. 
A second point is that, even if regions are targeted, some of them 
will not be sequenced. The most important reason for low coverage was 
found to be related to a high GC-content, followed by low-
complexity/highly repetitive regions, as discussed in chapter 5. This is in 
agreement with previous reports and also for other sequencing 
technologies, these regions can be difficult to cope with34,35.  
Consequently, when the results of several samples are compared, there 
will always be some variability in the sequencing depth of certain regions 
between samples. Some regions might be covered at a sufficient depth in 
one sample, while this might not be the case in others.  
A final issue relates to the detection of structural variants. A structural 
variant (SV) is defined as a genomic rearrangement of more than 50 bp 
and has already been associated with canine diseases (e.g. a 133 kb 
duplication is associated with dermoid sinus in the Rhodesian 
Ridgeback)36,37. Although WES has been used successfully to detect SVs, 
it remains difficult37–40. 
The problem of incomplete annotation is difficult to solve: clairvoyance 
is needed to know what has been missed. Due to the recent high-quality 
update, the annotation has certainly improved significantly. Details on the 
number of un(der)covered regions or base pairs of interest are presented 
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in chapter 4 and 5. Overall, with on average 90% of the base pairs 
consistently covered at a sequencing depth of at least 5x, the majority of 
the targets will be sequenced. Whether this will be sufficient or not, 
depends on the study. However, it is important to realize that a variable 
coverage is not uniquely related to WES. Even when WGS is performed, 
some regions will be un(der)represented and some of them might have 
been sequenced when WES was performed28.  
9.5.2 Future perspective of WES 
Realistically, the overall decrease of sequencing costs will pave the 
way for WGS as the additional preparatory steps for capturing are 
relatively expensive. We agree that the transition is likely to be made at 
some point, probably within the next five or ten years, but we believe 
that the current development of WES designs will serve their purpose for 
some time.  
Although the field of genomics is evolving at an incredible pace, 
“older” techniques are still used widely side-by-side to new ones. 
Although Sanger sequencing was invented almost 40 years ago, it is still 
used in routine clinical settings as it can be used to fill gaps missed by 
NGS or when the size of the target regions is small41,42. Even though the 
advantage of sequencing-based approaches compared to GWAS is clear, 
a PubMed search (("genome-wide association study") AND (human), 
limiting results to those published between 1/1/2015 to 16/7/2015) 
returned 484 hits, illustrating that the GWAS approach is still applicable. 
In addition, although the $1000 genome has been announced by Illumina 
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in 2014, it requires considerable investments initially and a large volume 
of samples to reach that price. 
Where other WES designs often only focus on the protein-coding 
regions, the large non-coding catalogue of the exome-plus provides an 
intermediate option between the pure “exome” and complete genome. 
Although sequencing itself is becoming less of a limitation, the 
computational burden remains important26,29. The entire genome is 
considerably larger (the exome-plus targets only 6% of the genome) and 
the analysis requires increased processing time and data storage. It will 
not be easy to solve this problem. 
9.5.3 Conclusion 
Currently, the developed WES enrichment designs provide a cost-
efficient alternative between GWAS and WGS. Although WGS will probably 
replace WES at some point, we believe WES is here to stay (for a 
while). 
9.6 Prior to and after the wet lab: optimal case-control selection 
and variant analysis with “Mendelian” 
Where the shelf life of the WES designs might be limited, the R-
package “Mendelian” and the results from the analysis of the various 
case-control designs are not. Whether the data are obtained from WES 
or WGS, from Illumina or newly developed sequencers, the end result will 
likely remain the same: a list of sequencing variants that need to be 
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filtered. In chapter 6, “Mendelian” was used successfully to revalidate 
mutations for two autosomal recessively inherited phenotypes (brown and 
yellow coat colour in the Labrador Retriever) and a de novo mutation 
associated with mental retardation in humans43–46.  
The power of heuristic filtering of sequencing variants for autosomal 
Mendelian disorders was demonstrated further in chapter 7. By comparing 
several case-control designs of individuals with variable degrees of 
relatedness for both dominant and recessive types of inheritance, practical 
guidelines for optimal sample selection are provided. Although the effect of 
the population bottlenecks has been thoroughly investigated, it was still 
surprising that dogs from two different breeds share up to 60% of their 
variants13,17,47. Within a breed, this increases to 70%. This has several 
implications. First of all, the number of animals necessary to retain only 
the disease-causing variant will be limited. In addition, due to the close 
relatedness between dogs, extensive genetic heterogeneity is rather 
unlikely, as reported previously16,31. Due to the high number of shared 
variants, it is more efficient to include one control than to include a 
second case, especially if this control is a close relative (full sibs or 
parents) of the case. This is an advantage: as long as the prevalence 
of a disease does not exceed 50%, it is much easier to collect additional 
controls than additional cases. 
Although “Mendelian” was not specifically designed for identifying X-
linked disorders, it can be used for this purpose, as discussed in the 
online manual. This might require some tweaking of the VCF-files, 
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depending on the program and the exact combination of male and female 
individuals.  
As the attention shifts towards complex disorders, the question is 
whether “Mendelian” will be of any help here. Basically, complex 
disorders are no more than a combination of genetic and environmental 
factors that lead to a reduced penetrance and detectance. As “Mendelian” 
allows both reduced penetrance and/or detectance, it should be technically 
possible. Realistically however, lowering the thresholds also results in less 
variants being filtered. Especially for rare variants, the thresholds will have 
to be set so low that almost no variant is being filtered. In chapter 7, 
the effect of lowering the thresholds for penetrance and/or detectance 
confirmed that heuristic filtering will be inefficient for complex disorders. To 
identify those variants, more statistical approaches need to be used, but 
even then the identification remains challenging19. Overall however, the 
high degree of shared variants makes one wonder what the allele 
frequency of (rare and common) variants is in canine complex disorders. 
Based on our results, we expect the allele frequencies of both to be 
higher, but this remains to be determined. 
9.7 Short-term evolution 
As demonstrated in previous sections, the combination of WES and 
“Mendelian” is promising. WES has already been used in the dog 1) 
after mapping with a GWAS to identify the causal mutation48 and 2) 
without mapping to revalidate a causal mutation (the coat colour loci in 
chapter 7). The next step is the identification of new causal genetic 
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variation for unstudied phenotypes. Due to the added complexity of 
common disorders, it might be safer to study Mendelian disorders first, but 
the transition to complex disorders will follow soon.  
Future studies will likely benefit from an extension of the dbSNP 
variant database. This database was very important in the development of 
the GWAS kits, but it was built with a limited number of samples (one 
dog from every breed, for a total of 11 breeds) which makes it less 
useful for filtering sequencing variants13,17. Due to the high prevalence of 
disorders in specific breeds, it is very likely that carriers of these breed-
specific diseases were unintentionally selected, resulting in contamination 
(i.e. the database contains mutant alleles associated with disease) of the 
database for that disease. For example, for a recessive disease with a 
prevalence of 5%, under the assumptions of HWE and 100% detectance 
and penetrance, 35% of the population is a carrier of the mutant allele 
for that disease (see Appendix A for calculations). To avoid exclusion of 
the causal variant when filtering sequencing data, it is important to use 
only those variants in the variant database that have allele frequencies 
higher or equal to a certain MAF. That MAF can be estimated based on 
the disease prevalence in a population. However, this requires a variant 
database with reliable allele frequencies which can only be obtained by 
sequencing several dogs from one breed. A joint effort will be required to 
sequence a sufficient amount of dogs from the majority of the dog 
breeds, but initiatives in these direction are being proposed49. 
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9.8 Final conclusion 
In 2000, Elaine Ostrander stated: “canine genetics comes of age”. 
Since then, the dog genome and several improved annotations have 
become publicly available and linkage studies have been (largely) 
replaced by GWAS. With the release of several WES designs, an R-
package for heuristic filtering and guidelines for case and control selection 
in sequencing studies, we hope to have contributed to the maturation of 
canine genetics and the healthy aging of the dog.  
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Summary 
Dogs (Canis familiaris) have been part of human society for 
thousands of years. Over this large time period, specific characteristics 
have developed in terms of hair colour, body size, skull shape, etc. 
Unfortunately, the processes that created the dog as we know it, 
inadvertently resulted in genetic diseases in the dog being far from rare. 
This dissertation studies several aspects of canine genetics and begins 
with a general overview on the methodologies that can be used to study 
genetic diseases (chapter 1). 
Genetic analyses start with defining the phenotype. Although this 
appears easy, the classification of an individual as healthy or sick can be 
difficult. A striking example of a complex phenotype is canine hip 
dysplasia (chapter 3). In the first study, the aim was to identify factors 
that influence the radiographic diagnosis and prevalence estimates of 
canine hip dysplasia. A total of 583 radiographs were assessed 
independently by two different observers for hip conformation and for 
positioning. Overall, the agreement between observers for positioning and 
hip conformation was limited and can affect estimates of the prevalence of 
hip dysplasia. Aside from these factors, the prevalence estimates were 
further influenced by selection bias and the population that was sampled 
from. This study stresses the importance of correct phenotypical 
classification for screening programs as well as genetic studies.  
A large section of this dissertation focuses on the development and 
performance of whole exome sequencing designs (chapter 4 and 5). 
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Whole exome sequencing is a targeted sequencing method that aims to 
selectively sequence all the regions from the genome that are transcribed 
to mRNA. Three different designs were made: the exome-1.0 (53 Mb), 
the exome-CDS (71 Mb) and the exome-plus (152 Mb). They differ 
mainly in terms of the choice to target (3’ and 5’) UTRs and whether 
the focus should be almost exclusively on protein-coding regions or 
whether a large non-protein coding catalogue is to be targeted as well. 
Both the performance of the exome-1.0 and the exome-plus were 
evaluated for several samples, while the performance of the exome-CDS 
was estimated based on the results of the exome-plus. Overall, the 
exome designs all performed well, with the differences between them 
being mostly related to region size and bait design. 
When Mendelian disorders are studied, several assumptions to filter the 
sequencing variants are typically relied on, until one or a very limited 
number of putative causal variants remain. The release of several whole 
exome sequencing designs for the dog, created the need for a heuristic 
filtering tool capable of analyzing variant data under the assumptions of 
recessive or dominant modes of inheritance, with variable degrees of 
penetrance and detectance. With this aim, the R-package “Mendelian” 
was developed. We demonstrated its performance by revalidating a de 
novo mutation responsible for human intellectual disability and two 
recessively inherited mutations responsible for the yellow and brown coat 
colours in the Labrador retriever (chapter 6).  
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As whole exome sequencing is relatively new, no guidelines on sample 
selection have been published. Which combinations result in the most 
efficient variant reduction is not yet known. In order to provide guidelines 
and some directions on what to expect, several combinations of cases 
and controls with variable degrees of familial relatedness and assuming 
dominant or recessive modes of inheritance with variable degrees of 
penetrance and detectance, were evaluated (chapter 7). Remarkably, up 
to 60% of the variants were shared between dogs from two distinct 
breeds. Within a breed, unrelated dogs shared up to 70% of their 
variants. Although the same processes that caused this phenomenon 
resulted in the high prevalence of genetic diseases, these same 
characteristics can be used when studying genetic diseases. Lower sample 
sizes are needed, genetic heterogeneity is reduced and, as the inclusion 
of one control is preferred over a second case, sample collection is made 
easier. 
One of the outcomes of disease-association studies is typically a DNA 
test. An important step in defining the optimal strategy for health 
improvement and to decide whether the disease should be treated with 
priority or not, is an assessment of the prevalence of the disorder. In a 
population of 476 dogs, we determined the allelic frequencies of mutant 
alleles associated with nine genetic disorders (chapter 8). For 5 
disorders, the mutant allele could not be identified in our population. For 
the other 4 disorders (degenerative myelopathy, exercise-induced collapse, 
neuronal ceroid lipofuscinosis 4A and a mutation found to be associated 
with hip dysplasia in a population in the United States), the prevalence 
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of the mutant alleles was strongly breed dependent. The high carrier 
frequencies in specific breeds reduce the efficacy of phenotypical selection 
programs. In addition, mutant alleles were found in many breeds where 
the disorder has not been reported yet. Whether the disease has not 
been recognized in these breeds or whether a difference in genetic 
background influences the effect of the mutant alleles, still needs to be 
determined.  
The final chapter of this dissertation, chapter 9, discusses the results 
of the previous chapters. In addition, it situates our research in the world 
of canine genetics and stresses the potential of the dog as an animal 
model for human diseases.  
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Samenvatting 
De hond ofte Canis familiaris, is reeds ettelijke duizenden jaren onze 
metgezel en heeft een opmerkelijke fenotypische diversiteit. De processen 
die tot deze diversiteit hebben geleid, hebben er echter onbedoeld ook 
voor gezorgd dat genetische aandoeningen verre van uitzonderlijk zijn. In 
deze thesis worden meerdere aspecten van deze genetische aandoeningen 
onderzocht. Alvorens over te gaan tot het eigenlijke onderzoek, wordt in 
hoofdstuk 1 een algemene inleiding gegeven over welke moderne 
methodologische middelen er bestaan om genetische aandoeningen te 
bestuderen. 
Het ontrafelen van genetische aandoeningen start met het bestuderen 
van het fenotype van die aandoening. Beslissen of iemand gezond of ziek 
is, is niet altijd gemakkelijk. Het ideale voorbeeld van een aandoening die 
moeilijk te fenotyperen is, is heupdysplasie (hoofdstuk 3). In de eerste 
studie werd het effect van factoren die de radiografische diagnose van 
heupdysplasie en schattingen van de prevalentie beïnvloeden, bestudeerd. 
Hiervoor werden er 583 radiografische opnames van het heupgewricht 
geblindeerd beoordeeld door 2 personen waarbij hen gevraagd werd om 
enerzijds de heupen te scoren en anderzijds te beoordelen of de 
positionering van de hond op de radiografie goed was. Algemeen kon er 
besloten worden dat de beoordelingen van zowel positionering als 
heupscore slechts in beperkte mate overeenkwamen. Dit beïnvloedt 
eveneens schattingen van de prevalentie. Andere factoren die het moeilijk 
maken om exact in te schatten hoe vaak heupdysplasie voorkomt, zijn 
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selectiebias en de populatie waarvan men steekproeven neemt. Selectiebias 
betekende in dit geval dat röntgenopnames van honden met duidelijke HD 
minder vaak ingezonden werden voor officiële beoordeling. Algemeen 
benadrukt deze studie het belang van correcte fenotypische classificatie 
voor zowel programma’s die screenen op genetische aandoeningen als in 
genetische studies.  
Een groot deel van deze thesis focust zich op de ontwikkeling en de 
prestaties van zogenaamde “whole exome sequencing” designs (hoofdstuk 
4 en 5). Whole exome sequencing is een techniek die gericht bepaalde 
delen van het genoom van de hond analyseert die worden vertaald naar 
het boodschapper RNA (= mRNA). In totaal werden er drie van deze 
designs gemaakt: de exome-1.0 (53 Mb), de exome-CDS (71 Mb) en 
de exome-plus (152 Mb). De verschillen tussen deze designs zijn 
voornamelijk te wijten aan de keuze om al dan niet 3’ en 5’ UTRs mee 
te sequeneren en of men zich voornamelijk op de regio’s richt die 
coderen voor eiwitten of eveneens een groot deel niet-eiwit coderende 
regio’s mee wilt nemen. Zowel de exome-1.0 als de exome-plus werden 
uitvoerig getest. De prestaties van de exome-CDS werden geschat op 
basis van de resultaten van de exome-plus. De voornaamste oorzaken 
van prestatieverschillen zijn gerelateerd aan de grootte van de te 
sequeneren regio’s en andere instellingen die werden gebruikt tijdens het 
ontwikkelen van de eigenlijke kit. Evenwel presteerden alle designs goed. 
Bij het bestuderen van Mendeliaanse aandoeningen, gaat men vaak uit 
van bepaalde assumpties. Deze assumpties worden dan gebruikt om van 
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alle varianten die geïdentificeerd worden het overgrote deel weg te filteren 
totdat uiteindelijk slechts één of een zeer beperkt aantal varianten 
overblijft. Door het uitbrengen van de whole exome designs ontdekten we 
dat er nood was aan een software pakket dat kon om gaan met deze 
verschillende assumpties en ook gebruikt kon worden bij de hond. Met dat 
doel voor ogen werd “Mendelian” ontwikkeld, software gebaseerd op de 
programmeertaal R. Om te demonstreren dat “Mendelian” geschikt is voor 
deze taak, werden een de novo mutatie, verantwoordelijk voor mentale 
retardatie bij de mens, en twee recessief overervende mutaties voor de 
bruine en gele vachtkleur bij de Labrador Retriever opnieuw aangetoond 
(hoofdstuk 6).  
Aangezien whole exome sequencing bij de hond nieuw is, bestonden 
er nog geen richtlijnen over welke combinatie of aantallen van gezonde en 
aangetaste dieren het meest efficiënt zijn om het aantal geïdentificeerde 
varianten te reduceren. Om enerzijds richtlijnen te kunnen aanbieden en 
anderzijds een idee te hebben over welke reductie men kan verwachten, 
werden er verscheidene combinaties van gezonde en aangetaste dieren, 
met variabele verwantschapsgraden en voor zowel dominante als recessieve 
kenmerken met variabele penetrantie en detectiegrenzen, getest (hoofdstuk 
7). Een opmerkelijk resultaat was dat honden uit verschillende rassen tot 
60% van hun varianten delen. Binnen een ras, loopt dit zelfs op tot 70% 
voor honden die niet verwant zijn. De processen die tot deze hoge 
percentages hebben geleid, zijn in dit geval positief voor het genetisch 
onderzoek, maar hebben terzelfdertijd net tot die hoge prevalentie aan 
genetische aandoeningen geleid. De voordelen van deze hoge percentages 
Summary/Samenvatting 
245 
 
zijn de kleinere aantallen honden die nodig zullen zijn om genetisch 
onderzoek uit te voeren en de beperktere genetische heterogeniteit. Uit 
deze resultaten bleek ook dat het voordeliger is om als tweede hond een 
gezonde hond te sequeneren in plaats van een tweede zieke hond. Dit 
vergemakkelijkt de staalcollectie aangezien gezonde honden (in dit geval, 
honden zonder die specifieke aandoening) meer zullen voorkomen dan 
een tweede aangetaste hond, zeker indien het gaat over zeldzame 
aandoeningen.  
Eén van de uiteindelijke doelen van genetisch onderzoek is de 
ontwikkeling van een DNA test. Om de optimale strategie te bepalen om 
een ziekte te bestrijden en ook om te kunnen uitmaken of een ziekte 
absolute prioriteit verdient of niet, is het belangrijk om de prevalentie van 
de aandoening te kennen. In hoofdstuk 8 werden de allelfrequenties 
bepaald van 9 verschillende genetische aandoeningen in een populatie van 
476 honden. De mutaties verantwoordelijk voor 5 van deze 9 
aandoeningen werden niet ontdekt. Van 4 andere aandoeningen 
(degeneratieve myelopathie, collaps geïnduceerd door inspanning, neuronale 
ceroïd lipofuscinosis 4A en een mutatie die geassocieerd zou zijn met 
heupdysplasie in een Amerikaanse populatie honden) werden de causale 
varianten teruggevonden. Afhankelijk van het ras verschilden de 
allelfrequenties sterk. Uit de grote aantallen dragers blijkt dat puur 
fenotypische selectie een stuk minder efficiënt zal verlopen dan selectie 
met behulp van DNA testen. Opmerkelijk is ook dat de mutaties werden 
teruggevonden in rassen waar de ziekte nog niet gerapporteerd werd. Het 
kan zijn dat de ziekte in deze rassen nog niet herkend werd. Een andere 
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mogelijkheid is dat het effect van de causale varianten beïnvloed wordt 
door de rasgebonden genetische achtergrond.  
In het laatste hoofdstuk, hoofdstuk 9, worden de resultaten uit de 
eerdere hoofstukken bediscussieerd. Het kadert ook dit doctoraat binnen 
het domein van het genetisch onderzoek bij de hond. Tot slot wordt er 
verwezen naar de belangrijke rol die de hond kan spelen als diermodel 
voor de mens. 
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Appendix 
For a recessive disease, the carrier frequency and the frequencies of the 
mutant and wild type alleles, are calculated starting from the disease 
prevalence. 
The following assumptions are made: 
1) The population is in HWE for the alleles studied 
2) 100% penetrance 
3) 100% detectance 
Due to the first assumption, the following relationship exists between 
alleles and genotypes: 
 Genotype 
 AA Aa aa 
Frequency p² 2pq q² 
With p and q the allele frequencies for A ( = the wild type allele) and 
a (= the mutant allele), respectively. 
 
Due to assumption two and three:  
P(disease phenotype) = P(aa) = q² 
 
To calculate q, the square root of the prevalence of disease is taken. As 
p+q=1, 2pq = 2(1-q)q = the carrier frequency 
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The relation between disease prevalence, q and the carrier frequency is 
depicted graphically in Figure A.1:  
 
Figure A.1. Relation between disease prevalence (%), carrier frequency and the 
allele frequency of the mutant allele q. 
It is clear that even for rare diseases, carriers occur at high 
frequencies in the population. 
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Dankwoord 
Vier jaar geleden leek dit nog zo ver weg en met momenten zelfs 
onmogelijk tijdens de onzekere periode van de beursaanvragen. 
Ondertussen is echter reeds het einde van de predoctorale periode 
aangebroken. Het is onvoorstelbaar hoe snel deze vier jaren zijn voorbij 
gevlogen. Een doctoraat wordt gekenmerkt door hoogtes en laagtes, 
periodes waarin alles lukt en periodes waarin het lijkt dat je niet vooruit 
komt. Daar nu op terugkijkend, kan ik alleen maar zeggen: het komt 
(altijd) goed! Altijd blijven gaan!  
Het is een speciaal moment als je dat boekje met jouw naam op 
daar ziet liggen: een combinatie van blijdschap, fier dat je het hebt 
voltooid, maar vooral ook dankbaar want dit werk zou nooit tot stand zijn 
gekomen zonder de nodige hulp en ondersteuning. Eerst en vooral, zou ik 
het Agentschap voor Innovatie door Wetenschap en Technologie (IWT) 
willen bedanken: mede dankzij hun geloof in het project en hun financiële 
steun ligt dit boekje hier.  
Naast de financiële steun is dit vooral ook een project dat tot stand is 
gekomen dankzij vele gemotiveerde personen die elk op hun manier 
hebben bijgedragen. Als eerste in de lijn zou ik graag mijn promotor en 
copromotoren willen bedanken: 
Prof. Dieter Deforce, u gaf mij de kans om als dierenarts in uw labo 
te doctoreren, de vrijheid om het project mee uit te stippelen en te 
groeien in wetenschappelijk onderzoek. Uw brede wetenschappelijk kennis 
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en inzicht, gecombineerd met de nodige “drive” hebben dit project 
ongetwijfeld gestimuleerd. Een oprechte dank u!  
Prof. Frank Coopman, ontsproten aan jouw gedachtegang, werd het de 
bron van de gemeenschappelijke passie: de zoektocht naar de genetische 
oorzaak voor heupdysplasie. Van samen grasduinen in een stapel rx’en tot 
het leren nemen van PennHIP, HD diagnostiek op zijn best! Op dit 
moment hebben we het nog niet gevonden, maar ik ben er van overtuigd 
dat er een hele stap in de goede richting is gezet.  
Prof. Geert Verhoeven, waar is de tijd dat ik voor het eerst 
binnenstapte in Dierenkliniek Randstad. Vanaf het eerste moment was ik 
onder de indruk van je theoretische kennis gecombineerd met je 
chirurgische vaardigheden. Als student diergeneeskunde leek “de praktijk” 
de logische optie, tot jij de vraag stelde om te doctoreren. Niet iedereen 
heeft het geluk een persoonlijke mentor te hebben die je helpt te 
ontwikkelen, bij deze is het dan ook mijn beurt om je te bedanken!  
Prof. Filip Van Nieuwerburgh, waarom doen we geen “whole exome 
sequencing”? Een goede vraag die de basis vormde voor het overgrote 
deel van het doctoraat. De nuchtere en kritische kijk op onderzoek, de 
sterke verhalen after hours: de ideale mix! 
Tevens zou ik de andere leden van de lees- en examencommissie 
willen bedanken voor de tijd die ze genomen hebben om dit werk te 
lezen en te beoordelen. Speciale dank aan Dr. Wim Van Haeringen voor 
de goede samenwerking! 
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Ik heb het geluk mijn doctoraat te hebben mogen doorbrengen omringd 
door geweldige collega’s, zowel op mijn “thuisbasis”, de Faculteit 
Farmaceutische Wetenschappen, als op de Faculteit Diergeneeskunde. 
Samen hebben we gelachen, gevloekt en samen raken we vooruit. 
Logischerwijs komen we dan onmiddellijk terecht bij mijn 
“medebokaalbewoners” op het tweede. Liesbeth en Katleen, elks op jullie 
eigen manier onmisbaar voor het labo, maar bij beide de altijd 
“openstaande deur” voor vragen en om te lachen. Katleen, de “mama” 
van het labo. De manier waarop jij de begeleiding combineert van 
externen en interne projecten en de rust die je uitstraalt. Liesbeth, 
gedreven en doorzettingsvermogen. Zoveel praktische zaken regelen en ook 
nog tijd vinden om te combineren met je eigen research, desnoods in de 
late/vroege uurtjes: we gaan je missen tijdens je verblijf in de VS! 
Paulien, samen met mij begonnen en ons door de IWT procedure 
geworsteld en ondertussen ook aan het afronden: ik ben blij dat ik met 
jou het hele traject heb kunnen afleggen. Ellen, altijd enthousiast en 
vrolijk. Elisabeth, de goedheid zelve, harde werker en perfectionist! You 
can do it! Maarten, mede-koffieverslaafd, altijd enthousiast en brenger van 
de Japanse origami’s en “chihuahuas”! Trees, altijd vrolijk en een 
geweldige lach. David, de wekelijkse leverancier van de groene 
cadeautjes, maar bovenal iemand waar je mee kan lachen en op kan 
rekenen. Christophe, het statistiek-clubje, loop-clubje en het R-clubje (ja, 
ja, het blijft R, zelfs al is het via Python ;-)): veel gemeenschappelijke 
interesses en altijd een plezier om “even” mee te babbelen. Ondertussen 
zit je “aan den overkant”, maar laat dat je niet tegen houden om 
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regelmatig binnen te springen! Laura, staat haar mannetje, weet wat ze 
wil! Yannick, ik kan mij zelfs niet meer voorstellen hoe we ooit computer 
problemen konden oplossen zonder jou. “When all else fails, read the 
manual” is bij ons ongetwijfeld, “just go to Yannick”! Dieter, mede R-
adept, allround bio-informaticus en gewoon “ne sympathieke mens”. Ellen 
en Sarah, queens of the wet lab! Lieselot, altijd lachen! Senne, king of 
the road, of het nu op de fiets is of te voet! Sander, internationalisering 
van het labo en samen met Heleen, de toekomst! Evelien, nog maar net 
gestart, maar ongelooflijk gedreven en ik kijk vol vertrouwen uit naar de 
verdere uitwerking van je project en samenwerking. Saskia, Sylvie, Sabine, 
Petra, Leen, Eveline, Evelien ofte de collega’s van “den DNA” en Sofie: 
we hadden misschien iets minder contact, maar het was daarom niet 
minder aangenaam! Bedankt voor de leuke babbels en fijne momenten! 
Nadine en Astrid, altijd bereid om te helpen, van groene enveloppen, 
onkostennota’s tot VAT en overhead: zonder jullie was ik nooit door de 
administratieve soep geraakt. Inge, altijd lachen en vrolijk en bereid om 
alles te regelen. 
Onze oud-collega’s, Mado, Marlies, Bert, Shahid, Pieter, Veerle, 
Yens, Nicky, we zijn jullie zeker niet vergeten, bedankt voor al de fijne 
momenten! Een speciaal woordje van dank voor Sandra: een ongelooflijke 
hulp tijdens het schrijven van mijn masterproef en nog meer tijdens de 
voorbereiding van mijn IWT. Zonder jou was dit project misschien nooit 
echt uit de startblokken geraakt. 
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Het woord dat dit doctoraat het beste kenmerkt is naar mijn mening 
niet DNA en zelfs niet heup, maar wel samenwerking. Aan de basis van 
dit doctoraat lag een brede samenwerking en de volgende personen 
hebben daar allemaal aan bijgedragen:  
Onder leiding van Prof. Bernadette Van Ryssen, het team van 
orthopedie. Speciale dank aan mijn (oud-)bureaugenoten: Stijn, Lynn en 
Astrid. Op een teambuilding of gewoon op het werk, de sfeer zat er altijd 
in!  
Onder leiding van Dr. Ingrid Gielen, het CT/MR team. Speciale dank 
aan Kaatje: ist oem da wij alletwiee van ’t stad zen, k wieet et ni, mor 
gij zijt de max! Aqui, you had to cross an ocean and go through Spain 
to end up in Ghent, but I’m glad you did! 
Onder leiding van Prof. Ingeborgh Polis, het team van anesthesisten. 
Zo slaapverwekkend jullie zijn voor de hond, zo fijn om mee samen te 
werken als mens! 
Het team van de dienst cardiologie. Samen naar die ene klep staren, 
lekt hij of lekt hij niet, samen die ene tabel van meer dan 200 
kolommen verwerken. Ik kijk uit naar het volgende onderzoek, the best is 
yet to come! 
Onder leiding van Prof. Jimmy Saunders, het voltallige team van 
medische beeldvorming. Speciale dank aan Elke, samen trekken en 
sleuren op zoek naar de perfecte heupfoto van de onmogelijk te 
positioneren hond: het was niet altijd evident om het doel te bereiken, 
maar we kwamen er steeds!  
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Speciale dank ook aan Prof. Em. Van Bree voor het vertrouwen en 
de aangename samenwerking!  
Naast collega’s op de Faculteit Diergeneeskunde, waren een heleboel 
praktijkdierenartsen uit het binnen- en buitenland onmisbaar voor dit 
onderzoek. Wat ben je met sequencing als je niets hebt om te 
sequeneren? Hun bijdrage is van onschatbare waarde. Graag zou ik dan 
ook de volgende collega’s en hun teams bedanken: 
In België: 
Dierenkliniek Sint-Jan – DAP aan de Heikant – Dierenkliniek Randstad 
– DAP Kleidal – Dierenkliniek Sint-Jan – Dierenkliniek Het Binnenhof – 
Huisdierchirurgie-Verdonck – Dierenkliniek De Vliet – Dierenkliniek 
Avanti/Vandecan – DAP Sonuwe – DAP De Bruycker-Criel – DAP 
Vetuatuca – DierenArtsenCentrum Assist – AC-DAP – Dierenkliniek 
Sanimalia – DAP Hulsterheide – Dierenkliniek De Bosdreef – DAP De 
Botermarkt – DAP Meirsschaut – Dierenartsencentrum Malpertuus – 
Dierenartsencentrum De Vledermuis – Dierenartsencentrum Herckenrode – 
Cabinet Buchet-Mathieu – Dierenkliniek Kerberos – DAP De Roeck Landen 
– DAP Hoogland – DAP Merckx – DAP Het Neerhof – DAP De Bosberg 
– Dierenkliniek Drogenboom – DAP Nachtegaele – Dierenkliniek Causus – 
DAP De Lovaart – Kasteel Vetcare – Centre vétérinaire Animalliance – Di 
Duca  
In Nederland:  
Sterkliniek Dierenartsen Ermelo – Dierenkliniek Brandersstad – 
Sterkliniek Dierenartsen Leeuwarden – DAP Horst e.o. – DAP de 
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Roosberg – Veterinair Centrum Holland Noord – KVGD Eersel – DAP De 
Meemortel – de Tweede Lijn – Dierenkliniek De Rashof – Dierenziekenhuis 
Drechtstreek – Sterkliniek Oss 
In Duitsland: 
Rosin Tiergesundheid 
Speciale dank aan:  
- Hans Nieuwendijk (de Tweede lijn): na een lange tocht door 
België en Nederland deed het bijzonder veel deugd om zo gastvrij 
ontvangen te worden in het verre Wilhelminaoord en mij te laten 
overnachten om uitgeslapen terug huiswaarts te kunnen keren. 
- het voltallige team van Dierenkliniek Randstad: om mij gedurende 
zoveel jaren te laten proeven van het mooiste beroep ter wereld. 
I would also like to thank Kerstin Lindblad-Toh, Jessica Alfoldi, 
Christophe Hitte and Thomas Derrien for our fruitful “exome” collaboration.  
Tijdens dit doctoraat kwam ik dankzij Daphné in contact met de wereld 
van de assistentiehonden. Keer op keer was ik onder de indruk van de 
drive en kennis van de medewerkers, de trainers, de gastgezinnen en 
overige vrijwilligers en de wil om samen te werken en vooruit te gaan. 
Mijn uitdrukkelijke dank aan de teams van Hachiko – Dyadis – Scale 
Dogs – Vrienden der Blinden Koksijde – het Belgisch centrum voor 
Geleidehonden - Blindengeleidehondenschool Genk – Stichting Hulphond en 
Martin Gaus Geleide- en Hulphondenschool. Daarnaast bedank ik 
eveneens graag de geleiders van “Rescue Dog Belgium” en 
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Diensthondenvereniging Zennevallei. Daphné kan er zelf jammer genoeg 
niet meer bij zijn, maar ze mag trots zijn op wat dankzij haar gestart is. 
Fysiek overal langsgaan zou meer dan een fulltime bezigheid zijn 
geweest. Dankzij de steun van de diergeneeskundige laboratoria, Medvet, 
Mediclab en Velab en in Nederland, ophaaldienst Miedema, werd de 
staalverzameling praktisch mogelijk gemaakt. De rol van het dr. Van 
Haeringen Laboratorium kan zeker niet geminimaliseerd worden: het 
praktische, overzichtelijke beheer kon niet beter gedaan worden! Ook mijn 
thesisstudenten Evelien en Sara zou ik graag willen bedanken voor hun 
hulp en enthousiasme! 
Jullie bijdrage was misschien onrechtstreeks, maar daarom niet minder 
belangrijk: mijn mede-jaargenoten van het jaar 2011: Ruth, Sofie D., 
Sofie M. en Olivier: van samen in de les tot samen afstuderen en 
uiteindelijk 3 verschillende richtingen uitgegaan. Ruth en Sofie D.: bedankt 
voor de ontspannende wandelingen met de hondjes en nog zoveel meer. 
Ondertussen zitten jullie niet meer aan de UGent, maar aan de andere 
kant van België en zelfs aan de andere kant van de wereld, even 
afspreken om te wandelen wordt dus wat moeilijker, maar dat komt 
ongetwijfeld nog goed! En aangezien we met slechts een half uur verschil 
synchroon aan het afleggen zijn: succes, you can do it, Sofie! Sofie M., 
bedankt voor de goede zorgen voor onze hondjes en de toffe babbels. 
Olivier, maat, ex-kotgenoot, merci! 
Papa, mama, alles beschrijven wat jullie hebben gedaan is niet 
mogelijk. Van de steun tijdens het studeren, tot het vervoer naar alle 
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mogelijke hobby’s, jullie hebben mij altijd alle kansen gegeven en mede 
dankzij jullie sta ik waar ik nu sta. Bedankt! Ben (en Charis), Michiel 
(en Nicky), Hanneleen: bedankt voor de broodnodige ontspanning, de 
geweldige Broeckx-humor en het samen knutselen van het “kanteldinges”!  
Bompa en Bomma, hoe ik er op gekomen ben om dierenarts te 
worden, weet ik niet meer, maar jullie hebben daar ongetwijfeld een 
belangrijke rol in gespeeld: van het slapen bij Douchka tot het opnemen 
van alle afleveringen van “All creatures great and small”, de liefde voor 
dieren werd er met de paplepel ingegoten. Bedankt! 
Zoals vaak is de laatste persoon zeker niet diegene die de kleinste 
bijdrage heeft geleverd. Astrid, research verloopt in ups en downs, maar 
op elk moment kon ik op je onvoorwaardelijke steun rekenen, was je 
daar om me te helpen relativeren, hielp je mij vooruit. Je bijdrage is 
onschatbaar, niet alleen voor het doctoraat, maar gewoon in mijn leven. 
Bedankt voor alles!  
 
Snoopy, Ruby, Bathida: woef! 
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Met dank aan: 
 
 
 
 
 
 
 
 
 
